NCCN Guidelines Version 1.2016 Panel Members
Acute Lymphoblastic Leukemia

NCCN Guidelines Panel Disclosures

Gary Kupfer, MD €
Yale Cancer Center/Smilow Cancer Hospital

Mark Litzow, MD ξ
Mayo Clinic Cancer Center

Arthur Liu, MD, PhD §
University of Colorado Cancer Center

Jae Park, MD †
Memorial Sloan Kettering Cancer Center

Arati V. Rao, MD † Þ
Duke Cancer Institute

Bijal Shah, MD †
Moffitt Cancer Center

Geoffrey L. Uy, MD † ξ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Eunice S. Wang, MD † ‡ ξ
Roswell Park Cancer Institute

Andrew D. Zelenetz, MD, PhD † ξ
Memorial Sloan Kettering Cancer Center

NCCN
Kristina Gregory, RN, MSN, OCN
Courtney Smith, PhD

NCCN Guidelines Index
ALL Table of Contents
Discussion

‡ Hematology/Hematology oncology
€ Pediatric oncology
≠ Pathology
† Medical oncology
þ Internal medicine
ξ Bone marrow transplantation
§ Radiotherapy/Radiation oncology
* Discussion Section Writing Committee

Continue
Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See NCCN Categories of Evidence and Consensus.
Updates in Version 1.2016 of the NCCN Guidelines for Acute Lymphoblastic Leukemia from Version 2.2015 include:

**ALL-1**
- Genetic Characterization: “Additional optional tests” modified: “Flow cytometric DNA index/ploidy testing (Additional assessment for hyperdiploidy and hypodiploidy)”
- Footnote “b” modified: “Criteria for classification of mixed phenotype acute leukemia (MPAL) should be based on the WHO 2008 criteria. Note that in ALL, myeloid-associated antigens such as CD13 and CD33 may be expressed, and the presence of these myeloid markers does not exclude the diagnosis of ALL, nor is it associated with adverse prognosis.”
- Footnote “d” modified: “While these guidelines pertain primarily to patients with leukemia, patients with lymphoblastic lymphoma (LL) (B- or T-cell) would likely also benefit from ALL-like regimens. There are limited data available regarding treatment options and Such patients should be treated in a center that has experience with LL. See Discussion.”
- Footnote “g” modified: “Cytogenetic risk groups for B-ALL are defined as follows: Good risk: Hyperdiploidy (51–65 chromosomes and/or DNA index >1.16; cases with trisomy of chromosomes 4, 10, and 17 appear to have the most favorable outcome); t(12;21)(p13;q22): ETV6-RUNX1; Poor risk: Hypodiploidy (<44 chromosomes and/or DNA index <0.81); t(v;11q23);t(4;11) and other MLL rearranged t(−;11q23); t(9;22) (q34;q11.2): BCR-ABL (defined as high risk in the pre-TKI era); complex karyotype (5 or more chromosomal abnormalities).” (also applies to ALL-5 and ALL-6)

**ALL-2**
- Bullet 5 modified: “CT/MRI of head with contrast, if neurologic symptoms.”
- Bullet 7 modified: “CT of chest (for patients with human T-ALL). CT of chest with IV contrast (for patients with T-ALL). For patients with a mediastinal mass, baseline PET imaging is also recommended.”
- Last bullet modified: “In patients with poor-risk features who lack a sibling donor, Consider early evaluation and search for an alternative donor.”

**ALL-3**
- Previous footnote with a link to the Response Criteria incorporated into the algorithm as “Response Assessment” with a link to ALL-E. (also applies to ALL-4, ALL-5, ALL-6)

**ALL-5**
- Treatment induction modified: “Pediatric-inspired (preferred) or other multiagent chemotherapy”
- Consolidation therapy modified: “Consider allogeneic HCT if a donor is available (especially MRD+; high WBC; or B-ALL with poor-risk cytogenetics)"

**ALL-6**
- Consolidation therapy modified: Consider allogeneic HCT if a donor is available (especially MRD+; high WBC; or B-ALL with poor-risk cytogenetics)

**ALL-7**
- Year 1; bullet 1: the following text added, “including testicular exam (where applicable).”
- Year 1; bullet 3; sub-bullet 1 modified: “If bone marrow aspirate is done: Flow cytometry with additional studies that may include comprehensive cytogenetics, FISH, and molecular testing Comprehensive cytogenetics, FISH, flow cytometry, and consideration of molecular tests”

**ALL-A**
- B-ALL with recurrent genetic abnormalities: “Hyperdiploidy (DNA index >1.16; 51–65 chromosomes without structural abnormalities): CD10+, CD19+, CD34+, CD45.”

**ALL-C 2 of 4**
- Gastroenterology: “Consider starting a bowel regimen to avoid constipation”
  - Sub-bullet deleted: “Docusate sodium daily.”
  - Sub-bullet deleted: “Laxatives promptly considered and used if symptoms arise.”
Hypersensitivity, Allergy, and Anaphylaxis

Sub-bullet 1 modified: “There is a significant incidence of hypersensitivity reactions with asparaginase products. Of particular concern are Grade 2 or higher systemic allergic reactions, urticaria or anaphylaxis, because these episodes are frequently can be (but are not necessarily) associated with neutralizing antibodies and lack of efficacy.”

Sub-bullet 2 modified: “Erwinia is commonly used as a second-line agent in patients who have developed a systemic allergic reaction or anaphylaxis due to PEG hypersensitivity.”

Sub-bullet 3 added: “Anaphylaxis or other allergic reactions of Grade 3-4 severity (CTCAE 4.0) merit permanent discontinuation of the type of asparaginase that caused the reaction.”

Sub-bullet 4 removed: “Reactions that are NOT associated with neutralizing antibodies (and therefore are NOT an indication to switch to Erwinia) include: 1) local injection-site reactions after IM administration; 2) Grade 1 IV infusion-related allergic reactions (ie, transient flushing or rash, drug fever <38°C; intervention not indicated); and 3) Grade 1 urticaria.”

New sub-bullet 4 added: “For Grade 1 reactions and Grade 2 reactions (rash, flushing, urticaria, and drug fever ≥38°C) without bronchospasm, hypotension, edema, or need for parenteral intervention, the asparaginase that caused the reaction may be continued, with consideration for anti-allergy premedication (such as hydrocortisone, diphenhydramine, and acetaminophen).”

Sub-bullet 5 modified: “If anti-allergy premedication with antihistamines or steroids is used prior to PEG or Erwinia administration, consideration should be given to therapeutic drug monitoring (TDM) using commercially available asparaginase activity assays, since premedication may “mask” the systemic allergic reactions that often can indicate the development of neutralizing antibodies.”

Protocols for AYA patients aged 15–39 years:

The following regimen added: EsPhALL regimen: imatinib; and a backbone of the Berlin-Frankford-Munster regimen.

Induction regimens for Ph-negative ALL

Category “Pediatric-inspired protocols for AYA patients aged 15–39 years” changed to “AYA patients aged 15-39 years” with 2 subcategories: “Pediatric-inspired protocols (preferred)” and “Other chemotherapy protocols showing equivalency reported for AYA patients.”

The following regimen added for “Other chemotherapy protocols reported for AYA patients”: Hyper-CVAD ± rituximab: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with or without rituximab for CD20-positive disease.”

Ph-positive ALL

Dasatinib and ponatinib listed as preferred.

Imatinib added as a preferred treatment option.

Bosutinib removed as a treatment option.

Bullet 6 added: The regimens listed below for Ph-negative ALL may be considered for Ph-positive ALL refractory to TKIs.

Ph-negative ALL:

Blinatumomab listed as preferred.

Footnote “i” removed: May be considered for Ph+ positive B-ALL, refractory to TKIs.

B-ALL added to clofarabine-containing regimens for clarification.
Updates in Version 1.2016 of the NCCN Guidelines for Acute Lymphoblastic Leukemia from Version 2.2015 include:

**ALL-D 4 of 4**
- References 13, 19-21, 29 are new to the page.

**ALL-E**
- Response Criteria for Blood and Bone Marrow
  - Sub-bullet modified under CR with incomplete blood count recovery (CRi): Recovery of platelets but <100,000 or ANC is <1000/microL. Meets all criteria for CR except platelet count and/or ANC
- Response Criteria for Mediastinal Disease
  - Bullet 1 added: CT of chest with IV contrast and PET imaging should be performed to assess response.
  - Bullet 2 modified: CR: Complete resolution of mediastinal enlargement by CT. For patients with a previous positive PET scan, a post-treatment residual mass of any size is considered a CR as long as it is PET negative.
  - Bullet deleted: CR Unconfirmed (CRu): Residual mediastinal enlargement that has regressed by >75% in the sum of the product of the greatest perpendicular diameters (SPD).
  - Bullet 3 modified: PR: >50% decrease in the sum of the product of the greatest perpendicular diameters (SPD) of the mediastinal enlargement. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.
  - Bullet 4 modified: PD: >25% increase in the SPD of the mediastinal enlargement. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.
  - Bullet 6 modified: Relapse: Recurrence of mediastinal enlargement after achieving CR or CRu. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.

**ALL-F**
- The following bullets were removed:
  - “Multicolor flow cytometry: sampling of bone marrow MNCs is preferred over peripheral blood samples; this requires at least 1 × 10⁶ MNCs for analysis (about 2 mL of bone marrow or 5–10 mL of peripheral blood provides a sufficient number of cells for multiple analysis).”
  - “RQ-PCR: sampling of bone marrow MNCs is preferred; this requires at least 1 × 10⁷ MNCs for initial marker characterization and generation of individual dilution series; 1 × 10⁶ MNCs are sufficient for follow-up analysis.”
  - “The minimal limit of assay sensitivity (to declare MRD negativity) should be <1 × 10⁻⁴ (<0.01%).”
  - “High-sensitivity PCR assays (for analysis of Ig or TCR gene rearrangements) require the identification of patient-specific markers that involve direct sequencing, and may therefore be labor- and resource-intensive for routine application in the clinical practice setting.”
  - “Recommendations on the minimal technical requirements for MRD assessment (both for PCR and flow cytometry methods) and definitions for response based on MRD results (eg, MRD negativity, non-quantifiable MRD positivity, quantifiable MRD positivity) have recently been published as a result of a consensus development meeting held by ALL study groups across Europe. The recommendations were made in an effort to standardize MRD measurements and MRD data reporting within the context of clinical trials.”
  - “MRD evaluations should be performed in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories with expertise in MRD assays; note that results from one lab to another may not be directly equivalent or comparable.”
Acute Lymphoblastic Leukemia

DIAGNOSIS

The diagnosis of ALL generally requires demonstration of ≥20% bone marrow lymphoblasts upon hematopathology review of bone marrow aspirate and biopsy materials, which includes:

- Morphologic assessment of Wright-Giemsa–stained bone marrow aspirate smears, and H&E–stained core biopsy and clot sections
- Comprehensive flow cytometric immunophenotyping

GENETIC CHARACTERIZATION

Optimal risk stratification and treatment planning requires testing marrow or peripheral blood lymphoblasts for specific recurrent genetic abnormalities using:

- Karyotyping of G-banded metaphase chromosomes (cytogenetics)
- Interphase fluorescence in situ hybridization (FISH) testing, including probes capable of detecting the major recurrent genetic abnormalities
- Reverse transcriptase-polymerase chain reaction (RT-PCR) testing for fusion genes (eg, BCR-ABL); other fusions that describe Ph-like ALL

Additional optional tests include:

- Additional assessment for hyperdiploidy and hypodiploidy

CLASSIFICATION

Together, these studies allow determination of the World Health Organization (WHO) ALL subtype and cytogenetic risk group

Strongly recommend that patients be treated in specialized centers

---

a Subtypes: B-cell lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities include hyperdiploidy, hypodiploidy, and commonly occurring translocations: t(9;22)(q34;q11.2)[BCR-ABL]; t(12;21)(p13;q22)[ETV6-RUNX1]; t(1;19)(q23;p13.3)[TCF3-PBX1]; t(5;14)(q31;q32)[IL3-IGH]; relatively rare. B-cell lymphoblastic leukemia/lymphoma, not otherwise specified. T-cell lymphoblastic leukemia/lymphoma.

b Criteria for classification of mixed phenotype acute leukemia (MPAL) should be based on the WHO 2008 criteria. Note that in ALL, myeloid-associated antigens such as CD13 and CD33 may be expressed, and the presence of these myeloid markers does not exclude the diagnosis of ALL, nor is it associated with adverse prognosis.


d While these guidelines pertain primarily to patients with leukemia, patients with lymphoblastic lymphoma (LL) (B- or T-cell) would likely also benefit from ALL-like regimens. Such patients should be treated in a center that has experience with LL. See Discussion.

e See Typical Immunophenotype by Major ALL Subtypes (ALL-A).

f For more information regarding Ph-like ALL, please see the Discussion.

g Cytogenetic risk groups for B-ALL are defined as follows: Good risk: Hyperdiploidy (51–65 chromosomes; cases with trisomy of chromosomes 4, 10, and 17 appear to have the most favorable outcome); t(12;21)(p13;q22): ETV6-RUNX1; Poor risk: Hypodiploidy (<44 chromosomes); t(4;11) and other MLL rearranged t(−;11q23); t(9;22)(q34;q11.2): BCR-ABL (defined as high risk in the pre-TKI era); complex karyotype (5 or more chromosomal abnormalities).

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**WORKUP**

- History and physical (H&P)
- Complete blood count (CBC), platelets, differential, chemistry profile
- Disseminated intravascular coagulation (DIC) panel: d-dimer, fibrinogen, prothrombin time (PT), partial thromboplastin time (PTT)
- Tumor lysis syndrome (TLS) panel: lactate dehydrogenase (LDH), uric acid, K, Ca, Phos (See Tumor Lysis Syndrome in the NCCN Guidelines for Non-Hodgkin’s Lymphomas)
- CT/MRI of head with contrast, if neurologic symptoms
- Lumbar puncture (LP)
  - See Evaluation and Treatment of Extramedullary Involvement (ALL-B)
  - Consider intrathecal (IT) chemotherapy
- CT of chest with IV contrast (for patients with T-ALL). For patients with a mediastinal mass, baseline PET imaging is also recommended.
- Testicular exam
- Infection evaluation:
  - Screen for active infections if febrile or for symptomatic opportunistic infections
  - Initiate empirical treatment, as appropriate (See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections)
- Echocardiogram or cardiac scan should be considered in all patients, since anthracyclines are important components of ALL therapy, but especially in patients with prior cardiac history and prior anthracycline exposure of clinical symptoms suggestive of cardiac dysfunction.
- Central venous access device of choice
- Human leukocyte antigen (HLA) typing (except for patients with a major contraindication to hematopoietic cell transplant [HCT])
- Consider early evaluation and search for an alternative donor

**RISK STRATIFICATION**

1. Ph+ ALL (AYA) (aged 15–39 y) → See Treatment (ALL-3)
2. Ph+ ALL (Adult) (aged ≥40 y) → See Treatment (ALL-4)
3. Ph- ALL (AYA) (aged 15–39 y) → See Treatment (ALL-5)
4. Ph- ALL (Adult) (aged ≥40 y) → See Treatment (ALL-6)

---

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
Ph+ ALL (AYA) (aged 15–39 y)\(^k, l\) → Clinical trial or Chemotherapy\(^o\) + tyrosine kinase inhibitor (TKI)\(^p\) → **Response Assessment (ALL-E)**

- Complete response (CR) → Monitoring for minimal residual disease (MRD)\(^q\)
- Less than CR → **See Relapse/Refractory Disease (ALL-7)**

---

**CONSOLIDATION THERAPY**

- Allogeneic HCT,\(^f\) if a donor is available or If allogeneic HCT is not available, continue multiagent chemotherapy\(^o\) + TKI\(^p\)
- Consider post-HCT TKI\(^p\) → **See Surveillance (ALL-7)**
- Maintenance therapy\(^o\) + TKI\(^p\) → **See Surveillance (ALL-7)**

---

\(^k\)Chronological age is a poor surrogate for fitness for therapy. Patients should be evaluated on an individual basis, including for the following factors: end-organ reserve, end-organ dysfunction, and performance status.

\(^l\)For additional considerations in the management of AYA patients with ALL, see the NCCN Guidelines for Adolescent and Young Adult Oncology.

\(^m\)All ALL treatment regimens include CNS prophylaxis.

\(^n\)See Principles of Supportive Care (ALL-C).

\(^o\)See Principles of Systemic Therapy (ALL-D).

\(^p\)See Discussion section for use of different TKIs in this setting.

\(^q\)See Minimal Residual Disease Assessment (ALL-F).


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
RISK
STRATIFICATION

Patients <65 years of age\(^k\) or with no substantial comorbidities

Clinical trial or Chemotherapy\(^o\)
+ TKI\(^p\)

Response Assessment (ALL-E)

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR

Less than CR

Less than CR

Less than CR

CR

CR

CR
### RISK STRATIFICATION

**Ph- ALL (AYA) (aged 15–39)**

- Clinical trial or Pediatric-inspired (preferred) or Other multiagent chemotherapy

<table>
<thead>
<tr>
<th>Clinical trial or Pediatric-inspired (preferred) or Other multiagent chemotherapy</th>
<th>Monitoring for MRDq</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>Continue multiagent chemotherapy (especially MRD-) or Consider allogeneic HCT (especially MRD+; high WBC; or B-ALL with poor-risk cytogenetics)</td>
</tr>
<tr>
<td>Less than CR</td>
<td>Maintenance therapy</td>
</tr>
</tbody>
</table>

**See Surveillance (ALL-7)**

**See Relapse/Refractory Disease (ALL-7)**

---

9. Cytogenetic risk groups for B-ALL are defined as follows:
   - **Good risk:** Hyperdiploidy (51–65 chromosomes; cases with trisomy of chromosomes 4, 10, and 17 appear to have the most favorable outcome); t(12;21)(p13;q22): **ETV6-RUNX1**; Poor risk: Hypodiploidy (<44 chromosomes); t(v;11q23):t(4;11) and other **MLL** rearranged t(−;11q23); t(9;22)(q34;q11.2): **BCR-ABL** (defined as high risk in the pre-TKI era); complex karyotype (5 or more chromosomal abnormalities).

**k** Chronic age is a poor surrogate for fitness for therapy. Patients should be evaluated on an individual basis, including for the following factors: end-organ reserve, end-organ dysfunction, and performance status.

**l** For additional considerations in the management of AYA patients with ALL, see the [NCCN Guidelines for Adolescent and Young Adult Oncology](https://www.nccn.org/professionals/physician_gls/pdf/adolescent.pdf).

**m** All ALL treatment regimens include CNS prophylaxis.

**n** [See Principles of Supportive Care (ALL-C)](https://www.nccn.org/professionals/physician_gls/pdf/adult_all_d.pdf).


**q** [See Principles of Systemic (ALL-D)](https://www.nccn.org/professionals/physician_gls/pdf/adult_all_d.pdf). All regimens include induction/delayed intensification (especially for pediatric-inspired regimens) and maintenance therapy.

**w** High WBC count (≥30 x 10^9/L for B lineage or ≥100 x 10^9/L for T lineage) is considered a high-risk factor based on some studies in ALL. Data demonstrating the effect of WBC counts on prognosis are less firmly established for adults than for the pediatric population.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
### Acute Lymphoblastic Leukemia

#### Risk Stratification

<table>
<thead>
<tr>
<th>Patients &lt;65 years of age (\text{or patients with no substantial comorbidities} )</th>
<th>Clinical trial or Multiagent chemotherapy (\text{or Corticosteroids} )</th>
<th><strong>Response Assessment (ALL-E)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients ≥65 years of age (\text{or patients with substantial comorbidities} )</td>
<td>Clinical trial or Multiagent chemotherapy (\text{or Corticosteroids} )</td>
<td><strong>Response Assessment (ALL-E)</strong></td>
</tr>
</tbody>
</table>

#### Treatment Induction

- **CR** → Monitoring for MRD
- Less than **CR**

#### Consolidation Therapy

- **CR** → Less than **CR**
- **Less than CR** → Chemotherapy \(\text{or Consider allogeneic HCT (especially MRD+; high WBC; } w \text{ or B-ALL with poor-risk cytogenetics)} \)

#### Maintenance Therapy

- **See Surveillance (ALL-7)**

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

---

*Cyto genetic risk groups for B-ALL are defined as follows:*

- **Good risk:** Hyperdiploidy (51–65 chromosomes; cases with trisomy of chromosomes 4, 10, and 17 appear to have the most favorable outcome); \(t(12;21)(p13;q22); ETV6-RUNX1\);
- **Poor risk:** Hypodiploidy (<44 chromosomes); \(t(v;11q23);t(4;11)\) and other \(MLL\) rearranged \(t(--;11q23); t(9;22)(q34;q11.2); BCR-ABL\) (defined as high risk in the pre-TKI era); complex karyotype (5 or more chromosomal abnormalities).

*Chronological age is a poor surrogate for fitness for therapy. Patients should be evaluated on an individual basis, including for the following factors: end-organ reserve, end-organ dysfunction, and performance status.*

*All ALL treatment regimens include CNS prophylaxis.*

*See Principles of Supportive Care (ALL-C).*

*See Principles of Systemic Therapy (ALL-D).*

*See Minimal Residual Disease Assessment (ALL-F).*

*For additional considerations in the management of older adult patients with ALL, see the NCCN Guidelines for Older Adult Oncology.*

*Allogeneic HCT may be considered based on performance status, comorbidities, availability of appropriate transplant donor, and transplant center expertise in treating older patients with allogeneic HCT.*

*See Principles of Systemic (ALL-D).* All regimens include induction/delayed intensification (especially for pediatric-inspired regimens) and maintenance therapy.

*High WBC count (≥30 x 10⁹/L for B lineage or ≥100 x 10⁹/L for T lineage) is considered a high-risk factor based on some studies in ALL. Data demonstrating the effect of WBC counts on prognosis is less firmly established for adults than for the pediatric population.*

---

Version 1.2016, 04/06/16 © National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
**SURVEILLANCE**

**Year 1 (every 1–2 months):**
- Physical exam, including testicular exam (where applicable), CBC with differential every month
- Liver function tests (LFTs) every 2 months until normal
- Bone marrow aspirate, cerebrospinal fluid (CSF), and echocardiogram as indicated
  - If bone marrow aspirate is done: Flow cytometry with additional studies that may include comprehensive cytogenetics, FISH, and molecular testing.

**Year 2:**
- Physical exam including testicular exam (where applicable), CBC with differential every 3 months

**Year 3+:**
- Physical exam including testicular exam (where applicable), CBC with differential every 6 months or as indicated

Refer to Survivorship recommendations in the [NCCN Guidelines for Adolescent and Young Adult Oncology](http://www.survivorshipguidelines.org/).

Refer to the ALL Long-term Follow-up Guidelines from Children's Oncology Group (COG):

**RELAPSE/REFRACTORY DISEASE**

**Year 1 (every 1–2 months):**
- Physical exam, including testicular exam (where applicable), CBC with differential every month
- Liver function tests (LFTs) every 2 months until normal
- Bone marrow aspirate, cerebrospinal fluid (CSF), and echocardiogram as indicated
  - If bone marrow aspirate is done: Flow cytometry with additional studies that may include comprehensive cytogenetics, FISH, and molecular testing.

**Year 2:**
- Physical exam including testicular exam (where applicable), CBC with differential every 3 months

**Year 3+:**
- Physical exam including testicular exam (where applicable), CBC with differential every 6 months or as indicated

Refer to Survivorship recommendations in the [NCCN Guidelines for Adolescent and Young Adult Oncology](http://www.survivorshipguidelines.org/).

**TREATMENT**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Treatment Options</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ph+ ALL (AYA &amp; Adult)</strong></td>
<td>Consider ABL gene mutation testing&lt;sup&gt;aa&lt;/sup&gt; or chemotherapya&lt;sup&gt;b&lt;/sup&gt; or Allogeneic HCT&lt;sup&gt;cc&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Ph- ALL (AYA &amp; Adult)</strong></td>
<td>Consider clinical trial or Allogeneic HCT&lt;sup&gt;cc&lt;/sup&gt; or Chemotherapy&lt;sup&gt;b,bd&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>Relapse/refractory</strong>&lt;sup&gt;y,z&lt;/sup&gt;</td>
<td>Consider clinical trial or Allogeneic HCT&lt;sup&gt;cc&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

<sup>o</sup>See [Discussion section](#) for use of different TKIs in this setting.

<sup>x</sup>Surveillance recommendations apply after completion of chemotherapy, including maintenance.

<sup>y</sup>Isolated extramedullary relapse (both CNS and testicular) requires systemic therapy to prevent relapse in marrow.

<sup>z</sup>See [NCCN Guidelines for Palliative Care](http://www.survivorshipguidelines.org/).

<sup>aa</sup>See Treatment Options Based on *BCR-ABL* Kinase Domain Mutation Status (ALL-D 3 of 4).

<sup>b</sup>See Principles of Chemotherapy (ALL-D 3 of 4). Nelarabine is available for patients with relapsed T-ALL/lymphoblastic lymphoma. Clofarabine is available for patients age ≤21 y with relapsed or refractory ALL after at least 2 prior regimens. Vincristine sulfate liposome injection is available for adult patients with Ph- ALL in ≥ second relapse or disease progression after ≥2 therapies.

<sup>cc</sup>For patients with relapsed disease after allogeneic HCT, a second allogeneic HCT and/or donor lymphocyte infusion (DLI) can be considered.

<sup>bd</sup>For AYA patients in late relapse (>3 years from initial diagnosis), consider treatment with the same induction regimen (See ALL-D 2 of 4).
TYPICAL IMMUNOPHENOTYPE BY MAJOR ALL SUBTYPES\textsuperscript{1,2}

The initial immunophenotyping panel should be sufficiently comprehensive to establish a leukemia-associated phenotype (LAP) that may include expression of non-lineage antigens. These LAPs are useful in classification, particularly mixed-lineage leukemias, and as a signature for MRD detection.

B-ALL, not otherwise specified: CD10+, CD19+, CD79a+, cCD22+, sCD22+, CD24+, PAX5+, TdT+, variable CD20, variable CD34
• Early precursor B-ALL (pro-B-ALL): CD10−, CD19+, cCD79a+, cCD22+, TdT+
• Common B-ALL: CD10+
• Precursor B-ALL (pre-B-ALL): cytoplasmic μ+, slg-, CD10+/-

B-ALL with recurrent genetic abnormalities:
• Hyperdiploidy (51–65 chromosomes without structural abnormalities): CD10+, CD19+, CD34+, CD45-
• Hypodiploidy (<44 chromosomes): CD10+, CD19+, CD34+
• t(9;22)(q34;q11.2); BCR-ABL1: CD10+, CD19+, TdT+, CD13+, CD33+, CD117-
• t(v;11q23); MLL rearranged: CD10−, CD19+, CD24−, CD15+
• t(12;21)(p13;q22); TEL-AML1: CD10+, CD19+, TdT+, CD13+, CD34+
• t(1;19)(q23;p13.3); E2A-PBX1: CD10+, CD19+, CD20 variable, CD34 -/+ , cytoplasmic μ+
• t(5;14)(q31;q32); IL3-Igh: CD10+, CD19+

T-ALL: TdT+, variable for all of the following: CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD34
• Pro-T-ALL: cCD3+, CD7+, CD1a−, CD2−, CD4−, CD8−, CD34+−
• Pre-T-ALL: cCD3+, CD7+, CD1a−, CD2+, CD4−, CD8−, CD34+−
• Cortical T-ALL: cCD3+, CD7+, CD1a+, CD2+, CD4+, CD8−, CD34−
• Medullary T-ALL: cCD3+, sCD3+, CD7+, CD1a−, CD2−, CD4+ or CD8+, CD34−
• ETP T-ALL: Lack of CD1a and CD8 expression, weak CD5 expression with less than 75% positive blasts, and expression of one or more of the following myeloid or stem cell markers on at least 25% of lymphoblasts: CD117, CD34, HLA-DR, CD13, CD33, CD11b, and/or CD65


\textsuperscript{1}Criteria for classification of mixed phenotype acute leukemia (MPAL) should be based on the WHO 2008 criteria. Note that in ALL, myeloid-associated antigens such as CD13 and CD33 may be expressed, and the presence of these myeloid markers does not exclude the diagnosis of ALL.

\textsuperscript{2}Treatment of Burkitt leukaemia/lymphoma – see NCCN Guidelines for Non-Hodgkin’s Lymphomas.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
EVALUATION AND TREATMENT OF EXTRAMEDULLARY INVOLVEMENT

• Given the risks of neurotoxicity associated with central nervous system (CNS)-directed therapy, baseline and post-treatment comprehensive neuropsychological testing may be useful.

• The aim of CNS prophylaxis and/or treatment is to clear leukemic cells within sites that cannot be readily accessed by systemic chemotherapy due to the blood-brain barrier, with the overall goal of preventing CNS disease or relapse.

• Factors associated with increased risks for CNS leukemia in adults include mature B-cell immunophenotype, T-cell immunophenotype, high presenting WBC counts, and elevated serum LDH levels.1,2

• CNS involvement should be evaluated (by LP) at the appropriate timing:
  - Timing of LP should be consistent with the chosen treatment regimen.
  - Pediatric-inspired regimens typically include LP at the time of diagnostic workup.
  - The panel recommends that LP, if performed, be done concomitantly with initial IT therapy.

• Classification of CNS status:
  - CNS-1: No lymphoblasts in CSF regardless of WBC count.
  - CNS-2: WBC <5/mcL in CSF with presence of lymphoblasts.
  - CNS-3: WBC ≥5/mcL in CSF with presence of lymphoblasts.
  - If the patient has leukemic cells in the peripheral blood and the LP is traumatic and WBC ≥5/mcL in CSF with blasts, then compare the CSF WBC/RBC ratio to the blood WBC/RBC ratio. If the CSF ratio is at least two-fold greater than the blood ratio, then the classification is CNS-3; if not, then it is CNS-2.

• All patients with ALL should receive CNS prophylaxis. Although the presence of CNS involvement at the time of diagnosis is uncommon (about 3%–7%), a substantial proportion of patients (>50%) will eventually develop CNS leukemia in the absence of CNS-directed therapy.

• CNS-directed therapy may include cranial irradiation, IT chemotherapy (eg, methotrexate, cytarabine, corticosteroids), and/or systemic chemotherapy (eg, methotrexate, cytarabine, mercaptopurine, pegaspargase).

• CNS leukemia (CNS-3 and/or cranial nerve involvement) at diagnosis typically warrants treatment with cranial irradiation of 18 Gy. The recommended dose of radiation, where given, is highly dependent on the intensity of systemic chemotherapy; thus, it is critical to adhere to a given treatment protocol in its entirety. The entire brain and posterior half of the globe should be included. The inferior border should be below C2.

• Note that areas of the brain targeted by the radiation field in the management of ALL are different from areas targeted for brain metastases of solid tumors.

• With the incorporation of adequate systemic chemotherapy (eg, high-dose methotrexate, cytarabine) and IT chemotherapy regimens (eg, methotrexate alone or with cytarabine and a corticosteroid, which constitutes the triple IT regimen), it may be possible to avoid the use of upfront cranial irradiation except in cases of overt CNS leukemia at diagnosis, and to reserve the use of irradiation for relapsed/refractory therapy settings.

• Adequate systemic therapy should be given in the management of isolated CNS relapse.

• Patients with clinical evidence of testicular disease at diagnosis that is not fully resolved by the end of the induction therapy should be considered for radiation to the testes in the scrotal sac, which is typically done concurrently with the first cycle of maintenance chemotherapy. Testicular total dose should be 24 Gy.

Best supportive care

• Infection control (See NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections)

  ▶ Prophylactic anti-infectives
    ◊ Antibacterial prophylaxis: consider fluoroquinolones
    ◊ Antiviral prophylaxis: HSV prophylaxis; VZV prophylaxis for at least 1 year after HCT in transplant patients; and HBV prophylaxis for at least 6–12 months after HCT depending on HBV serology.
    ◊ Cytomegalovirus (CMV) reactivation management: Consider CMV monitoring and pre-emptive therapy for all patients; for patients undergoing allogeneic HCT, CMV monitoring and pre-emptive therapy are strongly recommended until at least 6 months after transplantation.
    ◊ Antifungal prophylaxis: Consider prophylaxis for all patients treated with chemotherapy; for patients undergoing allogeneic HCT, antifungal prophylaxis is strongly recommended until at least day 75 after transplantation.
    ◊ Pneumocystis pneumonia (PCP) prophylaxis

  ▶ Heightened awareness for risk of sepsis/death due to steroid therapy and neutropenia

  ▶ Febrile neutropenia management
    ◊ Fever is defined as a single temperature ≥38.3 °C (101°F) or ≥38.0 °C (100.4°F) over a 1-hour period
    ◊ IV antibiotics/inpatient admission

• Acute TLS (See Tumor Lysis Syndrome in the NCCN Guidelines for Non-Hodgkin’s Lymphomas)

• Pegaspargase Toxicity Management — see ALL-C 3 of 4 and ALL-C 4 of 4

• Methotrexate and Glucarpidase
  ▶ Consider use of glucarpidase if significant renal dysfunction and methotrexate levels are >10 microM beyond 42–48 h. Leucovorin remains a component in the treatment of methotrexate toxicity and should be continued for at least 2 days following glucarpidase administration. However, be aware that leucovorin is a substrate for glucarpidase, and therefore should not be administered within two hours prior to or following glucarpidase.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
SUPPORTIVE CARE (2 of 4)

• Steroid management
  ▸ Acute side effects
    ◊ Steroid-induced diabetes mellitus
      – Tight glucose control using sliding scale insulin to decrease infection complications
    ◊ Steroid-induced psychosis and mood alteration
      – Consider dose reduction
    ◊ Use of a histamine-2 antagonist or proton pump inhibitor (PPI)\(^1\) is recommended during steroid therapy
      – There are significant interactions between PPIs and TKIs regarding the bioavailability of certain BCR-ABL TKIs with gastric acid suppression that should be considered.
  ▸ Long-term side effects of corticosteroids
    ◊ Osteonecrosis/avascular necrosis (also see Discussion)
      – Obtain vitamin D and calcium status and replete as needed
      – Consider radiographic evaluation with plain films or MRI or bone density study

• Transfusions
  ▸ Products should be irradiated

• Use of granulocyte colony-stimulating factor (G-CSF)
  ▸ Recommended for myelosuppressive blocks of therapy or as directed by treatment protocol

• Hyperleukocytosis
  ▸ Although uncommon in patients with ALL, symptomatic hyperleukocytosis may require emergent treatment (See Symptomatic Leukocytosis in the NCCN Guidelines for Acute Myeloid Leukemia)

• Antiemetics (See NCCN Guidelines for Antiemesis)
  ▸ Given as needed prior to chemotherapy and post chemotherapy
  ▸ Routine use of corticosteroids as antiemetics are avoided

• Gastroenterology
  ▸ Consider starting a bowel regimen to avoid constipation

• Nutritional support
  ▸ Consider enteral or parenteral support for >10% weight loss

• Palliative treatment for pain (See NCCN Guidelines for Cancer Pain)

\(^1\)There may be important drug interactions with methotrexate that need to be considered prior to initiation of methotrexate-based therapy.
SUPPORTIVE CARE (3 of 4)
ASPARAGINASE TOXICITY MANAGEMENT

• There are two formulations of asparaginase in clinical use: 1) Pegasparagase (PEG); and 2) asparaginase Erwinia chrysanthemi (Erwinia). PEG is a common component of therapy for children, adolescents, and young adults with ALL. Both agents can be given intramuscularly (IM) or intravenously (IV); the IV route is increasingly being used. The toxicity profile of both asparaginase products presents significant challenges in clinical management. The following guidelines are intended to help providers address these challenges.


Hypersensitivity, Allergy, and Anaphylaxis

• There is a significant incidence of hypersensitivity reactions with asparaginase products. Of particular concern are Grade 2 or higher systemic allergic reactions, urticaria, or anaphylaxis, because these episodes can be (but are not necessarily) associated with neutralizing antibodies and lack of efficacy.

• Erwinia is commonly used as a second-line agent in patients who have developed a systemic allergic reaction or anaphylaxis due to PEG hypersensitivity.

• Anaphylaxis or other allergic reactions of Grade 3-4 severity (CTCAE 4.0) merit permanent discontinuation of the type of asparaginase that caused the reaction.

• For Grade 1 reactions and Grade 2 reactions (rash, flushing, urticaria, and drug fever ≥38°C) without bronchospasm, hypotension, edema, or need for parenteral intervention, the asparaginase that caused the reaction may be continued, with consideration for anti-allergy premedication (such as hydrocortisone, diphenhydramine, and acetaminophen).

• If anti-allergy premedication is used prior to PEG or Erwinia administration, consideration should be given to therapeutic drug monitoring (TDM) using commercially available asparaginase activity assays, since premedication may “mask” the systemic allergic reactions that can indicate the development of neutralizing antibodies.1


Continued on ALL-C 4 of 4
SUPPORTIVE CARE (4 of 4)

ASPARAGINASE TOXICITY MANAGEMENT

Pancreatitis
• Permanently discontinue asparaginase in the presence of Grade 3 or 4 pancreatitis. In the case of Grade 2 pancreatitis (enzyme elevation or radiologic findings only), asparaginase should be held until these findings normalize and then resume.

Non-CNS Hemorrhage
• For Grade 2 or greater hemorrhage, hold asparaginase until Grade 1, then resume. Consider coagulation factor replacement. Do not hold for asymptomatic abnormal laboratory investigations.

Non-CNS Thromboembolism
• For Grade 2 or greater thromboembolic event, hold asparaginase until resolved and treat with appropriate antithrombotic therapy. Upon resolution of symptoms and antithrombotic therapy stable or completed, consider resuming asparaginase.

Intracranial Hemorrhage
• Discontinue asparaginase. Consider coagulation factor replacement. For Grade 3 or less, if symptoms/signs fully resolve, consider resuming asparaginase at lower doses and/or longer intervals between doses. For Grade 4, permanently discontinue asparaginase.

Cerebral Thrombosis, Ischemia, or Stroke
• Discontinue asparaginase. Consider antithrombotic therapy. For Grade 3 or less, if symptoms/signs fully resolve, consider resuming asparaginase at lower doses and/or longer intervals between doses. For Grade 4, permanently discontinue asparaginase.

Hyperglycemia
• Treat hyperglycemia with insulin as indicated. For Grade 3 or higher, hold asparaginase and steroids until blood glucose has been regulated with insulin, then resume.

Hypertriglyceridemia
• Treat hypertriglyceridemia as indicated. For Grade 4, hold asparaginase until normalized, then resume.

Hepatotoxicity (elevation in bilirubin, AST, ALT)
• For direct bilirubin ≤3.0 mg/dL, continue asparaginase. For direct bilirubin 3.1–5.0 mg/dL, hold asparaginase until <2.0 mg/dL, then resume. For direct bilirubin >5.0, either discontinue asparaginase or hold asparaginase until <2.0 mg/dL, then resume with very close monitoring.
• For Grade 3 AST or ALT elevation, hold until Grade 1, then resume. For Grade 4 AST or ALT elevation, hold until Grade 1. If resolution to Grade 1 takes 1 week or less, then resume. Otherwise, either discontinue or resume with very close monitoring.
PRINCIPLES OF SYSTEMIC THERAPY (1 of 4)

INDUCTION REGIMENS FOR Ph-POSITIVE ALL\textsuperscript{a}

**Adult patients aged ≥40 years:**
- TKIs + hyper-CVAD: imatinib or dasatinib; and hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate, and cytarabine\textsuperscript{1−4}
- TKIs + multiagent chemotherapy: imatinib; and daunorubicin, vincristine, prednisone, and cyclophosphamide\textsuperscript{5,6}
- TKIs (imatinib or dasatinib)\textsuperscript{7,8,9} + corticosteroids
- TKIs + vincristine + dexamethasone\textsuperscript{10,11}

**Protocols for AYA patients aged 15–39 years:**
- COG AALL-0031 regimen: vincristine, prednisone (or dexamethasone), and pegaspargase, with or without daunomycin; or prednisone (or dexamethasone) and pegaspargase with or without daunomycin; imatinib added during consolidation blocks\textsuperscript{12}
- EsPhALL regimen: imatinib; and a backbone of the Berlin-Frankford-Munster regimen\textsuperscript{13}
- TKIs + hyper-CVAD: imatinib or dasatinib; and hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate, and cytarabine\textsuperscript{1−4}
- TKIs + multiagent chemotherapy: imatinib; and daunorubicin, vincristine, prednisone, and cyclophosphamide\textsuperscript{5,6}

**Maintenance regimens:**
- Add TKIs (imatinib or dasatinib) to maintenance regimen
- Monthly vincristine/prednisone pulses (for 2–3 years). May include weekly methotrexate + daily 6-mercaptopurine (6-MP) as tolerated\textsuperscript{b,c}

\textsuperscript{a}All regimens include CNS prophylaxis with systemic therapy (eg, methotrexate, cytarabine, 6-mercaptopurine) and/or IT therapy (eg, IT methotrexate, IT cytarabine; triple IT therapy with methotrexate, cytarabine, corticosteroid).
\textsuperscript{b}For patients receiving 6-MP, consider testing for TPMT gene polymorphisms, particularly in patients who develop severe neutropenia after starting 6-MP.
\textsuperscript{c}Dose modifications for antimetabolites in maintenance should be consistent with the chosen treatment regimen. It may be necessary to reduce dose/eliminate antimetabolite in the setting of myelosuppression and/or hepatotoxicity.
INDUCTION REGIMENS FOR Ph-NEGATIVE ALL\(^a\)

**Adult patients aged ≥40 years:**
- CALGB 8811 Larson regimen: daunorubicin, vincristine, prednisone, pegaspargase, and cyclophosphamide; for patients aged ≥60 years, reduced doses for cyclophosphamide, daunorubicin, and prednisone\(^{14}\)
- Linker 4-drug regimen: daunorubicin, vincristine, prednisone, and pegaspargase\(^{15}\)
- Hyper-CVAD ± rituximab: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with or without rituximab for CD20-positive disease\(^{16,17}\)
- MRC UKALLXII/ECOG2993 regimen: daunorubicin, vincristine, prednisone, and pegaspargase (induction phase I); and cyclophosphamide, cytarabine, and 6-MP\(^b\) (induction phase II)\(^{18}\)

**AYA patients aged 15–39 years:**
- Pediatric-inspired protocols (preferred)
  - CALGB 10403 regimen: daunorubicin, vincristine, prednisone, and pegaspargase (ongoing study in patients aged <40 years)\(^{19}\)
  - COG AALL0232 regimen: daunorubicin, vincristine, prednisone, and pegaspargase (patients aged ≤21 years)\(^{20}\)
  - COG AALL0434 regimen with nelarabine (for T-ALL): daunorubicin, vincristine, prednisone, and pegaspargase; nelarabine added to consolidation regimen\(^{21}\)
  - DFCI ALL regimen based on DFCI Protocol 00-01: doxorubicin, vincristine, prednisone, high-dose methotrexate, and pegaspargase (ongoing study in patients aged <50 years)\(^{22}\)
  - USC ALL regimen based on CCG-1882 regimen: daunorubicin, vincristine, prednisone, and methotrexate with augmented pegaspargase (patients aged 18–57 years)\(^{23}\)
  - GRAALL-2003 regimen: daunorubicin, vincristine, prednisone, pegaspargase, and cyclophosphamide (patients aged <60 years)\(^{24}\)
  - PETHEMA ALL-96 regimen: daunorubicin, vincristine, prednisone, pegaspargase, and cyclophosphamide (patients aged <30 years)\(^{25}\)
- Other chemotherapy protocols reported for AYA patients:
  - Hyper-CVAD ± rituximab: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with or without rituximab for CD20-positive disease\(^{17}\)

**Maintenance regimen:**
- Weekly methotrexate + daily 6-MP\(^b\) + monthly vincristine/prednisone pulses (for 2–3 years)

\(^a\)All regimens include CNS prophylaxis with systemic therapy (eg, methotrexate, cytarabine, 6-mercaptopurine) and/or IT therapy (eg, IT methotrexate, IT cytarabine; triple IT therapy with methotrexate, cytarabine, corticosteroid).

\(^b\)For patients receiving 6-MP, consider testing for TPMT gene polymorphisms, particularly in patients who develop severe neutropenia after starting 6-MP.
PRINCIPLES OF SYSTEMIC THERAPY (3 of 4)

REGIMENS FOR RELAPSED OR REFRACTORY ALL

**Ph-positive ALL:**
- Dasatinib, Ponatinib, Imatinib, and Nilotinib (preferred)
- The TKIs noted above may also be used in combination with any of the induction regimens noted on ALL-D 1 of 4 that were not previously given.
- The regimens listed below for Ph-negative ALL may be considered for Ph-positive ALL refractory to TKIs.

**Ph-negative ALL:**
- Blinatumomab (for B-ALL) (preferred)
- Cytarabine-containing regimens
- Alkylator combination regimens
- Nelarabine (for T-ALL)
- Augmented hyper-CVAD: hyper-fractionated cyclophosphamide, intensified vincristine, doxorubicin, intensified dexamethasone, and pegaspargase; alternating with high-dose methotrexate and cytarabine
- Vincristine sulfate liposome injection (VSLI)
- Clofarabine-containing regimens (for B-ALL)

**References (ALL-D 4 of 4)**

**REGIMENS FOR RELAPSED OR REFRACTORY ALL**

- Dasatinib, Ponatinib, Imatinib, and Nilotinib (preferred)
- The TKIs noted above may also be used in combination with any of the induction regimens noted on ALL-D 1 of 4 that were not previously given.
- The regimens listed below for Ph-negative ALL may be considered for Ph-positive ALL refractory to TKIs.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**NCCN Guidelines Version 1.2016**

**Acute Lymphoblastic Leukemia**

---

### RESPONSE ASSESSMENT

**Response Criteria for Blood and Bone Marrow:**

- **CR**
  - No circulating blasts or extramedullary disease
    - No lymphadenopathy, splenomegaly, skin/gum infiltration/testicular mass/CNS involvement
  - Trilineage hematopoiesis (TLH) and <5% blasts
  - Absolute neutrophil count (ANC) >1000/microL
  - Platelets >100,000/microL
  - No recurrence for 4 weeks

- **CR with incomplete blood count recovery (CRI)**
  - Meets all criteria for CR except platelet count and/or ANC

- **Overall response rate (ORR = CR + CRI)**

- **Refractory disease**
  - Failure to achieve CR at the end of induction

- **Progressive disease (PD)**
  - Increase of at least 25% in the absolute number of circulating or bone marrow blasts or development of extramedullary disease

- **Relapsed disease**
  - Reappearance of blasts in the blood or bone marrow (>5%) or in any extramedullary site after a CR

**Response Criteria for CNS Disease:**

- **CNS remission:** Achievement of CNS-1 status (see ALL-C) in a patient with CNS-2 or CNS-3 status at diagnosis.

- **CNS relapse:** New development of CNS-3 status or clinical signs of CNS leukemia such as facial nerve palsy, brain/eye involvement, or hypothalamic syndrome.

**Response Criteria for Mediastinal Disease:**

- **CT of chest with IV contrast and PET imaging should be performed to assess response.**

- **CR:** Complete resolution of mediastinal enlargement by CT. For patients with a previous positive PET scan, a post-treatment residual mass of any size is considered a CR as long as it is PET negative.

- **PR:** >50% decrease in the sum of the product of the greatest perpendicular diameters (SPD) of the mediastinal enlargement. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.

- **PD:** >25% increase in the SPD of the mediastinal enlargement. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.

- **No Response (NR):** Failure to qualify for PR or PD.

- **Relapse:** Recurrence of mediastinal enlargement after achieving CR. For patients with a previous positive PET scan, post-treatment PET must be positive in at least one previously involved site.

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
MINIMAL RESIDUAL DISEASE ASSESSMENT

• MRD in ALL refers to the presence of leukemic cells below the threshold of detection by conventional morphologic methods. Patients who achieved a CR by morphologic assessment alone can potentially harbor a large number of leukemic cells in the bone marrow.
• MRD is an essential component of patient evaluation over the course of sequential therapy. If patient is not treated in an academic center, there are commercially available tests available for MRD assessment.
• Studies in both children and adults with ALL have demonstrated the strong correlation between MRD and risks for relapse, as well as the prognostic significance of MRD measurements during and after initial induction therapy.
• The most frequently employed methods for MRD assessment include multicolor flow cytometry to detect abnormal immunophenotypes and real-time quantitative polymerase chain reaction (RQ-PCR) assays to detect fusion genes (eg, **BCR-ABL1**), clonal rearrangements in immunoglobulin (Ig) heavy chain genes, and/or T-cell receptor (TCR) genes.
• Current multicolor flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of \( <1 \times 10^{-4} \) (<0.01%) bone resists (MNCs).1,2 The concordance rate for detecting MRD between these methods is generally high. The combined or tandem use of both methods allows for MRD monitoring in all patients, thereby avoiding potential false-negative results.

 Timing of MRD assessment:
  ◊ Upon completion of initial induction.
  ◊ Additional time points may be useful depending on the regimen used.

---

Acute Lymphoblastic Leukemia

Discussion
This discussion is being updated to correspond with the newly updated algorithm. Last updated 09/22/15

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ................................................................. MS-2
Literature Search Criteria and Guidelines Update Methodology MS-3
Diagnosis ................................................................. MS-3
   Clinical Presentation and Diagnosis ........................ MS-3
   Immunophenotyping ............................................. MS-4
   Cytogenetic and Molecular Subtypes ....................... MS-5
      Table 1: Common Chromosomal and Molecular
      Abnormalities in Acute Lymphoblastic Leukemia .... MS-7
Workup ................................................................. MS-7
Prognostic Factors and Risk Stratification ................. MS-8
   Prognostic Factors in AYA Patients with ALL .......... MS-8
   Prognostic Factors in Adults with ALL ................. MS-9
   NCCN Recommendations for Risk Assessment in ALL .... MS-11
Overview of Treatment Phases in ALL Management .... MS-11
   Induction ........................................................ MS-12
   CNS Prophylaxis and Treatment ............................. MS-12
   Consolidation .................................................. MS-13
   Maintenance .................................................... MS-13
   Targeted Agents ............................................... MS-14
Management of Ph-Positive ALL ........................... MS-14
   Initial Treatment in AYA Patients with Ph-Positive ALL MS-14
   Initial Treatment in Adults with Ph-Positive ALL .... MS-16
   Treatment of Relapsed Ph-Positive ALL ................ MS-21
   NCCN Recommendations for Ph-Positive ALL .......... MS-24
Management of Ph-Negative ALL ............................ MS-26
   Initial Treatment in AYAs with Ph-Negative ALL ...... MS-26
   Initial Treatment in Adults with Ph-Negative ALL .... MS-31
   Treatment of Relapsed Ph-Negative ALL ............. MS-33
   NCCN Recommendations for Ph-Negative ALL ....... MS-39
Evaluation and Treatment of Extramedullary Disease MS-41
   CNS Involvement in ALL .................................. MS-41
      NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement MS-41
Response Assessment and Surveillance ..................... MS-42
   Response Criteria ............................................ MS-42
   Surveillance .................................................... MS-43
Role of MRD Evaluation ......................................... MS-43
   MRD Assessment in Childhood ALL ..................... MS-44
   MRD Assessment in Adult ALL ............................ MS-47
   NCCN Recommendations for MRD Assessment .... MS-43
Supportive Care for Patients with ALL ..................... MS-50
   NCCN Recommendations for Supportive Care .... MS-50
References .......................................................... MS-55
Overview

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)–positive and Ph-negative ALL for both adolescent and young adult (AYA) and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL.

ALL is a heterogeneous hematologic disease characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs. The age-adjusted incidence rate of ALL in the United States is 1.77 per 100,000 individuals per year, with approximately 6250 new cases and 1450 deaths estimated in 2015. The median age at diagnosis for ALL is 14 years with 58.8% of patients diagnosed at younger than 20 years of age. In contrast, 25.5% of cases are diagnosed at 45 years or older and only approximately 11% of patients are diagnosed at 65 years or older. ALL represents 75% to 80% of acute leukemias among children, making it the most common form of childhood leukemia; by contrast, ALL represents approximately 20% of all leukemias among adults.

Risk factors for developing ALL include older age (>70 years), exposure to chemotherapy or radiation therapy, and genetic disorders, particularly Down syndrome. Although rare, other genetic conditions have been categorized as a risk factor for ALL and include neurofibromatosis, Klinefelter syndrome, Fanconi anemia, Shwachman syndrome, Bloom syndrome, and ataxia telangiectasia. The cure rates and survival outcomes for patients with ALL have improved dramatically over the past several decades, primarily among children. Improvements are largely owed to advances in the understanding of the molecular genetics and pathogenesis of the disease, the incorporation of risk-adapted therapy, and the advent of new targeted agents. Data from the SEER database have shown a 5-year overall survival (OS) of 86% to 89% for children; however, AYA patients were reported to have a 5-year OS between 42% to 63% depending on the age range. Adults have the poorest 5-year OS rate of 24.1% for patients between the ages of 40 and 59 years and an even lower rate of 17.7% for patients between the ages of 60 and 69 years. Although the exact OS percentage can vary based on how the age range is defined for pediatric, AYA, and adult patients, the trend is nonetheless clear that OS decreases substantially with increased age. The exception is infants younger than age 1, which is an age group that has not seen any improvement in survival over the last 30 years. The 5-year OS in this population is 55.8% (see Cytogenetic and Molecular Subtypes in this Discussion). Cure rates for AYAs with ALL remain suboptimal compared with those for children, although substantial improvements have been seen with the recent adoption of pediatric treatment regimens. AYA patients represent a unique population, because they may receive treatment based on either a pediatric or an adult protocol, depending on local referral patterns and institutional practices. Favorable cytogenetic subtypes, such as ETV6-RUNX1 ALL and hyperploidy, occur less frequently among AYA patients compared...
with children, whereas the incidence of ALL with $BCR-ABL$ (Ph-positive ALL) is higher in AYA patients.

**Literature Search Criteria and Guidelines Update Methodology**

Prior to the update of this version of the NCCN Guidelines for Acute Lymphoblastic Leukemia, an electronic search of the PubMed database was performed to obtain key literature published between January 1, 2014 and December 3, 2014, using the following search term: acute lymphoblastic leukemia. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes only peer-reviewed biomedical literature.

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, II; Clinical Trial, III; Clinical Trial, IV; Guideline; Meta-Analysis; Randomized Controlled Trial; Systematic Reviews; and Validation Studies.

The PubMed search resulted in 141 citations and their potential relevance was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available on the NCCN webpage.

**Diagnosis**

**Clinical Presentation and Diagnosis**

The clinical presentation of ALL is typically nonspecific, and may include fatigue or lethargy, constitutional symptoms (eg, fevers, night sweats, weight loss), dyspnea, dizziness, infections, and easy bruising or bleeding. Among children, pain in the extremities or joints may be the only presenting symptom. The presence of lymphadenopathy, splenomegaly, and/or hepatomegaly on physical examination may be found in approximately 20% of patients. Abdominal masses from gastrointestinal involvement, or chin numbness resulting from cranial nerve involvement, are more suggestive of mature B-cell ALL.

The diagnosis of ALL generally requires demonstration of 20% or greater bone marrow lymphoblasts on hematopathology review of bone marrow aspirate and biopsy materials. The 2008 WHO classification lists ALL and lymphoblastic lymphoma as the same entity, distinguished only by the primary location of the disease. When the disease is restricted to a mass lesion primarily involving nodal or extranodal sites with no or minimal involvement in blood or bone marrow (generally defined as <20% lymphoblasts in the marrow), the case would be consistent with a diagnosis of lymphoblastic lymphoma.

Lymphoblastic lymphoma was previously categorized with non-Hodgkin lymphomas and is associated with exposure to radiation or pesticide and congenital or acquired immunosuppression. However, based on morphologic, genetic, and immunophenotypic features, lymphoblastic lymphoma is indistinguishable from ALL.

Patients with lymphoblastic lymphoma generally benefit from treatment with ALL-like regimens. Chemotherapy should be initiated as soon as possible; combination chemotherapy has shown improved response though relapse is common. Studies show a 5-year disease-free
In children and between 55% and 95% in adults following a regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other CHOP-like regimens. Hyper-CVAD (cycles of fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of high-dose methotrexate and cytarabine) is also a common regimen used for lymphoblastic lymphoma. A response rate of 100% was seen in a singular study, with 91% of patients achieving a complete response (CR) and a 3-year progression-free survival (PFS) of 66%. However, it should be noted that 40% to 60% of adults relapse, suggesting that other treatments including hematopoietic cell transplantation (HCT) may be warranted.

Hematopathology evaluations should include morphologic examination of malignant lymphocytes using Wright-Giemsa–stained slides and hematoxylin and eosin–stained core biopsy and clot sections; comprehensive immunophenotyping with flow cytometry (see Immunophenotyping in this Discussion); and assessment of cytogenetic or molecular abnormalities. Identification of specific recurrent genetic abnormalities is critical for disease evaluation, optimal risk stratification, and treatment planning (see Cytogenetic and Molecular Subtypes in this Discussion). Subtypes of B-cell ALL with recurrent genetic abnormalities include the following: hyperdiploidy (DNA index >1.16; 51–65 chromosomes); hypodiploidy (<44 chromosomes); t(9;22)(q34;q11.2), BCR-ABL1; t(v;11q23), MLL rearrangement; t(12;21)(p13;q22), ETV6-RUNX1; t(1;19)(q23;p13.3), TCF3-PBX1; and t(5;14)(q31;q32), IL3-IGH. Presence of recurrent genetic abnormalities should be evaluated using karyotyping of G-banded metaphase chromosomes (conventional cytogenetics) and/or through interphase fluorescence in situ hybridization (FISH) assays that include probes capable of detecting the genetic abnormalities.

Immunophenotyping

Immunophenotypic classification of ALL involves flow cytometry to determine the presence of cell surface antigens on lymphocytes. ALL can be broadly classified into 3 groups based on immunophenotype, which include precursor B-cell ALL, mature B-cell ALL, and T-cell ALL. Among children, B-cell lineage ALL constitutes approximately 88% of cases in adult patients, subtypes of B-cell lineage ALL represent approximately 75% of cases (including mature B-cell ALL that constitutes 5% of adult ALL), whereas the remaining 25% comprise T-cell lineage ALL (T-ALL). Within the B-cell lineage, the profile of cell surface markers differs according to the stage of B-cell maturation, which include early precursor B-cell (early pre-B-cell), pre-B-cell, and mature B-cell ALL. Early pre-B-cell ALL is characterized by the presence of terminal deoxynucleotidyl transferase (TdT), the expression of CD19/CD22/CD79a, and the absence of CD10 (formerly termed common ALL antigen) or surface immunoglobulins. Pre-B-cell ALL is characterized by the presence of cytoplasmic immunoglobulins and CD10 expression and was previously termed common B-cell ALL due to the expression of CD10 at diagnosis. Mature B-cell ALL shows positivity for surface immunoglobulins and clonal lambda or kappa light chains, and is negative for TdT. CD20 may be expressed in approximately 50% of B-cell lineage ALL in adults, with a higher frequency (>80%) observed in cases of mature B-cell ALL. T-ALL is typically associated with the presence of cytoplasmic CD3 (T-cell lineage blasts) or cell surface CD3 (mature T-cells) in addition to variable expression of CD1a/CD2/CD5/CD7 and expression of TdT. CD5 may be expressed in 30% to 50% of T-ALL in adults. Combined data from the GMALL 06/99 study and the GMALL 07/03 study revealed a distribution of T-ALL among three subgroups: cortical/thymic (56%), medullary/mature (21%), and early (23%) T-cell ALL. The latter is further divided between early T-cell precursor (ETP) ALL and early
immature T-ALL. Early immature T-ALL includes both pro-T-ALL and pre-T-ALL immunophenotypes (for specific markers, see Typical Immunophenotype By Major ALL Subtypes on page ALL-A).

ETP ALL represents a distinct biologic subtype of T-ALL that accounts for 12% of pediatric T-ALLs (and about 2% of ALL), and is associated with poor clinical outcomes even with contemporary treatment regimens. This subtype is characterized by the absence of CD1a/CD8, weak expression of CD5 (<75% positive lymphoblasts), and the presence of 1 or more myeloid or stem cell markers (CD117, CD34, HLA-DR, CD13, CD33, CD11b, or CD65) on at least 25% of lymphoblasts. In a study of 239 patients with T-ALL, gene expression profiling, flow cytometry, and single nucleotide polymorphism array analysis were employed to identify patients with ETP-ALL. ETP-ALL was associated with a 10-year OS of 19% (95% CI, 0%–92%) compared with 84% (95% CI, 72%–96%) in the non-ETP-ALL patients. The 10-year event-free survival (EFS) was similarly poor in patients with ETP-ALL (22%; 95% CI, 5%–49%) compared with non-ETP-ALL patients (69%; 95% CI, 53%–84%). Remission failure and hematologic relapse were significantly higher for patients with ETP-ALL (P < .0001). A pivotal study from Zhang et al identified a high frequency of activating mutations in the cytokine receptor and RAS signaling pathways that included NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3, and BRAF. Furthermore, inactivating mutations of genes that encode hematopoietic developmental transcription factors, including GATA3, ETV6, RUNX1, IKZF1, and EP300, were observed. These mutations are more frequent in myeloid neoplasms than in other subtypes of ALL, suggesting that myeloid-derived therapies and targeted therapy may be better treatment options for select ALL subtypes. The data indicate a need for alternative treatments to standard intensive chemotherapy in this subpopulation. Due to the nature of ETP-ALL, myeloablative therapy followed by HCT in first remission may be an alternative. This regimen had previously demonstrated superior results for patients with T-ALL and poor early responses.

Hematologic malignancies related to ALL include acute leukemias with ambiguous lineage, such as the mixed phenotype acute leukemias (MPALs). MPALs include bilineage leukemias, in which 2 distinct populations of lymphoblasts are identified, with 1 meeting the criteria for acute myeloid leukemia. Another type of MPAL is the biphenotypic type, in which a single population of lymphoblasts expresses markers consistent with B-cell or T-cell ALL, in addition to expressing myeloid or monocytic markers. Notably, myeloid-associated markers such as CD13 and CD33 may be expressed in ALL, and the presence of these markers does not exclude this diagnosis. The identification of mixed-lineage leukemias should follow the criteria presented in the 2008 WHO classification of neoplasms. The initial immunophenotyping panel should be sufficiently comprehensive to establish a leukemia-associated phenotype that may include expression of nonlineage antigens; these are useful in classification, particularly for MPAL.

Cytogenetic and Molecular Subtypes

Recurrent chromosomal and molecular abnormalities characterize ALL subtypes in both adults and children (Table 1), and often provide prognostic information that may weigh into risk stratification and treatment decisions. The frequency of certain subtypes differs between adult and childhood ALL, which partially explains the difference in clinical outcomes between patient populations. Among children with ALL, the most common chromosomal abnormality is hyperdiploidy (>50 chromosomes; 25% of cases) seen in B-cell lineage ALL compared to 7% in the adult ALL patient population. The ETV6-RUNX1 subtype (also within the B-cell lineage) resulting from chromosomal translocation t(12;21) is among the most commonly occurring subtypes (22%) in childhood ALL compared to adults (2%). Both hyperdiploidy and
ETV6-RUNX1 subtypes are associated with favorable outcomes in ALL.\textsuperscript{38-40} Ph-positive ALL, associated with poor prognosis, is relatively uncommon among childhood ALL (3%), whereas this abnormality is the most common subtype among adults (25%).\textsuperscript{31} The frequency of Ph-positive ALL increases with age (10%, patients 15–39 years; 25%, patients 40–49 years; 20%–40%, patients >50 years of age).\textsuperscript{39,41-43} Moreover, younger children (1–9 years of age) with Ph-positive ALL have a better prognosis than adolescents with this subtype.\textsuperscript{44}

Philadelphia-like (Ph-like) ALL is a subgroup of B-cell lineage ALL associated with unfavorable prognosis.\textsuperscript{45,46} Similar to Ph-positive ALL, the 5-year DFS in this population is estimated to be 60%\textsuperscript{45} however, this genotype is 4 to 5 times more frequent in children and young adults than the Ph-positive ALL phenotype. Although this subgroup is Ph-negative, there is an otherwise similar genetic profile to the Ph-positive ALL subgroup including mutation of the \textit{IKZF1} gene. Genomically, this subtype is further identified by mutations in the Ras and JAK/STAT5 pathways as the common mechanism of transformation. These include mutations in the \textit{ABL1}, \textit{EPOR}, \textit{JAK2}, \textit{PDGFRß}, \textit{EBF1}, \textit{FLT2}, \textit{IL7R}, and \textit{SH2B3} genes.\textsuperscript{45-47} A recent publication found kinase-activating alternations in 91% of Ph-like ALL cases.\textsuperscript{48} Therefore, use of the ABL1 tyrosine kinase inhibitor (TKI) imatinib or other targeted therapies may significantly improve patient outcomes in this subgroup.

Other cytogenetic and molecular subtypes are associated with ALL and prognosis. Although not as common, translocations in the \textit{MLL} gene [in particular, cases with t(4;11) translocation] are known to have poor prognosis.\textsuperscript{22,33} Hypoploidy is associated with poor prognosis and is observed in 1% to 2% of patients.\textsuperscript{22,49} Low hypoploidy (30–39 chromosomes)/near triploidy (60–68 chromosomes) and complex karyotype (≥25 chromosome abnormalities) are also associated with poor prognosis, and occur more frequently with increasing age (1%–3%, patients 15–29 years; 3%–6%, patients 30–59 years; 5%–11%, patients >60 years of age).\textsuperscript{39}

In B-cell ALL, \textit{IKZF1} mutations are associated with a poor prognosis and a greater incidence of relapse. \textit{IKZF1} mutations are seen in approximately 15% to 20% of pediatric B-cell ALL\textsuperscript{50,51} and at a higher frequency of greater than 75% in patients who are also BCR-ABL positive.\textsuperscript{46,51} Incidence in adults is about 50% in B-cell ALL\textsuperscript{52,53} and about 65% when also BCR-ABL positive.\textsuperscript{54,55} A study evaluating the relationship between BCR-ABL1-like and IKZF1 in children with B-cell precursor ALL showed that 40% of cases had co-occurrence of these mutations.\textsuperscript{56} The presence of either mutation was indicative of poor prognosis and was independent of conventional risk factors. Both mutations are considered strong independent risk factors for B-cell ALL and are applicable across a broad range of stratified ALL including patients with intermediate minimal residual disease (MRD). The DCOG ALL-11 trial will incorporate \textit{IKZF1} as a risk factor and patients will receive an additional year of maintenance therapy if \textit{IKZF1} is detected. However, despite the prognostic value and potential for risk stratification based on the presence of \textit{IKZF1} mutations, there are no suitable testing methods for these mutations, thereby limiting current clinical applications.
### Table 1. Common Chromosomal and Molecular Abnormalities in Acute Lymphoblastic Leukemia

<table>
<thead>
<tr>
<th>Cytogenetics</th>
<th>Gene</th>
<th>Frequency in Adults</th>
<th>Frequency in Children</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperdiploidy (&gt;50 chromosomes)</td>
<td>--</td>
<td>7%</td>
<td>25%</td>
</tr>
<tr>
<td>Hypodiploidy (&lt;44 chromosomes)</td>
<td>2%</td>
<td>1%</td>
<td></td>
</tr>
<tr>
<td>t(9;22)(q34;q11): Philadelphia chromosome (Ph)</td>
<td>BCR-ABL1</td>
<td>25%</td>
<td>2%–4%</td>
</tr>
<tr>
<td>t(12;21)(p13;q22)</td>
<td>ETV6-RUNX1 (TEL-AML1)</td>
<td>2%</td>
<td>22%</td>
</tr>
<tr>
<td>t(v;11q23) [eg, t(4;11), t(9;11), t(11;19)]</td>
<td>MLL</td>
<td>10%</td>
<td>8%</td>
</tr>
<tr>
<td>t(1;19)(q23;p13)</td>
<td>TCF3-PBX1 (E2A-PBX1)</td>
<td>3%</td>
<td>6%</td>
</tr>
<tr>
<td>t(5;14)(q31;q32)</td>
<td>IL3-IGH</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
</tr>
<tr>
<td>t(8;14), t(2;8), t(8;22)</td>
<td>c-MYC</td>
<td>4%</td>
<td>2%</td>
</tr>
<tr>
<td>t(1;14)(p32;q11)</td>
<td>TAL-1(^{a})</td>
<td>12%</td>
<td>7%</td>
</tr>
<tr>
<td>t(10;14)(q24;q11)</td>
<td>HOX11 (TLX1)(^{a})</td>
<td>8%</td>
<td>1%</td>
</tr>
<tr>
<td>t(5;14)(q35;q32)</td>
<td>HOX11L2(^{a})</td>
<td>1%</td>
<td>3%</td>
</tr>
<tr>
<td>t(11;14)(q11) [eg, (p13;q11), (p15;q11)]</td>
<td>TCRα and TCRδ</td>
<td>20%–25%</td>
<td>10%–20%</td>
</tr>
<tr>
<td>BCR-ABL1-like</td>
<td>various(^{a})</td>
<td>10%–30%</td>
<td>15%</td>
</tr>
<tr>
<td>ETP</td>
<td>various(^{a})</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Ikaros</td>
<td>IKZF1</td>
<td>50%</td>
<td>12%–17%</td>
</tr>
</tbody>
</table>

\(^{a}\)Abnormalities observed exclusively in T-cell lineage ALL; all others occur exclusively or predominantly in B-cell lineage ALL. \(^{b}\)See text for more details.

### Workup

The initial workup for patients with ALL should include a thorough medical history and physical examination, along with laboratory and imaging studies (where applicable). Laboratory studies include a complete blood count (CBC) with platelets and differential, a blood chemistry profile, a disseminated intravascular coagulation panel (including measurements for D-dimer, fibrinogen, prothrombin time, and partial thromboplastin time), and a tumor lysis syndrome (TLS) panel (including measurements for serum lactate dehydrogenase [LDH], uric acid, potassium, phosphates, and calcium). Procurement of cells should be considered for purposes of future research (in accordance with institutional practices or policies). All male patients should be evaluated for testicular involvement of disease; testicular involvement is especially common in cases of T-cell ALL. For patients with T-cell ALL, CT scans of the chest are warranted. All patients should be evaluated for infections, including screening for active infections if febrile or for symptomatic opportunistic infections. Empiric anti-infective therapy should be initiated, as appropriate (see NCCN Guidelines for Prevention and Treatment of Cancer-Related Infections; to view the most recent version of these guidelines, visit NCCN.org). In addition, an echocardiogram or cardiac scan should be considered for all patients due to the use of anthracyclines as the backbone of nearly all treatment regimens. Assessment of cardiac function is particularly important for patients with prior cardiac history, prior anthracycline exposure, or clinical symptoms suggestive of cardiac dysfunction, and for elderly patients. Except in patients with major contraindications to HCT, human leukocyte antigen (HLA) typing should be performed at workup. Appropriate imaging studies should be performed to detect meningeal disease, chloromas, or central nervous system (CNS) bleeding for patients with major neurologic signs or symptoms at diagnosis. CNS involvement should be evaluated through lumbar puncture at timing that is consistent with the treatment protocol. Pediatric-inspired regimens typically include lumbar puncture at diagnostic workup; however, the NCCN ALL Panel recommends that lumbar puncture, if performed, be done concomitantly with initial intrathecal therapy (see NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement in the Discussion).
It should be noted that the recommendations included in the Guidelines represent a minimum set of workup considerations, and that other evaluations or testing may be needed based upon clinical symptoms.

**Prognostic Factors and Risk Stratification**

Various disease-related and patient-specific factors may have prognostic significance in patients with ALL. In particular, patient age, white blood cell (WBC) count, immunophenotypic/cytogenetic subtype, and response to induction therapy have been identified as important factors in defining risks and assessing prognosis for both adult and childhood ALL.

**Prognostic Factors in AYA Patients with ALL**

Initially, risk assessment for childhood ALL was individually determined by the institution, complicating the interpretation of data. However, in 1993, a common set of risk criteria was established by the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG) at an international conference hosted by the NCI. In this system, two risk groups were designated: standard risk and high risk. Standard risk was assigned to patients age 1 to younger than 10 years of age and with a WBC count less than 50 × 10⁹ cells/L, whereas all other patients with ALL, including T-cell ALL (regardless of age or WBC count), were considered high risk. It should be noted that despite exclusion from this report, patients younger than age 1 should also be considered very high risk. The POG and CCG have since merged to form the Children’s Oncology Group (COG) and subsequent risk assessment strategy has produced additional risk factors, particularly in precursor B-cell ALL, to further refine therapy. Specifically, in B-cell ALL, a group identified as very high risk was defined as patients with any of the following characteristics: t(9;22) chromosomal translocation (ie, Ph-positive ALL) and/or presence of BCR-ABL fusion protein; hypodiploidy (<44 chromosomes) or a DNA index below 0.81, or failure to achieve remission with induction therapy. MLL rearrangements and a poor response to induction chemotherapy also re-categorized patients into this group. Conversely, criteria were refined for lower risk and included patients with hyperdiploidy, the t(12;21) chromosomal translocation (ETV6-RUNX1 subtype), or simultaneous trisomies of chromosomes 4, 10, and 17. Presence of extramedullary disease and the early response to treatment also modified risk. Early marrow response to therapy was a strong positive prognostic factor while the presence of extramedullary disease at diagnosis was correlated with a poorer prognosis. Using the refined risk assessment, four risk categories for B-cell ALL, designated as low risk, standard risk, high risk, and very high risk were identified encompassing 27%, 32%, 27%, and 4% of cases, respectively.

Risk stratification of T-cell ALL has been more difficult than in B-cell ALL. Although T-cell ALL is often categorized as very high risk depending on the institute, newer treatment options have resulted in improved survival outcomes for these patients. Furthermore, the identification of genetic mutations and the use of targeted therapies may change the way T-cell ALL is treated and ultimately how these patients are assessed for risk.

Variability exists across studies with regard to the age ranges defined for AYA patients. The NCI defines the age range for AYA patients as 15 to 39 years. This definition has been adopted for the AYA sections of the NCCN Guidelines for ALL. Historically, the AYA population has been treated on either a pediatric or an adult ALL regimen, depending on referral patterns and the institution. However, studies in the past have shown poorer outcomes among patients in the AYA group compared with children younger than 10 years. This may be attributed to factors that are based on biology and social differences. Compared to...
the pediatric population, AYA patients have a lower frequency of favorable chromosomal/cytogenetic abnormalities, such as hyperdiploidy or *ETV6-RUNX1* and a greater incidence of poor-risk cytogenetics including Ph-positive ALL, hypodiploidy, and complex karyotype, and a higher incidence of ETP-ALL. Furthermore, the positive prognostic values of the *ETV6-RUNX1* mutation and hyperdiploidy are greater in the pediatric population, suggesting that the benefits decline with age. The effects of the treatment are also shown to be different in the AYA population compared to the pediatric population. In vitro studies showed that ALL cells from children older than 10 years are more resistant to chemotherapy compared to the cells from children younger than 10 years. This observation has extended into clinical trials where an inferior response to chemotherapy is observed. In addition to the biological differences, the social component of treating AYA patients is important. Enrollment in clinical trials has been shown to improve patient outcomes; however, only 2% of AYA patients enroll in clinical trials compared to the 60% enrollment of pediatric patients. Pediatric patients have also been shown to be more compliant to treatment protocols compared to AYA patients, which may be due to greater parental supervision of the treatment and better insurance.

In recent years, several retrospective studies from both the United States and Europe have shown that AYA patients (15–21 years of age) treated on a pediatric protocol have substantially improved EFS outcomes compared to same-aged patients treated on adult ALL regimens. Comparison of adult and pediatric protocols has shown that adults received lower doses of nonmyelosuppressive chemotherapy and less intense intrathecal chemotherapy regimens. Adult protocols also entail a greater use of allogeneic HCT compared to pediatric protocols, but the benefits of HCT in the AYA population have not been sufficiently studied and the available data have conflicting findings. However, this is a significant difference between the way adults and pediatric patients are treated and may be a variable in the treatment of AYA patients. Thus, the choice of initial treatment regimen can have a profound impact on overall clinical outcomes in AYA patients.

**Prognostic Factors in Adults with ALL**

Both age and initial WBC count have historically been considered clinically significant prognostic factors in the management of adult patients with ALL. Early prospective multicenter studies defined values for older age (>35 years) and higher initial WBC count (>30 × 10⁹/L) that were predictive of significantly decreased remission duration. Subsequent studies have confirmed the prognostic importance of these clinical parameters, although the cutoff values differed between studies. In one of the largest studies to date (n = 1521) conducted by the Medical Research Council (MRC) UKALL/ECOG, both age (>35 years) and WBC count (>30 × 10⁹/L for B-cell lineage; >100 × 10⁹/L for T-cell lineage) were found to be significant independent prognostic factors for decreased DFS and OS among patients with Ph-negative ALL; the independent prognostic value remained significant when these factors were evaluated as continuous variables in multivariate analysis. All patients, regardless of Ph status, had received induction therapy followed by intensification (for patients with a complete remission postinduction) with contemporary chemotherapy combination regimens. Patients with a CR after induction received allogeneic HCT (for patients <50 years old and with HLA-compatible siblings), autologous HCT, or consolidation/maintenance treatment. Because Ph-positive ALL is associated with a very poor prognosis, patients with this subtype were
assigned to undergo allogeneic HCT (including matched, unrelated donor [URD] HCT), when possible. The 5-year OS rate among patients with Ph-positive and Ph-negative disease was 25% and 41%, respectively. Among the patients with Ph-negative ALL, those older than 35 years or with elevated WBC count (>30 × 10⁹/L for B-cell lineage; >100 × 10⁹/L for T-cell lineage) at diagnosis were initially identified as high risk, whereas all others were classified as standard risk. The 5-year OS rates for the Ph-negative high-risk and standard-risk subgroups were 29% and 54%, respectively. Further analysis of the Ph-negative population according to risk factors showed that patients could be categorized as low risk (no risk factors based on age or WBC count), intermediate risk (either aged >35 years or elevated WBC count), or high risk (both aged >35 years and elevated WBC count). The 5-year OS rates based on these risk categories were 55%, 34%, and 5%, respectively, suggesting that patients with Ph-negative ALL in the high-risk subgroup had even poorer survival outcomes than patients in the overall Ph-positive subgroup.

In a subsequent analysis from this MRC UKALL XII/ECOG E2993 study, cytogenetic data were evaluated in approximately 1000 patients. The analysis confirmed the negative prognostic impact of Ph-positive status compared with Ph-negative disease, with a significantly decreased 5-year EFS rate (16% vs. 36%; P < .001, adjusted for age, gender, and WBC count) and OS rate (22% vs. 41%; P < .001, adjusted for age, gender, and WBC count). Among patients with Ph-negative disease, the following cytogenetic subgroups had significantly decreased 5-year EFS (13%–24%) and OS rates (13%–28%) based on univariate analysis: t(4;11) MLL translocation, t(8;14), complex karyotype (≥5 chromosomal abnormalities), and low hypodiploidy (30–39 chromosomes)/near triploidy (60–78 chromosomes). In contrast, del(9p) or hyperdiploidy (51–65 chromosomes) was associated with more favorable 5-year EFS (49%–50%) and OS rates (53%–58%). An earlier report of data from patients treated on the French ALL study group (LALA) protocols suggested that near triploidy (60–78 chromosomes) may be derived from duplication of hypodiploidy (30–39 chromosomes); both aneuploidies were associated with poor DFS and OS outcomes similar to that of patients with Ph-positive ALL. Based on multivariate Cox regression analysis reported in the MRC UKALL XII/ECOG E2993 study, t(8;14), low hypodiploidy/near triploidy, and complex karyotype remained significant independent predictors for risk of relapse or death. The prognostic impact of these cytogenetic markers was independent of factors such as age, WBC count, or T-cell immunophenotype, and their significance was retained even after excluding patients who had undergone postinduction HCT.

The importance of cytogenetics as a prognostic factor for survival outcomes was shown in other studies, including the Southwest Oncology Group (SWOG) study conducted with 200 adult patients with ALL. In this study, the prognostic impact of the different cytogenetic categories outweighed that of the more traditional factors, such as age and WBC count. In multivariate analysis for both relapse-free survival (RFS) and OS, cytogenetics remained a significant independent predictor of outcomes, whereas factors such as age and WBC count lost prognostic significance. Moreover, the subgroup (n = 19) of patients with “very high risk” cytogenetic features (identified based on outcomes from the MRC/ECOG study mentioned earlier: presence of t(4;11) MLL translocation; t(8;14); complex karyotype; or low hypodiploidy) had substantially decreased 5-year RFS and OS rates (22%, for both endpoints). Analysis by ploidy status was not possible because only 2 patients were considered to have low hypodiploidy/near triploidy. The 5-year RFS and OS rates among patients with Ph-positive ALL (n = 36) were 0% and 8%, respectively.
NCCN Recommendations for Risk Assessment in ALL

Although some debate remains regarding the risk stratification approach to ALL, the panel suggests the following approaches for defining risk in these patients.

Because AYA patients (defined as aged 15–39 years) may benefit from pediatric-inspired ALL treatment protocols, this patient population is considered separately from the adult population (defined as aged ≥40 years). Given the poor prognosis associated with Ph-positive ALL and the wide availability of agents that specifically target the BCR-ABL kinase, initial risk stratification for all patients (AYA or adult) is based on the presence or absence of the t(9;22) chromosomal translocation and/or BCR-ABL fusion protein.

AYA patients with Ph-negative ALL can be further categorized as having high-risk disease, which may be particularly helpful when consolidation with allogeneic HCT is being considered. High risk is generally defined as having any of the following poor-risk cytogenetic factors: hypodiploidy (<44 chromosomes); t(v;11q23) or MLL rearrangements; t(9;22) or BCR-ABL gene mutations; or complex karyotype (≥5 chromosomal abnormalities). The absence of all of the described poor-risk factors is considered standard risk. Elevated WBC count (≥30 × 10^9/L for B-cell lineage; ≥100 × 10^9/L for T-cell lineage) has been considered a high-risk factor based on some earlier studies. However, more recent studies in adult patients have demonstrated that WBC counts may lose independent prognostic significance when cytogenetic factors are considered. Data showing the effect of WBC counts on prognosis in adult patients with ALL are less firmly established than in the pediatric population. Therefore, adult patients with ALL may not necessarily be classified as high risk based on high WBC count alone.

Overview of Treatment Phases in ALL Management

The treatment approach to ALL represents one of the most complex and intensive programs in cancer therapy. Although the specific treatment regimens and selection of drugs, dose schedules, and treatment durations differ between AYA patients and adults, and among different subtypes of ALL, the basic treatment principles are similar. The most common treatment regimens used in patients with ALL include modifications or variations of multiagent chemotherapy regimens.
originally developed by the Berlin-Frankfurt-Münster (BFM) group for pediatric patients (eg, regimens used by COG for children and AYA patients, or the CALGB regimen for adult patients), and the hyper-CVAD regimen developed at MD Anderson Cancer Center (MDACC). In general, the treatment phases can be largely grouped into induction, consolidation, and maintenance. All treatment regimens for ALL include CNS prophylaxis and/or treatment.

**Induction**

The intent of initial induction therapy is to reduce tumor burden by clearing as many leukemic cells as possible from the bone marrow. Induction regimens are typically based on a backbone that includes a combination of vincristine, anthracyclines (eg, daunorubicin, doxorubicin), and corticosteroids (eg, prednisone, dexamethasone) with or without L-asparaginase and/or cyclophosphamide. In addition, antimetabolites, such as methotrexate, cytarabine, and/or 6-mercaptopurine (6-MP), are often included at induction therapy, primarily for CNS prophylaxis (see next section).

The BFM/COG regimens are mainly based on a 4-drug induction regimen that includes a combination of vincristine, an anthracycline (eg, daunorubicin, doxorubicin), and a corticosteroid (eg, prednisone, dexamethasone) with or without L-asparaginase and/or cyclophosphamide. In addition, antimetabolites, such as methotrexate, cytarabine, and/or 6-mercaptopurine (6-MP), are often included at induction therapy, primarily for CNS prophylaxis (see next section).

The CALGB regimens are typically based on a 5-drug regimen, which adds cyclophosphamide to the above 4-drug combination. The CALGB regimens are typically based on a 5-drug regimen, which adds cyclophosphamide to the above 4-drug combination. Randomized studies comparing the use of dexamethasone versus prednisone as part of induction therapy in children with ALL showed that dexamethasone significantly decreased the risk of isolated CNS relapse and improved EFS outcomes compared with prednisone. The observed advantage in outcomes with dexamethasone may partly be attributed to improved penetration of dexamethasone in the CNS. In a recently published meta-analysis comparing outcomes with dexamethasone versus prednisone in induction regimens for childhood ALL, dexamethasone was associated with a significantly reduced risk for events (ie, death from any cause, refractory or relapsed leukemia, or second malignancy; risk ratio [RR], 0.80; 95% CI, 0.68–0.94) and CNS relapse (RR, 0.53; 95% CI, 0.44–0.65). However, no advantage was seen with dexamethasone regarding risk for bone marrow relapse (RR, 0.90; 95% CI, 0.69–1.18) or overall mortality (RR, 0.91; 95% CI, 0.76–1.09), and dexamethasone was associated with a significantly higher risk of mortality during induction therapy (RR, 2.31; 95% CI, 1.46–3.66), neuropsychiatric adverse events (RR, 4.55; 95% CI, 2.45–8.46), and myopathy (RR, 7.05; 95% CI, 3.00–16.58) compared with prednisone. Although dexamethasone seems beneficial in terms of reduced risks for CNS relapse and improved EFS, toxicities may be of concern, and an advantage for OS has yet to be conclusively shown.

The hyper-CVAD regimen may be considered a less complex treatment regimen compared with the CALGB regimen, and comprises 8 alternating treatment cycles with the “A” regimen (hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) and the “B” regimen (high-dose methotrexate and cytarabine). CNS prophylaxis and/or CNS-directed treatment (which may include cranial irradiation for patients with CNS leukemia at diagnosis) and maintenance treatment (as discussed in the next section) are also used with the hyper-CVAD regimen.

**CNS Prophylaxis and Treatment**

The goal of CNS prophylaxis and/or treatment is to prevent CNS disease or relapse by clearing leukemic cells within sites that cannot be readily accessed with systemic chemotherapy because of the blood-brain barrier. CNS-directed therapy may include cranial irradiation, intrathecal chemotherapy (eg, methotrexate, cytarabine,
Factors that affect the bioavailability of 6-MP can significantly impact patient care. Oral 6-MP can have highly variable drug and metabolite concentrations among patients. Furthermore, age, gender, and genetic polymorphisms can affect bioavailability. The concomitant use of other chemotherapeutic agents such as methotrexate can also alter toxicity. The efficacy of maintenance therapy is determined by the metabolism of 6-MP to the antimetabolite chemotherapeutic agent 6-thioguanine (6-TGN); however, other pathways compete for 6-MP, thereby reducing the amount of active metabolite produced. The three enzymes that metabolize 6-MP are xanthine oxidase (XO), hypoxanthine phosphoribosyltransferase (HPRT), and thiopurine methyltransferase (TPMT). Because 6-MP is administered orally, it can be converted to the inactive metabolite 6-thiouric acid by XO in the intestinal mucosa and liver. There is little genetic variation in XO, but diet has been shown to affect absorption of 6-MP. 6-MP that is not metabolized by XO is available for thiol methylation by TPMT to form 6-methyl mercaptopurine or for metabolism by HPRT to form 6-TGN. The balance between metabolism by HPRT is inversely related to the activity of TPMT as demonstrated by the ability of TPMT polymorphism to affect metabolite production. Compared to the wild-type TPMT phenotype, patients who are homozygous TPMT-deficient require a 10- to 15-fold reduction in 6-MP to alleviate hematopoietic toxicity. Heterozygosity at the TPMT gene locus occurs in 5% to 10% of the population and has been shown to have intermediate enzyme activity. Therefore, a 10% to 15% reduction in 6-MP dose is necessary in these patients to prevent toxicity. Determination of patient TPMT genotype using genomic DNA is recommended to optimize 6-MP dosing, especially in patients who experience myelosuppression at standard doses.
Dose reductions may be necessary if patients have genetic polymorphisms and/or hepatotoxicity, whereas dose escalation may be necessary in patients who demonstrate myelosuppression. This should be performed in accordance with the protocol being used; generally protocols (including the ECOG/CALGB study) recommend a dose increase by 25% if an ANC greater than 1500 is observed for more than 6 weeks. The FDA recently approved an oral suspension of 6-MP, which may be more amenable to dose adjustments than the tablet form. This may be especially beneficial for dose adjustment in pediatric patients. Outcomes are better in patients who achieve myelosuppression during maintenance compared with patients who have higher neutrophil counts, emphasizing the need for optimal dosing of 6-MP.

Noncompliance also results in undertreatment and has entered the forefront, particularly in the AYA population. Compliance issues should be addressed for patients without cytopenia. If increasing doses of 6-MP are given during maintenance but no drop in the counts is observed, this may be indicative of noncompliance. Quantification of 6-MP metabolites (6-TGN and 6-MMPN) can be very useful in determining whether lack of myelosuppression is due to non-compliance or hypermetabolism.

Targeted Agents

During the past decade, the advent of novel agents targeted to specific genetic abnormalities, such as those associated with Ph-positive ALL, or to specific cell surface antigens, has contributed to improvements in outcomes in some ALL subtypes. These agents include BCR-ABL–selective TKIs for Ph-positive ALL, and an anti-CD20 monoclonal antibody (eg, rituximab) for CD20-expressing B-cell lineage ALL (especially for mature B-cell ALL). In addition, nelarabine has been approved for the treatment of relapsed/refractory T-ALL or lymphoblastic lymphoma. These agents may be incorporated as part of frontline induction, consolidation, and/or maintenance regimens during the course of initial ALL therapy, and in relapsed/refractory disease settings. Single-agent TKI treatment in Ph-positive ALL has demonstrated improved response to induction over chemotherapy, but both imatinib and dasatinib had a short duration with no remission. TKIs have shown the most benefit when given in concert with corticosteroids. Not only are DFS and OS rates significantly improved, but there is a reduction in adverse events making this a possible treatment option for older or less fit patients with Ph-positive ALL (see Initial Treatment in Adults with Ph-Positive ALL). Incorporation of TKIs into treatment regimens should include evaluation of clinical pharmacokinetics. Clinicians should be aware of variation among the TKIs relating to absorption from the gastrointestinal tract. Additionally, histamine-2 antagonist or proton pump inhibitors can affect the bioavailability of some TKIs.

Management of Ph-Positive ALL

Initial Treatment in AYA Patients with Ph-Positive ALL

Ph-positive ALL is rare in children with ALL, occurring in only approximately 3% of pediatric cases compared with 25% of adult cases. The frequency of Ph-positive ALL is slightly higher (5%–7% of cases) among AYA patients, although this subtype is still uncommon relative to its incidence in older adults. Historically, children and adolescents with Ph-positive disease had a poorer prognosis compared with patients with Ph-negative B-cell ALL. However, recent improvements in the treatment options are closing this gap. In a retrospective analysis of children with Ph-positive ALL treated between 1986 and 1996 (n = 326) with intensive chemotherapy regimens with or without allogeneic HCT, the 5-year EFS (calculated from time of
The 7-year EFS and OS rates were 25% and 36%, respectively. Even among the subgroup of patients considered to have a better prognosis (ie, WBC count <50 × 10^9/L and age <10 years), the 5-year DFS rate (calculated from time of first CR) was only 49%. In the subgroup of patients who underwent allogeneic HCT with an HLA-matched related donor (n = 38), significantly higher 5-year DFS (65% vs. 25%; P < .001) and OS rates (72% vs. 42%; P = .002) were observed than in patients who received only chemotherapy. This benefit with HCT versus chemotherapy alone was not observed with autologous HCT or with HCT from matched URDs. This study showed that allogeneic HCT from a matched related donor offered improvements in outcomes over chemotherapy alone. In a subsequent analysis of outcomes in children with Ph-positive ALL treated more recently (1995–2005) but also without targeted TKIs, the 7-year EFS and OS rates were 32% and 45%, respectively. Outcomes with allogeneic HCT from either matched related or URDs appeared similar, and HCT was shown to provide improved disease control over intensive chemotherapy alone. Although this analysis showed improvements in 7-year EFS rates, outcomes remain suboptimal in patients with Ph-positive ALL.

The emergence of targeted therapies for hematologic malignancies, including the treatment of Ph-positive disorders with TKIs, represents an important advancement in ALL therapy. Imatinib mesylate is an inhibitor of BCR-ABL tyrosine kinase and is approved by the FDA for the treatment of adult patients with relapsed or refractory Ph-positive ALL, and the treatment of previously untreated pediatric patients with Ph-positive ALL. Phase II studies in adults with ALL have shown imatinib to be efficacious as single-agent therapy in the relapsed/refractory and frontline settings, and in combination with chemotherapy regimens during initial induction, consolidation, and/or maintenance.

Although allogeneic HCT has been considered the standard of care (SOC) for AYA patients with Ph-positive ALL, its role has become less clear with the advent of BCR-ABL–targeted TKIs such as imatinib. Several studies evaluated the role of allogeneic HCT in the era of imatinib and whether imatinib-based therapies provided an additional benefit to HCT.

A single-center retrospective study in children and adolescents with Ph-positive ALL who underwent allogeneic HCT (n = 37; age 1–16 years) compared outcomes between patients who received pre- and/or post-HCT imatinib (n = 13) and those who did not receive imatinib (n = 24). The 3-year DFS (62% vs. 53%, respectively) and relapse rates (15% vs. 26%, respectively) were not significantly improved with the use of imatinib. Patients who received HCT in first CR had significantly improved DFS rates (71% vs. 29%; P = .01) and lower relapse rates (16% vs. 36%; P = .05) than those who underwent HCT in second CR or later.

A recent study from the Spanish Cooperative Group compared outcomes of children and adolescents (age 1–15 years) treated with intermediate-dose imatinib combined with intensive chemotherapy followed by allogeneic HCT (n = 16; 94% proceeded to HCT) versus those of historical controls who did not receive imatinib before allogeneic HCT (n = 27; 63% proceeded to HCT). The 3-year EFS rate was significantly higher in the imatinib group compared with the historical controls (79% vs. 30%; P = .01).

A phase II study at MDACC evaluated imatinib combined with the hyper-CVAD regimen in patients with previously untreated or minimally
treated ALL (n = 54; median age, 51 years; range, 17–84 years); 14 patients underwent subsequent allogeneic HCT. The 3-year OS rate with this regimen was 54%. Among the patients aged 40 years or younger (n = 16), a strong trend was observed for OS benefit with allogeneic HCT (3-year OS rate, 90% vs. 33%; 《．．05) [146].

In a multicenter COG study (AALL-0031) of children and adolescents with high-risk ALL, the group of patients with Ph-positive ALL (n = 92; age 1–21 years) were treated with an intensive chemotherapy regimen combined with imatinib (340 mg/m²/d; given during postremission induction therapy and maintenance). Among the cohort (n = 44) who received continuous imatinib exposure (280 consecutive days before maintenance initiation), the 3-year EFS rate was 80.5% (95% CI, 64.5%–89.8%). This outcome compared favorably with that of a historical population of patients with Ph-positive ALL (n = 120) treated on a POG protocol, which showed a 3-year EFS rate of only 35% (《．．0001) [130]. Moreover, the 3-year EFS rates were similar among the groups of patients who received chemotherapy combined with continuous imatinib (88%; n = 25) or allogeneic HCT from a related donor (57%; n = 21) or URD (72%; n = 11). No major toxicities were found to be associated with the addition of imatinib to the intensive chemotherapy regimen. [130]

**Initial Treatment in Adults with Ph-Positive ALL**

Historically, treatment outcomes for adult patients with Ph-positive ALL have been extremely poor. Before the era of targeted TKIs, the 3-year OS rate with chemotherapy regimens was generally less than 20%. Allogeneic HCT, in the pre-imatinib era, resulted in some improvements over chemotherapy alone, with 2-year OS rates of 40% to 50% [149,150] and 3-year OS rates of 36% to 44% [77,151]. In the large, international, collaborative MRC UKALL XII/ECOG E2993 trial conducted in patients with previously untreated ALL, the subgroup with Ph-positive disease (n = 267; median age, 40 years; range, 15–60 years) was eligible for allogeneic HCT if they were younger than 50 (in the ECOG E2993 trial) or 55 (in the MRC UKALL XII trial) years of age and had a matched sibling or matched URD. Among the Ph-positive patient cohort, postremission treatment included matched sibling allogeneic HCT (n = 45), matched URD allogeneic HCT (n = 31), and chemotherapy alone (n = 86). The 5-year OS rate according to postremission therapy was 44%, 36%, and 19%, respectively, and the 5-year EFS rate was 41%, 36%, and 9%, respectively. Both the OS and EFS outcomes for patients who underwent allogeneic HCT (related or unrelated) were significantly improved compared with those who received only chemotherapy. The incidence of transplant-related mortality was 27% with matched sibling allogeneic HCT and 39% with matched URD HCT. An intent-to-treat analysis of patients with a matched sibling donor versus those without a matched sibling donor showed no statistically significant difference in 5-year OS rates (34% vs. 25%, respectively) [152].

The incorporation of imatinib in the treatment regimen for Ph-positive ALL has led to substantial improvements in outcomes over chemotherapy alone. Numerous phase II studies have evaluated the efficacy of imatinib combined with chemotherapy regimens in patients with previously untreated disease; these studies showed positive results with the combined regimen, particularly when treatment was followed by allogeneic HCT. [124,131-133,144-146,153]

In the phase II study from GRAALL (GRAAPH-2003), patients with previously untreated Ph-positive ALL (n = 45; median age, 45 years; range, 16–59 years) received imatinib in combination with chemotherapy during either induction or consolidation therapy. Patients in CR with a donor received allogeneic HCT (n = 24), whereas those with CR and good molecular response but without a donor were...
eligible for autologous HCT (n = 10). Nine patients did not receive HCT and were treated with imatinib-based maintenance therapy. The 4-year OS rate did not differ significantly for patients with a sibling donor compared to patients undergoing autologous HCT (76% vs. 80%); however, patients receiving an allogeneic HCT from a URD had the lowest 4-year survival (11%). The 4-year OS for patients who received only maintenance imatinib was 33%.145 These data suggest that improved survival with imatinib-based therapy can be further enhanced by the addition of HCT.

In the subgroup of patients with Ph-positive ALL (n = 94; median age, 47 years; range, 19–66 years) from the Northern Italy Leukemia Group study (NILG-09/00), outcomes were compared among patients who received chemotherapy with imatinib (n = 59) or without imatinib (n = 35), with or without subsequent HCT (allogeneic or autologous).153 The patients who received imatinib (63% of eligible patients underwent allogeneic HCT) had significantly higher 5-year OS (38% vs. 23%; \( P = .009 \)) and DFS rates (39% vs. 25%; \( P = .005 \)) compared with those who did not receive imatinib (39% of eligible patients underwent allogeneic HCT).153 The 5-year OS rates by treatment type were 47% for allogeneic HCT (n = 45), 67% for autologous HCT (n = 9), 30% for imatinib without HCT (n = 15), and 8% for no imatinib and no HCT (n = 13); the corresponding treatment-related mortality rates were 17%, 0%, 36%, and 23%, respectively. The 5-year relapse rates were 43%, 33%, 87%, and 100%, respectively.153

In a phase II study from the Spanish Cooperative Group, patients with Ph-positive ALL (n = 30; median age, 42 years; range, 8–62 years; only 1 patient was <15 years of age) were treated with intensive chemotherapy combined with imatinib, followed by HCT and imatinib maintenance.154 Overall, 53% of patients proceeded to allogeneic HCT and 17% received autologous HCT. At a median follow-up of 4.1 years, the OS and DFS rates were both 30%. The incidence of transplant-related mortality was 27%.154 Post-transplant maintenance with imatinib was not feasible in most patients, primarily because of transplant-related complications.

Imatinib combined with the hyper-CVAD regimen was evaluated in a phase II study in patients with previously untreated or minimally treated ALL (n = 54; median age, 51 years; range 17–84 years), with 14 patients undergoing subsequent allogeneic HCT.146 The 3-year OS rate with this regimen was 54% overall. Among patients aged 60 years or younger, no statistically significant difference was observed in the 3-year OS rate between patients who received HCT and those who did not (77% vs. 57%). This finding is in contrast to results for younger patients (aged ≤40 years) who received HCT.

Another phase II study from GRAALL (GRAAPH-2005) compared induction therapy with high-dose imatinib (800 mg daily, days 1–28) combined with vincristine and dexamethasone (arm A) versus imatinib (800 mg daily, days 1–14) combined with hyper-CVAD (arm B) in patients younger than 60 years with previously untreated Ph-positive ALL.155,156 Eligible patients proceeded to HCT (allogeneic or autologous) after induction/consolidation phases. The primary endpoint was non-inferiority of the less intensive arm A regimen in terms of MRD response (\( BCR-ABL/ABL \) ratio <0.1% by quantitative polymerase chain reaction [PCR]) after induction/consolidation. In an early report from this study (n = 118; n = 83 evaluable; median age 42 years), 52 patients proceeded to HCT (allogeneic, n = 41; autologous, n = 11). The estimated 2-year OS rate was 62%, with no significant difference between patients who received imatinib with vincristine and dexamethasone and those who received imatinib with hyper-CVAD (68% vs. 54%, respectively).155 The 2-year DFS rate was 43%, with no significant difference between induction arms (54% vs. 32%, respectively). In an updated analysis
from the GRAAPH-2005 study with a median follow-up of 40 months (N = 270; n = 265 evaluable; median age, 47 years), MRD response rates after induction/consolidation were similar between arm A and arm B (68% vs. 63.5%); MRD was undetectable in a similar proportion of patients (28% vs. 22%, respectively). The less intensive regimen with high-dose imatinib combined with vincristine and dexamethasone was therefore considered non-inferior to imatinib combined with hyper-CVAD. No significant differences were observed between arm A and arm B in terms of estimated 3-year EFS (46% vs. 38%) or OS (53% vs. 49%) outcomes. Interestingly, among the patients who proceeded to HCT after MRD response, those who received autologous HCT showed a trend for improved 3-year RFS (63% vs. 49.5%) and OS (69% vs. 58%) compared with patients who received allogeneic HCT. This study suggested that outcomes with less intensive chemotherapy regimens (using high-dose imatinib) may offer similar benefits to more intensive imatinib-containing chemotherapy regimens.

In a phase II study from the Japan Adult Leukemia Study Group (ALL-202), patients with Ph-positive ALL (n = 100) were treated with chemotherapy combined with imatinib administered during induction, consolidation, and maintenance phases. An early analysis (n = 80; median age, 48 years; range, 15–63 years) reported a 1-year OS rate of 73% among patients who underwent allogeneic HCT, compared with 85% for those who did not. A subsequent analysis compared outcomes for the subgroup of patients who received allogeneic HCT at first CR in this study (n = 51; median age, 38 years; range, 15–64 years) versus those for a historical cohort of patients who received allogeneic HCT without prior imatinib (n = 122). The 3-year OS (65% vs. 44%; P = .015) and DFS rates (58% vs. 37%; P = .039) were significantly higher among patients treated with imatinib compared with the historical cohort; the 3-year non-relapse mortality rate was similar between cohorts (21% vs. 28%, respectively).

Collectively, these studies suggest that incorporation of imatinib into the therapeutic regimen improves outcomes for adult patients with Ph-positive ALL, particularly when administered before allogeneic HCT. Given that patients can experience relapse following allogeneic HCT, strategies are needed to prevent disease recurrence. One strategy involves the incorporation of post-HCT maintenance therapy with TKIs, which has been investigated in several studies. In a small prospective study in patients with Ph-positive leukemias who underwent allogeneic HCT (n = 15 with ALL; median age, 37 years; range, 4–49 years), imatinib was administered from the time of engraftment until 1 year after HCT. The median time after HCT until initiation of imatinib was short, at 27 days (range, 21–39 days). Molecular remission (by PCR) was observed in 46% of patients (6 of 13) prior to HCT and 80% (12 of 15) after HCT. Two patients died after hematologic relapse and 1 patient died due to acute respiratory distress syndrome approximately 1 year post-HCT. At a median follow-up of 1.3 years, 12 patients (80%) were alive without detectable disease. This was one of the first prospective studies to show the feasibility of administering imatinib maintenance early in the post-HCT period (<90 days) when the leukemic tumor burden tends to be low. Maintenance therapy with imatinib was also evaluated in a more recent prospective study in patients who underwent allogeneic HCT (n = 82; median age, 28.5 years; range, 3–51 years). Imatinib was scheduled for a period of 3 to 12 months (until three consecutive tests were negative for BCR-ABL transcripts or sustained molecular CR for at least 3 months). Among the patients who received imatinib (n = 62), the median time after HCT until initiation of imatinib was 70 days (range, 20–270 days). In this group of patients, 84% were alive with a molecular CR at a median follow-up of 31 months.
Imatinib was discontinued in 16% of patients receiving treatment due to toxicities. The remaining patients (n = 20) who did not receive maintenance with imatinib (due to cytopenias, infections, graft-versus-host disease [GVHD], or patient choice) constituted the non-imatinib group. The estimated 5-year relapse rate was significantly lower with imatinib compared with no imatinib (10% vs. 33%; \( P = .0016 \)) and the estimated 5-year DFS (81.5% vs. 33.5%; \( P < .001 \)) and OS rates (87% vs. 34%; \( P < .001 \)) were significantly longer with imatinib compared with no imatinib.\(^{158} \)

The previous study was not designed as a randomized controlled trial, and the number of patients in the non-imatinib group was small. A recent multicenter randomized trial evaluated imatinib given prophylactically (n = 26) compared with imatinib given at the time of MRD detection (ie, molecular recurrence; n = 29) in patients who underwent allogeneic HCT with a planned duration of imatinib therapy for 1 year.\(^ {159} \) MRD was defined by appearance of \( BCR-ABL \) transcripts, as assessed by quantitative RT-PCR performed at a central laboratory. In the prophylactic arm, imatinib was started in 24 patients (92%) at a median time of 48 days (range, 23–88 days) after HCT. In the MRD-triggered arm, imatinib was started in 14 patients (48%) at a median time of 70 days (range, 39–567 days) after HCT. Imatinib was discontinued prematurely in the majority of patients in both arms (67% in the prophylaxis arm; 71% in the MRD-triggered arm), primarily because of toxicities.\(^ {159} \) Ongoing CR was observed in 81% of patients in the prophylaxis arm (median follow-up, 30 months) and in 78% of patients in the MRD-triggered arm (median follow-up, 32 months). No significant differences were found between the prophylaxis and MRD-triggered arms in terms of relapse rate (8% vs. 17%), 5-year DFS (84% vs. 60%), EFS (72% vs. 54%), or OS (80% vs. 74.5%).\(^ {159} \) However, MRD positivity was predictive of relapse regardless of treatment arm; the 5-year RFS rate was significantly lower among patients with detectable MRD compared with those who remained MRD negative (70% vs. 100%; \( P = .017 \)). Moreover, early MRD positivity (within 100 days after HCT) was associated with significantly decreased EFS compared with late MRD detection (median, 39 months vs. not reached; 4-year EFS, 39% vs. 65%; \( P = .037 \)).\(^ {159} \) This trial suggested that imatinib given post-allogeneic HCT (either prophylactically or based on MRD detection) resulted in low relapse rates and durable remissions. However, imatinib may not provide benefit for patients who experience early molecular relapse or persistent MRD following HCT. Although no randomized controlled trials have yet been conducted to establish the efficacy of TKIs (compared with observation only or other interventions) following allogeneic HCT, the collective results from these studies suggest that TKI maintenance may have a potential role in reducing the risk for relapse.

A proportion of patients with Ph-positive ALL may have disease resistant to initial therapy with imatinib-containing regimens or may experience relapse after imatinib therapy. Resistance to imatinib is attributed, at least partly, to the presence of point mutations within the \( ABL \) kinase domain.\(^ {160-163} \) Moreover, CNS relapse has been reported in both patients with disease responsive to imatinib therapy (isolated CNS relapse with CR in marrow) and patients with disease resistant to imatinib therapy.\(^ {164-167} \) The concentration of imatinib in the cerebrospinal fluid (CSF) has been shown to be approximately 2 logs lower than that achieved in the blood, suggesting that this agent does not adequately penetrate the blood-brain barrier to ensure CNS coverage.\(^ {165,167} \) A study showed that among patients with ALL treated with imatinib and who did not receive routine prophylactic intrathecal therapy or cranial irradiation, 12% developed CNS leukemia.\(^ {166} \) Patients with imatinib-resistant disease who developed CNS disease rapidly died from progressive disease.
disease; conversely, patients with imatinib-sensitive disease who developed isolated CNS relapse could be successfully treated with intrathecal therapy with or without cranial irradiation.\textsuperscript{164,166}

Dasatinib is a second-generation TKI that inhibits both the BCR-ABL kinase and SRC family kinase, the latter of which is thought to be involved in an alternative signaling pathway in imatinib-resistant ALL. Moreover, dasatinib displayed a 325-fold increased potency in inhibiting in vitro growth of cells with wild-type $\textit{BCR-ABL}$ compared with imatinib,\textsuperscript{168} and maintained activity against cells harboring imatinib-resistant $\textit{ABL}$ kinase domain mutations, with the exception of the T315I, V299L, and F317L mutations.\textsuperscript{168-170} In phase II and III dose-comparison studies, dasatinib showed activity in patients with relapsed or refractory ALL who could not tolerate or had disease resistant to imatinib.\textsuperscript{127,170,171}

Additionally, dasatinib showed activity against CNS leukemia in preclinical in vivo models and in a small group of patients with Ph-positive ALL with CNS involvement.\textsuperscript{172} Thus, it seems that dasatinib may provide some benefit over imatinib in terms of increased potency in inhibiting signaling pathways, activity against various $\textit{ABL}$ kinase mutations, and greater penetration of the blood-brain barrier.

Recent studies have shown the promising activity of dasatinib when incorporated into frontline regimens for patients with ALL. In a phase II study from MDACC, dasatinib was combined with hyper-CVAD and subsequent maintenance therapy in patients with previously untreated Ph-positive ALL ($n = 35$; median age, 53 years; range, 21–79 years; 31% were older than 60 years); 4 of the patients received allogeneic HCT at first CR.\textsuperscript{129} The 2-year OS and EFS rates were 64% and 57%, respectively. In a study from GIMEMA (LAL-1205), patients with Ph-positive ALL ($n = 53$ evaluable; median age, 54 years; range, 24–76.5 years) received induction therapy with dasatinib and prednisone.\textsuperscript{139} Postinduction therapy included no further therapy ($n = 2$), TKI only ($n = 19$), TKI combined with chemotherapy ($n = 10$) with or without autologous HCT ($n = 4$), or allogeneic HCT ($n = 18$). All patients experienced a CR after induction therapy. The median OS was 31 months and the median DFS (calculated from day +85) was 21.5 months. At 20 months, the OS and DFS rates were 69% and 51%, respectively.\textsuperscript{139} T315I mutation was detected in 12 of 17 patients with relapsed disease (71%).

The treatment of older patients with Ph-positive ALL may pose a challenge, because elderly patients or those with comorbidities may not tolerate aggressive regimens with multiagent chemotherapy combined with TKIs. Several studies have evaluated outcomes with imatinib induction, with or without concurrent corticosteroids, in the older adult population with Ph-positive ALL. In a study that randomly assigned older patients with Ph-positive ALL ($n = 55$; median age, 68 years; range, 54–79 years; 94.5% were aged 60 years or older) to induction therapy with imatinib versus chemotherapy alone, followed by imatinib-containing consolidation therapy, the estimated 2-year OS rate was 42%; no significant difference was observed between induction treatment arms.\textsuperscript{128} The median OS was numerically higher (but not statistically significant) among patients who received imatinib induction compared with those randomized to chemotherapy induction (23.5 vs. 12 months). However, the incidence of severe adverse events was significantly lower with imatinib induction (39% vs. 90%; $P = .005$), which suggested that induction therapy with imatinib may be better tolerated than chemotherapy in older patients with Ph-positive ALL.\textsuperscript{128} In a small phase II study from GRAALL (AFR-09 study), older patients (aged ≥55 years) with Ph-positive ALL ($n = 29$ evaluable; median age, 63 years) were treated with chemotherapy induction followed by a consolidation regimen with imatinib and methylprednisolone.\textsuperscript{173} The 1-year OS rate in this study was significantly higher compared with the
historical control population who received the same induction therapy but did not receive imatinib as part of consolidation (66% vs. 43%; \( P = .005 \)), and the median OS in this study was longer than that of the control group (23 vs. 11 months, respectively). In addition, the 1-year RFS rate was significantly increased with the addition of imatinib (58% vs. 11%; \( P < .001 \)). A phase II study by GIMEMA (LAL0201-B study) also evaluated imatinib combined with corticosteroids in older patients (aged >60 years) with Ph-positive ALL (n = 29 evaluable; median age, 69 years). Patients received imatinib in combination with prednisone for induction. The estimated 1-year DFS and OS rates were 48% and 74%, respectively; the median OS was 20 months.

In a recent European multicenter trial (EWALL-Ph-01 study), induction therapy with dasatinib combined with low-intensity chemotherapy (vincristine and dexamethasone) was evaluated in older patients (aged ≥55 years) with Ph-positive ALL (n = 71; median age, 69 years; range, 58–83 years). The CR rate after induction was 94%; MRD response (BCR-ABL/ABL ratio ≤0.1%) occurred in 54% of patients and 22% had undetectable MRD. The estimated 3-year RFS and OS were 43% and 45%, respectively. Relapse occurred in 29 patients (41%) after a median of 9 months (range, 3–34 months); 24 patients died. The ABL mutation T315I was found in 63% of relapsed cases; mutations in F317L and V299L were found in 7% and 4% of relapsed cases, respectively. These studies suggest that the use of TKIs, either alone or in combination with less intensive therapies (eg, corticosteroids with or without vincristine), may provide an alternative treatment option for older patients with Ph-positive ALL for whom intensive regimens are not appropriate.

### Treatment of Relapsed Ph-Positive ALL

The treatment of patients who experience relapse after initial therapy for ALL remains a challenge, because these patients have a very poor prognosis. Several large studies have reported a median OS of only 4.5 months to 6 months, and a 5-year OS rate of 3% to 10% among patients who experience relapse after initial treatment. One major factor associated with poorer survival outcomes after subsequent therapy for relapsed ALL is the duration of response to frontline treatment. In an analysis of data from the PETHEMA trials, patients with disease that relapsed more than 2 years after frontline therapy had significantly higher 5-year OS rates than the groups of patients who relapsed within 1 to 2 years or within 1 year of frontline therapy (31% vs. 15% vs. 2%; \( P < .001 \)). Similarly, in the MRC UKALL XII/ECOG E2993 trial, patients with disease that relapsed more than 2 years after initial diagnosis and frontline therapy had a significantly higher 5-year OS rate than those who relapsed within 2 years (11% vs. 5%; \( P < .001 \)). In the pre-imatinib era, patients with Ph-positive ALL who relapsed after frontline therapy had dismal outcomes; subgroup data from the large, prospective trials LALA-94 and MRC UK XII/ECOG E2993 showed a median OS of 5 months and a 5-year OS rate of 3% to 6% among patients subsequently treated for relapsed Ph-positive ALL.

The incorporation of TKIs such as imatinib in the frontline treatment regimen for Ph-positive ALL has become the established SOC. However, the emergence of resistance to TKI therapy poses a challenge for patients with disease that is primary refractory to or that relapses after initial treatment with TKI-containing regimens. Point mutations within the ABL kinase domain and alternative signaling pathways mediated by the SRC family kinase have been implicated as mechanisms of resistance to imatinib. These mutations within the
ABL kinase domain have been identified in a large proportion of patients who experience disease recurrence after imatinib-containing therapy.\textsuperscript{161,162} Moreover, ABL kinase domain mutations may be present in a small group of imatinib-naïve patients even before initiation of any TKI therapy.\textsuperscript{181,182} Dasatinib and nilotinib are second-generation TKIs that have shown greater potency in inhibiting BCR-ABL compared with imatinib, and retention of antileukemic activity in cells with certain imatinib-resistant ABL mutations.\textsuperscript{168-170,183,184} Both TKIs have been evaluated as single-agent therapy in patients with Ph-positive ALL that is resistant or intolerant to imatinib treatment.\textsuperscript{125,127,171,185} A randomized phase III study examined the activity of dasatinib administered as once-daily (140 mg daily) versus twice-daily (70 mg twice daily) dosing in patients with Ph-positive leukemia resistant to imatinib.\textsuperscript{171} The once-daily dosing resulted in higher response rates (major cytogenetic response) than the twice-daily dosing (70% vs. 52%). Although the median OS was shorter with the once-daily dosing (6.5 vs. 9 months), the median PFS was longer (4 vs. 3 months).\textsuperscript{171} These differences in outcomes between the dosing arms were not statistically significant. Dasatinib is currently approved in the United States for the treatment of patients with Ph-positive ALL who are intolerant or resistant to prior therapy.

Dasatinib in combination with hyper-CVAD was investigated in a phase II trial (n = 34) including patients with Ph-positive relapsed ALL (n = 19) and patients with lymphoid blast phase chronic myelogenous leukemia (CML) (n = 15).\textsuperscript{186} An overall response rate of 91% was obtained with 26 patients achieving complete cytogenetic remission, 13 patients having complete molecular response, and 11 patients having a major molecular response. There were 9 patients who went on to receive allogeneic HCT, including 2 patients with ALL. In the patients with relapsed ALL, 30% remained in CR at 3 years (median, 8.8 months) with a 3-year OS of 26% (median, 9 months). At the median follow-up of 52 months (range, 45–59 months), 2 patients with ALL were still alive (11%).

Not all imatinib-resistant ABL mutations are susceptible to the newer TKIs. For instance, dasatinib is not as active against cells harboring the ABL mutations T315I, V299L, and F317L.\textsuperscript{163,168-170,187-189} Thus, for patients with disease resistant to TKI therapy, it becomes important to identify potential ABL mutations that may underlie the observed resistance to treatment. A panel of experts from the European LeukemiaNet published recommendations for the analysis of ABL kinase domain mutations in patients with CML, and treatment options according to the presence of different ABL mutations.\textsuperscript{190}

Ponatinib is another TKI that was initially approved by the FDA in December 2012 for the treatment of adult patients with chronic, accelerated, or blast phase Ph-positive CML or Ph-positive ALL, with resistance or intolerance to prior therapy.\textsuperscript{191} Though temporarily removed from the market in November 2013, ponatinib distribution resumed in December 2013 following revision to both the prescribing information and REMS program to address the risk for serious cardiovascular adverse events. This TKI has been shown to inhibit both native and mutant forms of BCR-ABL (including those resulting from T315I mutation) in preclinical studies.\textsuperscript{123,191} In a phase I dose-escalation study that evaluated ponatinib in heavily pretreated patients with Ph-positive leukemias resistant to prior TKI agents, major hematologic response was reported in 36% of the subgroup of patients with accelerated or blast phase CML or Ph-positive ALL (n = 22).\textsuperscript{123} Major cytogenetic response occurred in 7 patients (32%), with a complete cytogenetic response in 3 patients (14%). Response outcomes in the small group of patients with T315I mutation (n = 7) appeared similar to those in the overall subgroup.\textsuperscript{123} In the multicenter, open-label, phase II study (PACE trial; n = 449 enrolled; median age, 59 years, range 18–94
years), ponatinib showed substantial activity in patients with Ph-positive leukemias resistant or intolerant to second-generation TKIs. Patients in this trial were heavily pretreated, with 58% having previously received at least 3 TKIs. Among the subgroup of patients with Ph-positive ALL (n = 32), the median age was 62 years (range, 20–80 years) and 41% were aged 65 years or older. Major hematologic response among the subgroup with Ph-positive ALL was 41%; major and complete cytogenetic response was 47% and 38%, respectively. The estimated PFS rate at 12 months was 7% (median, 3 months), and the OS rate at 12 months was estimated to be 40% (median, 8 months). In the subset of patients with Ph-positive ALL with ABL T315I mutation (n = 22), major hematologic response was 36%, and major and complete cytogenetic response was 41% and 32%, respectively. No significant differences in duration or OS outcomes were apparent based on ABL T315I mutation status; however, the patient numbers were small. The most common overall treatment-related adverse events in the PACE trial included thrombocytopenia (37%), rash (34%), dry skin (32%), abdominal pain (22%), neutropenia (19%), and anemia (13%); pancreatitis was the most common serious event, reported in 5% of patients. These studies demonstrated the activity of ponatinib in patients with Ph-positive leukemias resistant to other TKIs, including those with Ph-positive ALL harboring a T315I mutation.

Bosutinib, a TKI that acts as a dual inhibitor of BCR-ABL and SRC family kinases, was approved (in September 2012) by the FDA for the treatment of chronic, accelerated, or blast phase Ph-positive CML in adult patients with resistance or intolerance to prior therapy. The FDA approval was based on an open-label, multicenter phase I/II trial in patients with either chronic, accelerated, or blast phase CML previously treated with at least one prior TKI therapy; all patients had received prior imatinib therapy. The efficacy and safety of this agent in patients with relapsed/refractory Ph-positive ALL have not been established.

Treatment options are extremely limited for patients with Ph-positive ALL who experience relapse after receiving allogeneic HCT. Several published cases have reported on the feasibility of inducing a molecular CR with dasatinib in patients with Ph-positive ALL who have experienced an early relapse after first allogeneic HCT. The patients subsequently received a second allogeneic HCT. Studies entailing donor lymphocyte infusion (DLI) to induce further graft-versus-leukemia effect in patients with Ph-positive ALL experiencing disease relapse after allogeneic HCT have reported little to no benefit, though it has been suggested that this is due to a leukemic burden that may have been too high to control effectively. Indeed, published case reports have suggested that the use of DLI for residual disease or molecular relapse (as noted by levels of BCR-ABL fusion mRNA measured with PCR) after allogeneic HCT may eliminate residual leukemic clones and thereby prevent overt hematologic relapse. Moreover, case reports have suggested using newer TKIs, such as dasatinib and nilotinib, along with DLI to manage relapse after allogeneic HCT. A case report described the treatment course and outcome in a patient who experienced early hematologic relapse after allogeneic HCT (performed in first CR), responded to imatinib-based multiagent chemotherapy and DLI (with persistent residual disease based on BCR-ABL transcripts), but then experienced a second hematologic relapse. The disease progressed through second-line therapy with imatinib-based multiagent chemotherapy, and the patient received dasatinib, which resulted in a complete hematologic response. The patient subsequently underwent a second allogeneic HCT and maintained a molecular CR lasting 18 months. Although these approaches are promising, only limited data based on case reports are available. Evidence from prospective studies
is needed to establish the role of DLI, with or without TKIs, in the treatment of relapsed disease.

In December 2014, the FDA approved blinatumomab for the treatment of relapsed or refractory Ph-negative precursor B-cell ALL (see Treatment of Relapsed Ph-Negative ALL). Blinatumomab was shown to eliminate residual disease in 80% of patients with relapsed or MRD-positive B-precursor ALL after intensive chemotherapy (N = 21; n = 20 evaluable); five patients with Ph-positive B-cell precursor ALL were enrolled. Three patients responded within the first 2 cycles of treatment. While there were not enough patients for definitive analysis of this subgroup, data suggest that blinatumomab may also improve outcomes for relapsed or refractory Ph-positive precursor B-cell ALL. The Alcantara trial is currently investigating blinatumomab in a larger cohort of patients with Ph-positive B-cell ALL with relapsed disease or disease refractory to at least one second-generation TKI (dasatinib, nilotinib, bosutinib, ponatinib) or intolerant to second-generation TKI and intolerant or refractory to imatinib mesylate (clinicaltrials.gov; NCT02000427).

Chimeric antigen receptor (CAR) T cells are a newer strategy for treating patients with relapsed or refractory ALL and has shown significantly greater OS than current regimens. CAR T cells can be used in the treatment of patients with Ph-positive or Ph-negative disease; however, the use of this regimen is restricted to clinical trials and data are not yet sufficient for incorporation into routine treatment of patients with ALL (see Treatment of Relapsed Ph-negative ALL in this Discussion).

Currently, bone marrow transplant is the only cure for relapsed/refractory ALL, but many patients are not eligible for transplant based on age or progression of the disease. The pre-treatment of patients with CAR T cells has served as a bridge for transplant, and patients who were formally unable to be transplanted due to poor remission status have a CR and ultimately transplantation. There are fewer side effects to this treatment compared to the current standard-of-care regimens. While side effects from CAR T cells may be severe, they have been reversible. Adverse events are attributed to cytokine release syndrome and macrophage activation that occur in direct response to adoptive cell transplant resulting in high fever, hypotension, breathing difficulties, delirium, aphasia, and neurologic complications. Improvement in patient monitoring has shown successful treatment of these symptoms with the monoclonal antibody tocilizumab, an antagonist of interleukin-6. Based on their ability to elicit a significant response towards elimination of tumor cells, multicenter phase II studies are planned for CAR T cells in the treatment of relapsed/refractory ALL.

NCCN Recommendations for Ph-Positive ALL

AYA Patients (Aged 15–39 Years) with Ph-Positive ALL

The panel recommends that AYA patients with Ph-positive ALL be treated in a clinical trial, when possible. In the absence of an appropriate clinical trial, the recommended induction therapy would comprise multiagent chemotherapy combined with a TKI. Treatment regimens should include adequate CNS prophylaxis for all patients. It is also important to adhere to the treatment regimens for a given protocol in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. For AYA patients experiencing a CR after initial induction therapy, consolidation with allogeneic HCT should be considered if a matched donor is available. However, in younger AYA patients (aged ≤21 years), emerging data suggest that allogeneic HCT may not confer an advantage over chemotherapy combined with TKIs. After HCT, maintenance therapy (for 2–3 years) with a TKI, with or without monthly pulses of vincristine/prednisone, is
weekly methotrexate and daily 6-MP may be added to the maintenance regimen, as tolerated; however, the doses of these antimitabolite agents may need to be reduced in the setting of hepatotoxicity or myelosuppression. For patients without a donor, consolidation therapy after a CR should comprise a continuation of multiagent chemotherapy combined with a TKI. These patients should continue to receive post-consolidation maintenance therapy with a regimen that includes a TKI. Individuals who inherit a nonfunctional variant allele of the TPMT gene are known to be at high risk for developing hematopoietic toxicity (in particular, severe neutropenia) after treatment with 6-MP. Testing for TPMT gene polymorphism should be considered in patients receiving 6-MP as part of maintenance therapy, particularly those who experience severe bone marrow toxicities.

The treatment approach for AYA patients experiencing less than a CR after initial induction therapy (ie, having primary refractory disease) would be similar to that for patients with relapsed/refractory ALL (see Patients With Relapsed/Refractory Ph-Positive ALL in this Discussion).

**Adult Patients (Aged ≥40 Years) with Ph-Positive ALL**

For adult patients with Ph-positive ALL, the panel recommends treatment in a clinical trial, when possible. In the absence of an appropriate clinical trial, the recommended induction therapy would initially depend on the patient’s age and/or presence of comorbid conditions. Treatment regimens should include adequate CNS prophylaxis for all patients, and a given treatment protocol should be followed in its entirety. Although the age cutoff indicated in the guidelines has been set at 65 years, it should be noted that chronologic age alone is not a sufficient surrogate for defining fitness; patients should be evaluated on an individual basis to determine fitness for therapy based on factors such as performance status, end-organ function, and end-organ reserve.

For relatively fit adult patients (aged <65 years or with no substantial comorbidities), the recommended treatment approach is similar to that for AYA patients. Induction therapy would comprise multiagent chemotherapy combined with a TKI. For patients experiencing a CR after induction, consolidation with allogeneic HCT should be considered if a matched donor is available. After HCT, maintenance therapy (for 2–3 years) with a TKI, with or without monthly pulses of vincristine/prednisone for 2 to 3 years is recommended. Weekly methotrexate and daily 6-MP may be added to the maintenance regimen, as tolerated; however, the doses of these antimitabolite agents may need to be reduced in the setting of hepatotoxicity or myelosuppression. For patients without a donor, consolidation therapy after a CR should comprise a continuation of multiagent chemotherapy combined with a TKI. These patients should continue to receive post-consolidation maintenance therapy with a regimen that includes a TKI. Again, testing for TPMT gene polymorphism should be considered for patients receiving 6-MP as part of maintenance therapy, especially those who develop severe bone marrow toxicities after its initiation. For patients with less than a CR after induction, the treatment approach would be similar to that for patients with relapsed/refractory disease (see later discussion).

For adult patients who are less fit (aged ≥65 years or with substantial comorbidities), the recommended induction therapy includes a TKI with corticosteroids or with chemotherapy regimens. Dose modifications may be required for chemotherapy agents, as needed. Patients with a CR to induction should continue consolidation therapy with a TKI with or without corticosteroids or a TKI with or without chemotherapy; maintenance therapy (for 2–3 years) with a TKI, with or without monthly
pulses of vincristine/prednisone for 2 to 3 years, is recommended. Weekly methotrexate and daily 6-MP may be added to the maintenance regimen, as tolerated; however, the doses of antimetabolites may need to be reduced in the setting of hepatotoxicity or myelosuppression. Adult patients with less than a CR after induction should be managed similarly to those with relapsed/refractory disease (see discussion section below).

**Patients with Relapsed/Refractory Ph-Positive ALL**

Mutation testing for the *ABL* gene should be considered in patients with Ph-positive ALL that has relapsed after or is refractory to initial TKI-containing therapy given that certain mutations may account for the observed resistance to induction therapy. The panel has largely adopted the recommendations for treatment options based on *ABL* mutation status for CML, as published by the European LeukemiaNet. Based on these published recommendations, dasatinib (if not administered during initial induction) could be considered for patients with relapsed/refractory Ph-positive disease that have the mutations Y253H, E255K/V, or F359V/C/I. For patients with relapsed/refractory disease that have the mutations V299L, T315A, or F317L/V/I/C, nilotinib could be considered. The TKI bosutinib has been added for patients with the mutations E255K/V, F317L/V/I/C, F359V/C/I, T315A, or Y253H. Ponatinib has activity against and is effective in treating the T315I mutation. However, due to the high frequency of serious vascular events with ponatinib therapy, the FDA indication is restricted to the treatment of patients with the T315I mutation or in patients with disease resistant to other TKI therapies. For all other mutations of the *ABL* gene, high-dose imatinib, dasatinib, or nilotinib may be considered.

For patients with relapsed/refractory disease, participation in a clinical trial is preferred. In the absence of an appropriate trial, patients may be considered for second-line therapy with an alternative TKI (ie, different from the TKI used as part of induction therapy) alone, TKI combined with multiagent chemotherapy, TKI combined with corticosteroids (especially for elderly patients who may not tolerate multiagent combination therapy), or allogeneic HCT if a donor is available. For patients with disease that relapses after an initial allogeneic HCT, other options may include a second allogeneic HCT and/or DLI. Blinatumomab may be considered for patients with Ph-positive precursor B-cell ALL that is refractory to TKIs based on the lack of other treatment alternatives.

**Management of Ph-Negative ALL**

**Initial Treatment in AYAs with Ph-Negative ALL**

The AYA population with ALL can pose a unique challenge given that patients may be treated with either a pediatric or an adult protocol, depending on local referral patterns and institutional practices. Retrospective analyses based on cooperative group studies from both the United States and Europe have consistently shown the superior outcomes for AYA patients (aged 15–21 years) treated on pediatric versus adult ALL regimens. In the AYA population, 5-year EFS rates ranged from 63% to 74% for patients treated on a pediatric study protocol versus 34% to 49% for those receiving the adult protocol. In a recent retrospective comparative study that analyzed outcomes of AYA patients (aged 16–20 years) treated on a pediatric CCG study protocol (n = 197; median age, 16 years) versus an adult CALGB study protocol (n = 124; median age, 19 years), the 7-year EFS rate was significantly improved for patients treated on the pediatric protocol compared with those on the adult regimen (63% vs. 34%; \( P < .001 \)); the 7-year OS rate was 67% versus 46%, respectively (\( P < .001 \)). Moreover, AYA patients treated on the adult protocol experienced a significantly higher rate of isolated CNS relapse at 7 years (11% vs. 1%; \( P = .006 \)). The substantial improvements in
outcomes observed with the pediatric regimen in this study, and in the earlier retrospective analyses from other cooperative groups, may be attributed largely to the use of greater cumulative doses of drugs, such as corticosteroids (prednisone and/or dexamethasone), vincristine, and L-asparaginase, and to earlier, more frequent, and/or more intensive CNS-directed therapy compared with adult regimens.91 Favorable outcomes with the use of pediatric-based treatment protocols in the AYA population have also been reported in other recent studies. In an analysis of outcomes in children and AYA patients treated in the Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols (1991–2000), the 5-year EFS rate among younger AYA patients (aged 15–18 years; n = 51) was 78%, which was not significantly different from the EFS rates observed for children aged 10 to 15 years (77%; n = 108) or those aged 1 to 10 years (85%; n = 685).208 The CCG 1961 study was designed to evaluate the benefit of augmented versus standard postinduction intensification therapy in children aged 1 to 9 years with high WBC counts (≥50 × 10^9/L) or in older children and adolescents aged 10 to 21 years.90 Patients were stratified by their initial response to induction therapy as either slow early responders (patients with >25% bone marrow blasts on day 7 of induction) or rapid early responders. Among the patients who were rapid early responders to induction (n = 1299), the augmented postinduction intensification arm was associated with significantly increased rates of 5-year EFS (81% vs. 72%; P < .0001) and OS (89% vs. 83%; P = .003) compared with the standard-intensity arm.90 In the subgroup of AYA patients (aged 16–21 years; n = 262) from the CCG 1961 study treated with either augmented or standard-intensity regimens, the 5-year EFS and OS rates were 71.5% and 77.5%, respectively.209 Among the AYA patients who were considered rapid early responders, the augmented-intensity (n = 88) and standard-intensity (n = 76) arms showed no statistically significant differences in rates of 5-year EFS (82% vs. 67%, respectively) or OS (83% vs. 76%, respectively). For the AYA patients who were considered slow early responders (all of whom received the augmented-intensity regimen), the 5-year EFS rate was 71%.209 Data from the most recent Total Therapy (XV) study by the St. Jude Children’s Research Hospital showed dramatic improvements in survival outcomes for the AYA population. In this study, patients were primarily risk-stratified based on treatment response; patients were treated according to risk-adjusted intensive chemotherapy, with the incorporation of MRD evaluation during induction (day 19) to determine the need for additional doses of asparaginase.210,211 The 5-year EFS rate for the AYA population (aged 15–18 years; n = 45) was 86% (95% CI, 72%–94%), which was not significantly different from the 87% EFS rate (95% CI, 84%–90%; P = .61) observed for the younger patients (n = 448). The 5-year OS rates for the AYA patients and younger patients were 88% and 94%, respectively (P = not significant).210,211 The favorable EFS and OS outcomes in AYA patients in this study were attributed partly to the use of intensive dexamethasone, vincristine, and asparaginase, in addition to early intrathecal therapy (ie, triple intrathecal chemotherapy with cytarabine, hydrocortisone, and methotrexate) for CNS-directed therapy. In addition, the use of prophylactic cranial irradiation was safely omitted in this study; the 5-year cumulative incidence of isolated CNS relapse and any CNS relapse was 3% and 4%, respectively, for the entire study population (n = 498).210 Moreover, all 11 patients with isolated CNS relapse were children younger than 12 years of age. This study showed that, with intensive risk-adjusted therapy and effective CNS-directed intrathecal regimens, AYA patients can obtain long-term EFS without the need for cranial irradiation or routine allogeneic HCT.210,211
Given the success seen with multiagent intensive chemotherapy regimens for pediatric patients with ALL, several clinical trials have evaluated pediatric-inspired regimens for the AYA patient population. In one of these trials (PETHEMA ALL-96), adolescent (n = 35; aged 15–18 years) and young adult (n = 46; aged 19–30 years) patients with standard-risk Ph-negative ALL [defined as WBC count <30 × 10^9/L; absence of t(9;22), t(1;19), t(4;11), or any other 11q23 rearrangements] received frontline therapy with a 5-drug induction regimen (vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide), consolidation/reinduction, and maintenance, along with triple intrathecal therapy throughout the treatment period. The 6-year EFS and OS rates for the entire patient cohort were 61% and 69%, respectively. No difference in EFS rate was observed between adolescents (60%; 95% CI, 43%–77%) and adults (63%; 95% CI, 48%–78%); similarly, no significant difference was observed in OS for adolescents (77%; 95% CI, 63%–91%) versus adults (63%; 95% CI, 46%–80%). Based on multivariate regression analysis, slow response to induction therapy (defined as having >10% blast cells in the bone marrow aspirate performed on day 14 of treatment) was the only factor associated with a poor EFS (odds ratio [OR], 2.99; 95% CI, 1.25–7.17) and OS (OR, 3.26; 95% CI, 1.22–8.70).

A multicenter phase II trial evaluated a pediatric-inspired regimen (based on the DFCI Childhood ALL Consortium Protocol 00-01) in AYA and adult patients (aged 16–50 years) with previously untreated ALL; 20% of the patients in this study had Ph-positive disease. The treatment regimen comprised induction (vincristine, doxorubicin, prednisone, L-asparaginase, and high-dose methotrexate), triple intrathecal therapy, intensification, and maintenance. Among the 75 patients with evaluable data, the estimated 2-year EFS and OS rates were 72.5% and 77%, respectively. Adverse events included 1 death from sepsis (during induction), pancreatitis in 9 patients (12%; including 1 death), osteonecrosis in 2 patients (3%), thrombosis/embolism in 14 patients (19%), and neutropenic infection in 23 patients (31%).

Although this intensive regimen was feasible in adult patients, further follow-up data are needed to evaluate long-term survival outcomes.

The prospective phase II GRAALL-2003 study evaluated a pediatric-inspired regimen (using intensified doses of vincristine, prednisone, and asparaginase) for adolescents and adults with Ph-negative ALL (n = 225; median age, 31 years; range, 15–60 years). The induction regimen comprised vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide. Patients with high-risk disease and donor availability were allowed to proceed to allogeneic HCT. The EFS and OS rates at 42 months were 55% and 60%, respectively. When data from patients who underwent transplantation at first CR were censored, the DFS rates at 42 months were 52% for patients with high-risk disease and 68% for patients with standard-risk disease (risk assignment based on GRAALL protocol); these DFS outcomes by risk groups were similar to outcomes using the MRC UKALL/ECOG definition for risk classification. Advanced age was predictive of poorer survival outcomes on this study; the OS rate at 42 months was 41% for patients older than 45 years compared with 66% for those aged 45 years or younger. Moreover, advanced age (using 45 years as the cutoff) was associated with a higher cumulative incidence of therapy-related deaths (23% vs. 5%) and deaths in first CR (22% vs. 5%). Thus, it seems that the benefit of this pediatric-inspired regimen outweighed the risks for therapy-related deaths only for those patients up to 45 years of age with Ph-negative ALL.

The USC ALL trial (based on the pediatric CCG-1882 regimen) has studied the regimen of daunorubicin, vincristine, prednisone, and methotrexate with augmented pegaspargase in patients between the...
ages of 18 years and 57 years of age with newly diagnosed ALL (n = 51). The augmented arm included one long-lasting pegaspargase dose in each cycle of the 6 total scheduled doses. Each dose of pegaspargase (2000 IU/m² IV) was preceded with hydrocortisone for hypersensitivity prophylaxis followed by 1 to 2 weeks of oral steroids. Patients on this trial received a mean of 3.8 doses per patient with 45% of patients receiving all 6 doses, while 20% of patients discontinued treatment based on toxicity. The 7-year OS was 51% (58% of these patients were Ph-negative) and the 7-year DFS was 58%. The dose of pegaspargase was lower than the FDA-approved dose of 2500 IU/m², and adjustments to the dosing interval were made to be greater than or equal to 4 weeks. This deviated from the pediatric protocol to account for the difference in drug enzymatic activity in adults. Study data suggest that adaptation of the pediatric regimen to the adult population may be feasible with modifications to reduce toxicity.

A multicenter phase II Intergroup study (CALGB 10403) is currently ongoing to evaluate a pediatric-inspired regimen in the treatment of AYA patients with Ph-negative ALL. One of the objectives of this study is to compare the outcomes of patients treated in this trial with those of a similar group of patients (in regard to age and disease characteristics) treated by pediatric oncologists in the COG trial (AALL-0232). The treatment protocol includes a 4-drug induction regimen with intrathecal cytarabine and intrathecal methotrexate, consolidation, interim maintenance, delayed intensification, maintenance (for 2–3 years), and radiotherapy (for patients with testicular or CNS disease or those with T-cell ALL). Early results from 296 evaluable patients (median age, 24 years; range 17–39 years) report 70 deaths and 87 patients still on protocol therapy. The median EFS is 59.4 months (95% CI, 38.4 months to not reached) and the 2-year EFS rate is 66% (95% CI, 60%–72%). Patients with negative MRD on day 28 of induction had a 100% EFS (P = .0006). It was also noted that patients with Ph-like signatures had a significantly lower 2-year EFS compared to those without Ph-like disease (52% vs. 81%; P = .04).

For patients with T-cell ALL, the addition of nelarabine may be a promising approach. Nelarabine is a nucleoside metabolic inhibitor and a prodrug of ara-G, approved for the treatment of patients with T-cell ALL with disease that has not responded to or that has relapsed after at least 2 chemotherapy regimens. This drug is currently under evaluation as part of frontline chemotherapy regimens in AYA patients with T-cell ALL. The safety results from the randomized phase III COG study (AALL-0434) of the augmented BFM chemotherapy regimen, with or without nelarabine, showed that the toxicity profiles were similar between patients with high-risk T-cell ALL who received nelarabine (n = 47) and those who did not (n = 47). No significant differences were observed in the occurrence of neurologic adverse events between these groups, including peripheral motor neuropathy, peripheral neuropathy, or CNS neurotoxicity. The incidence of adverse events such as febrile neutropenia and elevation of liver enzymes was also similar between treatment groups. These initial safety data suggest that nelarabine may be better tolerated in frontline regimens than in the relapsed/refractory setting. Results from the efficacy phase of this study are awaited.

For AYA patients in first CR, allogeneic HCT may be considered for high-risk cases, such as those with elevated WBC counts and poor-risk cytogenetics (eg, hypodiploidy, MLL rearrangement) at diagnosis. A large multicenter trial (LALA-94 study) evaluated the role of postinduction HCT as one of the study objectives in adolescent and adult ALL patients receiving therapy for previously untreated ALL (n = 922; median age, 33 years; range, 15–55 years). Patients were stratified into 4 risk groups: 1) Ph-negative standard-risk disease [defined as achievement of CR after 1 course of chemotherapy;
absence of CNS disease; absence of t(4;11), t(1;19), or other 11q23 rearrangements; WBC count <30 x 10^9/L; 2) Ph-negative high-risk ALL (defined as patients with non-standard-risk disease and without CNS involvement); 3) Ph-positive ALL; and 4) evidence of CNS disease. After induction therapy, patients with Ph-negative high-risk ALL were eligible to undergo allogeneic HCT if a matched sibling donor was available; those without a sibling donor were randomized to undergo autologous HCT or chemotherapy alone.

Among the subgroup of patients with Ph-negative high-risk ALL (n = 211), the 5-year DFS and OS rates were 30% (median, 16 months) and 38% (median, 29 months), respectively. Based on intent-to-treat analysis, outcomes in patients with Ph-negative high-risk ALL were similar for autologous HCT (n = 70) and chemotherapy alone (n = 59) in terms of median DFS (15 vs. 11 months), median OS (28 vs. 26 months), and 5-year OS rate (32% vs. 21%).

Outcomes were improved in patients with Ph-negative high-risk ALL and those with CNS involvement allocated to allogeneic HCT. The median DFS was 21 months for these patients, and the median OS has not yet been reached; the 5-year OS rate was 51%.

Thus, it appeared that in patients with Ph-negative high-risk disease, allogeneic HCT in first CR improved DFS outcomes, whereas autologous HCT did not result in significant benefit compared with chemotherapy alone.

In the PETHEMA ALL-93 trial, adult patients with high-risk ALL [defined as 30–50 years of age; WBC count ≥25 x 10^9/L; or t(9;22), t(4;11), other 11q rearrangements, or t(1;19)] received postremission induction therapy (n = 222 eligible; median age, 27 years; range, 15–50 years) with allogeneic HCT (n = 84; if matched related donor available), autologous HCT (n = 50), or chemotherapy alone (n = 48).

Based on intent-to-treat analysis of data from patients with Ph-negative high-risk disease, no significant advantage was observed in a donor versus no-donor comparison of median DFS (21 months vs. 38 months), median OS (32 months vs. 67 months), 5-year DFS rate (37% vs. 46%), or 5-year OS rate (40% vs. 49%). In addition, when the analysis was conducted based on the actual postremission treatment received, no significant differences were noted between treatment arms for 5-year DFS rates (50% for allogeneic HCT; 55% for autologous HCT; and 54% for chemotherapy alone).

The role of allogeneic HCT in adults with ALL was also evaluated in the large multicenter MRC UKALL XII/ECOG E2993 study (n = 1913; aged 15–59 years).

In this study, high risk was defined as 35 years of age or older; time to CR greater than 4 weeks from induction; elevated WBC counts (>30 x 10^9/L for B-cell ALL; >100 x 10^9/L for T-cell ALL); or the presence of Ph chromosome; all others were considered to be standard risk. Patients experiencing a remission with induction therapy were eligible to undergo allogeneic HCT if a matched sibling donor was available or, in the absence of a sibling donor, were randomized to undergo autologous HCT or chemotherapy. The 5-year OS rate was higher for patients randomized to chemotherapy alone compared with autologous HCT (46% vs. 37%; P = .03). A donor versus no-donor comparison in all patients with Ph-negative ALL showed that the 5-year OS rate was significantly higher in the donor group than in the no-donor group (53% vs. 45%; P = .01). This advantage in OS outcomes for the donor group was observed for patients with standard risk (62% vs. 52%; P = .02) but not for those with Ph-negative high-risk disease (41% vs. 35%).

This was partly because of the high rate of nonrelapse mortality observed with the donor group compared with the no-donor group (53% vs. 45%; P = 0.01). This advantage in OS outcomes for the donor group was observed for patients with standard risk (62% vs. 52%; P = .02) but not for those with Ph-negative high-risk disease (41% vs. 35%).

This was partly because of the high rate of nonrelapse mortality observed with the donor group compared with the no-donor group in patients with high-risk disease (36% vs. 14% at 2 years). Among patients with standard risk, the nonrelapse mortality rate at 2 years was 19.5% for the donor group and 7% for the no-donor group. Relapse rate was significantly lower in the donor group than in the no-donor group for
both patients with standard risk (24% vs. 49%; \( P < .001 \)) and those with high risk (37% vs. 63%; \( P < .001 \)). Nevertheless, the high nonrelapse mortality rate in the donor group among patients with high-risk disease seemed to diminish the advantage of reduced risks for relapse in this group. This study suggested that allogeneic HCT in first CR was beneficial in patients with standard-risk ALL.

The benefit of matched sibling allogeneic HCT in adult patients with standard-risk ALL was also reported by the HOVON cooperative group. In a donor versus no-donor analysis of patients with standard-risk ALL undergoing postremission therapy with matched sibling allogeneic HCT or autologous HCT, the donor arm was associated with a significantly reduced 5-year relapse rate (24% vs. 55%; \( P < .001 \)) and a higher 5-year DFS rate (60% vs. 42%; \( P = .01 \)) compared with the no-donor arm. In the donor group, the nonrelapse mortality rate at 5 years was 16% and the 5-year OS rate was 69%.

As evidenced by the previously described studies, matched sibling HCT has been established as a valuable treatment strategy for patients with high-risk Ph-negative ALL, but more recently URD transplants have been proposed. In a retrospective analysis of 169 patients who underwent URD HCT during first CR, 60 patients (36%) had one poor prognostic factor and 97 (57%) had multiple risk factors. The 5-year survival was 39%, which is higher than survival reported in studies of high-risk patients receiving chemotherapy alone. The most significant percentage of treatment-related mortality occurred in patients who were given mismatched donors compared to partially or well-matched donors. This study further demonstrated no significant difference in outcome between older and younger patients, suggesting that URD transplants may be an option for older patients. In a follow-up retrospective study by the same group, reduced-intensity conditioning (RIC) was incorporated to try to lower treatment-related mortality. RIC conditioning most commonly comprised busulfan (9 mg/kg or less), melphalan (150 mg/m²), low-dose total body irradiation (TBI) (less than 500 cGy single dose or less than 800 cGy fractionated), or fludarabine plus TBI of 200 cGy. RIC is more prominent in the treatment of older patients; therefore, the median age for patients receiving full intensity (FI) conditioning was 28 years (range, 16–62 years), and for patients receiving RIC, the median age was 45 years (range, 17–66 years). Despite the variation in age, results from the study have shown no difference in relapse at 3 years (35% vs. 26%, \( P = .08 \)) or in treatment-related mortality at 3 years (FI 33%; 95% CI, 31%–36% vs. RIC 32%; 95% CI, 23%–43%; \( P = .86 \)). The 3-year survival for HCT was similar following CR1 (FI 51%; 95% CI, 48%–55% vs. RIC 45%; 95% CI, 31–59%) and CR2 (FI 33%; 95% CI, 30%–37% vs. RIC 28%; 95% CI, 14%–44%). The DFS was also similar in both groups following CR1 (FI 49%; 95% CI, 45%–53% vs. RIC 36%; 95% CI, 23%–51%) and in CR2 (FI 32%; 95% CI, 29%–36% vs. RIC 27%; 95% CI, 14%–43%).

A systematic review and meta-analysis of published randomized trials on postremission induction therapy in adults with ALL reported a significant reduction in all-cause mortality with allogeneic HCT in first CR (RR, 0.88; 95% CI, 0.80–0.97) compared with autologous HCT or chemotherapy. A subgroup analysis showed a significant survival advantage with allogeneic HCT in standard-risk ALL, whereas a nonsignificant advantage was seen in high-risk ALL. Autologous HCT in first remission was not shown to be beneficial relative to chemotherapy in several large studies and meta-analyses.

### Initial Treatment in Adults with Ph-Negative ALL

Typically, induction regimens for adult ALL are also based on a backbone of vincristine, corticosteroids, and anthracyclines. The CALGB 8811 trial evaluated a 5-drug induction regimen (comprising
 vincristine, daunorubicin, prednisone, L-asparaginase, and cyclophosphamide) as part of an intensive chemotherapy regimen for patients with previously untreated ALL (n = 197; Ph-positive in 29%; median age, 32 years; range, 16–80 years). The median OS for all patients was 36 months, after a median follow-up of 43 months. Among patients who experienced a CR (85% of all patients), the median remission duration was 29 months. The estimated 3-year OS rate was higher for the subgroup of patients younger than 30 years compared with those aged 30 to 59 years (69% vs. 39%). Among the subgroup of patients who had both Ph-negative and BCR-ABL–negative disease (n = 57), median OS was 39 months and the 3-year OS rate was 62%. Linker et al evaluated an intensified chemotherapy regimen that incorporated a 4-drug induction regimen (comprising vincristine, daunorubicin, prednisone, and asparaginase) in adolescent and adult patients with ALL (n = 84; Ph-positive in 16%; median age, 27 years; range, 16–59 years). The 5-year EFS and OS rates for all patients were 48% and 47%, respectively. Among the patients who experienced a CR (93% of all patients), the 5-year EFS rate was 52%. Among the subgroup of patients without high-risk features (n = 53), the 5-year EFS rate was 60%.

In one of the largest multicenter prospective trials conducted to date (MRC UKALL XII/ECOG E2993 study), previously untreated adolescent and adult patients (n = 1521; aged 15–59 years) received induction therapy comprising vincristine, daunorubicin, prednisone, and L-asparaginase for 4 weeks (phase I) followed by cyclophosphamide, cytarabine, oral 6-MP, and intrathecal methotrexate for 4 weeks (phase II). After completion of induction therapy, patients who experienced a CR received intensification therapy with 3 cycles of high-dose methotrexate (with standard leucovorin rescue) and L-asparaginase. After intensification, those younger than 50 years who had an HLA-compatible sibling underwent allogeneic HCT; all others were randomized to receive autologous HCT or consolidation/maintenance treatment. For Ph-negative disease, high risk was defined as having any of the following factors: aged 35 years or older; time to CR greater than 4 weeks; or elevated WBC count (>30 × 10^9/L for B-cell lineage; >100 × 10^9/L for T-cell lineage). All other Ph-negative patients were considered to have standard-risk disease. The 5-year OS rate for all patients with Ph-negative ALL was 41%; the OS rate for the subgroups with standard risk (n = 533) and high risk (n = 590) was 54% and 29%, respectively. In the subgroup of patients with T-cell ALL (n = 356), the 5-year OS rate was 48%; the OS rate was improved to 61% for those with a matched sibling donor, primarily because of a lower incidence of cumulative relapse. Among the patients with T-cell ALL, those with complex cytogenetic abnormalities had poor 5-year OS outcomes (19%).

The hyper-CVAD regimen constitutes another commonly used ALL treatment regimen for adult patients. A phase II study from MDACC evaluated hyper-CVAD in adolescents and adults with previously untreated ALL (n = 288; median age, 40 years; range, 15–92 years; Ph-positive in 17%). The median OS for all patients was 32 months and the 5-year OS rate was 38%, with a median follow-up of 63 months. Among patients who experienced a CR (92% of all patients), the 5-year CR duration rate was 38%. Death during induction therapy occurred in 5% of patients, and was more frequent among patients aged 60 years or older. Among the patients with Ph-negative ALL (n = 234), the 5-year OS rate was 42%.

Based on retrospective analyses of data from adults with B-cell ALL treated in clinical trials, CD20 positivity (generally defined as CD20 expression on >20% of blasts) was found to be associated with adverse outcomes in terms of a higher cumulative incidence of relapse,
decreased CR duration, or decreased survival.\textsuperscript{34,227} Given the prognostic significance of CD20 expression in these patients, treatment regimens incorporating the CD20 monoclonal antibody rituximab have been evaluated. A phase II study from MDACC evaluated hyper-CVAD with or without rituximab in previously untreated patients with Ph-negative B-lineage ALL (n = 282; median age, 41 years; range, 13–83 years).\textsuperscript{135} Among the subgroup of patients with CD20-positive ALL who were treated with hyper-CVAD combined with rituximab, the 3-year CR duration and OS rates were 67% and 61%, respectively. In addition, among the younger patients (aged <60 years) with CD20-positive disease, modified hyper-CVAD plus rituximab resulted in significantly improved CR duration (70% vs. 38%; \( P < .001 \)) and OS rate (75% vs. 47%; \( P = .003 \)) compared with the standard hyper-CVAD regimen without rituximab.\textsuperscript{135} No significant differences in outcomes with the addition of rituximab were noted for the subgroup of patients with CD20-negative disease. Notably, older patients (aged ≥60 years) with CD20-positive disease did not seem to benefit from the addition of rituximab, partly because of a high incidence of death in CR.

Studies evaluating HCT in first CR for AYA patients with Ph-negative ALL have generally been inclusive of adult patients and therefore have been discussed previously (see Initial Treatment in AYA With Ph-Negative ALL). Recently, more aggressive therapies are being considered for older or less fit patients. A retrospective study of 576 adults, 45 years of age or older, compared RIC or myeloablative conditioning allogeneic HCT from HLA-matched siblings.\textsuperscript{228} Patients who received RIC (n = 127) versus myeloablative conditioning (n = 449) did not show any statistically significant difference in leukemia-free survival (\( P = .23; \) HR, 0.84) thereby supporting the incorporation of more aggressive treatments for this population.\textsuperscript{228}

### Treatment of Relapsed Ph-Negative ALL

Despite major advances in the treatment of childhood ALL, approximately 20% of pediatric patients experience relapse after initial CR to frontline treatment regimens.\textsuperscript{229-231} Among those who experience relapse, only approximately 30% experience long-term remission with subsequent therapies.\textsuperscript{136,232,233} Based on a retrospective analysis of historical data from COG studies (for patients enrolled between 1998 and 2002; n = 9585), early relapse (<18 months from diagnosis) was associated with very poor outcomes, with an estimated 5-year survival (from time of relapse) of 21%.\textsuperscript{229} For cases of isolated bone marrow relapse, the 5-year survival estimates among early (n = 412), intermediate (n = 324), and late (n = 387) relapsing disease were 11.5%, 18%, and 43.5%, respectively (\( P < .0001 \)). Intermediate relapse was defined as relapses occurring between 18 and 36 months from time of diagnosis; late cases were defined as relapses occurring 36 months or more from time of diagnosis. For cases of isolated CNS relapse, the 5-year survival estimates among early (n = 175), intermediate (n = 180), and late (n = 54) relapsing disease were 43.5%, 68%, and 78%, respectively (\( P < .0001 \)).\textsuperscript{229} Based on multivariate analysis (adjusted for both timing and site of relapse), age (>10 years), presence of CNS disease at diagnosis, male gender, and T-cell lineage disease were found to be significant independent predictors of decreased survival after relapse.\textsuperscript{229} In a separate analysis of data from one of the above COG studies (CCG-1952), the timing and site of first relapse were significantly predictive of EFS and OS outcomes, even among the patients with standard-risk ALL (n = 347; based on NCI criteria: 1 to <10 years of age and WBC count <50 × 10\(^9\)/L).\textsuperscript{234} Early bone marrow relapse (duration of first CR <36 months) was associated with significantly shorter estimated 3-year EFS (30% vs. 44.5%; \( P = .002 \)) and OS (35% vs 58%; \( P = .001 \)) compared with late bone marrow relapse.\textsuperscript{234} Similarly, early isolated extramedullary relapse (duration of...
first CR <18 months) was associated with significantly shorter estimated 3-year EFS (37% vs. 71%; \(P = .01\)) and OS (55% vs. 81.5%; \(P = .039\)) compared with late extramedullary relapse. In a multivariate regression analysis, early bone marrow and extramedullary relapse were independent predictors of poorer EFS outcomes.\(^{234}\)

AYA and adult patients with ALL who relapse after initial therapy have extremely poor long-term outcomes. Based on data from patients with disease relapse after frontline therapy in the MRC UKALL XII/ECOG E2993 study and PETHEMA studies, the median OS after relapse was only 4.5 to 6 months; the 5-year OS rate was 7% to 10%.\(^{176,177}\) Approximately 20% to 30% of patients experience a second CR with second-line therapies.\(^{177,179}\) Factors predictive of more favorable outcomes after subsequent therapies included younger age and a first CR duration of more than 2 years.\(^{152,177}\) Among younger patients (aged <30 years) whose disease relapsed after experiencing a first CR duration longer than 2 years with frontline treatment in PETHEMA trials, the 5-year OS rate from the time of first relapse was 38%.\(^{177}\)

The treatment of AYA and adult patients with relapsed and/or refractory ALL remains a challenge. Clofarabine is a nucleoside analog approved for the treatment of pediatric patients (aged 1–21 years) with ALL that is relapsed or refractory after at least 2 prior regimens.\(^{235}\) In a phase II study of single-agent clofarabine in heavily pretreated pediatric patients with relapsed or refractory ALL (n = 61; median age, 12 years; range, 1–20 years; median 3 prior regimens), the response rate (CR + CR without platelet recovery [CRp]) was 20%.\(^{236}\) Among the patients with responding disease, the median duration of remission was 29 weeks. Although the median OS for all patients was only 13 weeks, the median OS for patients with a CR had not yet been reached at the time of publication; median OS was 54 weeks for patients with a CRp and 30 weeks for patients with a partial remission.\(^{236}\)

Single-agent clofarabine in the relapsed/refractory setting has been associated with severe liver toxicities (generally reversible) and frequent febrile episodes including grade 3 or 4 infections and febrile neutropenia.\(^{236,237}\)

In a small phase II study evaluating the combination of clofarabine with cyclophosphamide and etoposide in pediatric patients with refractory or multiple relapsed ALL (n = 25; median age, 12.5 years), the regimen resulted in a CR rate of 52% (plus an additional 4% CRp), with an 18-month OS probability of 39% among responders.\(^{238}\) In subsequent, small phase II studies in pediatric patients (aged 1–21 years) with relapsed/refractory ALL, this combination induced response rates (CR plus CRp) of 42% to 44%.\(^{239,240}\) A multicenter retrospective study of data from pediatric patients treated with clofarabine outside of the clinical trial setting (n = 23; aged 0–17 years) reported that among those treated with the combination of clofarabine, cyclophosphamide, and etoposide (n = 18), the CR rate was 56%.\(^{241}\) The combination regimen of clofarabine, cyclophosphamide, and etoposide has been associated with prolonged and severe myelosuppression, febrile episodes or severe infections (including sepsis or septic shock), mucositis, and liver toxicities including fatal veno-occlusive disease (the latter occurring in the post-allogeneic HCT setting).\(^{239–241}\) Moreover, data are very limited with this combination regimen in adult patients with ALL. Because the use of this regimen requires close monitoring and intensive supportive care measures, patients should only be treated in centers with expertise in the management of ALL.

Clofarabine has also been shown to be active in combination with other chemotherapy regimens in adults with relapsed/refractory disease. In a study from GRAALL, clofarabine in combination with conventional chemotherapy (cyclophosphamide, or a more intensive regimen with dexamethasone, mitoxantrone, etoposide, and asparaginase) yielded a CR rate of 44% in patients with relapsed/refractory ALL (n = 55); the
median OS was 6.5 months after a short median follow-up of 6 months. The most common grade 3 or 4 toxicities included infection (58%) and liver toxicities (24%). Another regimen for advanced disease, comprising ifosfamide, etoposide, and mitoxantrone, was evaluated in a small phase II study in adult patients with relapsed or refractory ALL (n = 11); 8 patients (73%) experienced a CR, and the median DFS and OS durations from time of remission were 3.1 and 7.7 months, respectively. The combination of high-dose cytarabine and idarubicin was evaluated as a regimen in adult patients with relapsed/refractory ALL (n = 29). In this study, 11 patients (38%) experienced a CR with a median OS of 8 months. Four patients who experienced a CR with this therapy proceeded to allogeneic HCT. The median OS for all patients on the study was 6 months.

A phase II study from MDACC evaluated an augmented hyper-CVAD regimen (that incorporated asparaginase, intensified vincristine, and intensified dexamethasone) as therapy in adults with relapsed/refractory ALL (n = 90; median age, 34 years; range, 14–70 years; median 1 prior regimen). Among evaluable patients (n = 88), the CR rate was 47%; an additional 13% experienced a CRp and 5% experienced a partial remission. The 30-day mortality rate was 9%, and was lower among the subgroup who received pegaspargase than those who received L-asparaginase (1% vs. 12%). Median remission duration was 5 months. The median OS for all evaluable patients was 6.3 months; median OS was 10.2 months for patients who experienced a CR. In this study, 32% of patients were able to proceed to HCT.

Nelarabine is a nucleoside analog that is currently approved for the treatment of patients with T-cell ALL who have not experienced disease response to or who have relapsed disease after at least 2 chemotherapy regimens. A phase II study of nelarabine monotherapy in children and adolescents with relapsed/refractory T-cell ALL or T-cell non-Hodgkin’s lymphoma (n = 121) showed a 55% response rate among the subgroup with T-cell ALL with first bone marrow relapse (n = 34) and a 27% response rate in the subgroup with a second or greater bone marrow relapse (n = 36). Major toxicities included grade 3 or higher neurologic (both peripheral and CNS) adverse events in 18% of patients. Nelarabine as single-agent therapy was also evaluated in adults with relapsed/refractory T-cell ALL or T-cell lymphoblastic leukemia in a phase II study (n = 39; median age, 34 years; range, 16–66 years; median 2 prior regimens; T-cell ALL, n = 26). The CR rate (including CR with incomplete blood count recovery [CRi]) was 31%; an additional 10% of patients experienced a partial remission. The median DFS and OS were both 20 weeks and the 1-year OS rate was 28%. Grade 3 or 4 myelosuppression was common, but only 1 case of grade 4 CNS toxicity (reversible) was observed.

Vincristine remains an important part of the backbone of chemotherapy agents used in ALL treatment. Vinca alkaloids are known to be associated with neurologic toxicities, generally limiting their use at higher doses. Vincristine sulfate liposome injection (VSLI) is a novel nanoparticle formulation of vincristine encapsulated in sphingomyelin and cholesterol liposomes; the liposome encapsulation prolongs the exposure of active drug in the circulation, and may allow for delivery of increased doses of vincristine without increasing toxicities. VSLI was recently evaluated in an open-label, multicenter, phase II study in adult patients with Ph-negative ALL (n = 65; median age, 31 years; range, 19–83 years) in second or greater relapse, or with disease that progressed after 2 or more prior lines of therapy (RALLY study). Approximately 50% of patients had received 3 or more prior lines of therapy. In addition, 48% of patients had undergone prior HCT, and all patients had previously been treated with a regimen containing standard vincristine. The CR (CR + CRi) rate with single-agent VSLI...
was 20%. The median duration of CR was 23 weeks (range, 5–66 weeks) and median OS for all patients was 20 weeks (range, 2–94 weeks); median OS for patients achieving a CR was 7.7 months. The incidence of early induction death (30-day mortality rate) was 12%. These outcomes appeared favorable compared with published historical data in patients with Ph-negative ALL treated with other agents at second relapse (n = 56; CR rate, 4%; median OS, 7.5 weeks; early induction death, 30%). The most common grade 3 or greater treatment-related toxicities with VSLI included neuropathy (23%), neutropenia (15%), thrombocytopenia (6%), anemia (5%; no grade 4), and TLS (5%). Febrile neutropenia occurred in 3% of patients (no grade 4). Based on data from the RALLY study, VSLI was approved (in September 2012) by the FDA for the treatment of adult patients with Ph-negative ALL in second or greater relapse or whose disease progressed after 2 or more therapies.

Blinatumomab is a component of the growing arsenal of immunotherapies for the treatment of cancer. Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody that showed high CR rates (67%; including rapid MRD-negative responses) in patients with relapsed/refractory B-precursor ALL (n = 18). In an earlier phase II study, blinatumomab was shown to eliminate residual disease in 80% of patients with relapsed or MRD-positive B-precursor ALL after intensive chemotherapy (N = 21; n = 20 evaluable). After a median follow-up of 33 months, the hematologic RFS rate was 61%. FDA approval of blinatumomab followed the release of data from a large phase II confirmatory study of 189 patients with Ph-negative relapsed or refractory B-cell ALL that demonstrated a CR or CRp in 43% of patients within the first 2 cycles of treatment. Data demonstrate a profound improvement in the treatment of patients with relapsed/refractory ALL, a population that has a historically poor prognosis and limited treatment options; however, there are significant and unique side effects to this treatment compared to the current standard-of-care regimens. Cytokine release syndrome is a serious adverse event with peak cytokine levels in the first 2 days following initiation of blinatumomab infusion. Symptoms of cytokine release syndrome include pyrexia, headache, nausea, asthenia, hypotension, increased alanine aminotransferase, increased aspartate aminotransferase, and increased total bilirubin. Neurologic toxicities have been reported in 50% of patients (median onset, 7 days). Grade 3 or higher neurological toxicities have occurred in 15% of patients. Serious risks may also occur with preparation or administration errors. The incidence of adverse events can be reduced with patient monitoring for early intervention at the onset of symptoms. However, the serious nature of these events underscores the importance of receiving treatment in a specialized cancer center that has experience with blinatumomab.

One of the early treatments for patients with advanced ALL included adoptive cell therapy to induce a graft-versus-leukemia effect through allogeneic HCT or DLI. However, this method resulted in a significant risk of GVHD. To circumvent this issue, current advances are focused on the use of the patient’s own T cells to target the tumor. The generation of CAR T cells to treat ALL is a significant advancement in the field. Briefly, T cells from the patient are harvested and engineered with a receptor that targets a cell surface tumor-specific antigen (eg, CD19 antigen on the surface of leukemic cells). The ability of CAR T cells to be reprogrammed to target any cell-surface antigen on leukemic cells is advantageous and avoids the issue of tumor evasion of the immune system via receptor down regulation. The viral vector in CAR T cells causes T cell expansion and proliferation following antigen recognition, and once modified, CAR T cells can be expanded ex vivo for approximately two weeks to produce high numbers before IV
infusion back into the patient. Following infusion, debulking of tumors occurs in less than a week and these cells may remain in the body for extended periods of time to provide immunosurveillance against relapse.

Clinical trials in patients with relapsed/refractory ALL have shown promising results. There are several trials using CAR T cells that differ in the receptor construct. One trial involving the modified receptor, termed 19-28z, found an overall CR in 14 out of 16 patients with relapsed or refractory B-cell ALL following infusion with CAR T cells. This average remission rate is significantly improved compared to the average remission rate for patients receiving standard-of-care chemotherapy following relapse (88% vs. approximately 30%). Furthermore, 7 out of 16 patients were able to receive an allogeneic HCT, suggesting that CAR T cells may provide a bridge to transplant. No relapse has been seen in patients who had allogeneic HCT (follow-up, 2–24 months); however, 2 deaths occurred from transplant complications. In a recent abstract, follow-up data of adult patients enrolled on this trial (n = 24, 22 evaluable) showed a 91% CR rate after the infusion and 18 of these 20 patients achieved an MRD-negative CR. Out of the 13 patients who were transplant eligible, 10 underwent allogeneic HCT. The median follow-up was 7.4 months and a durable response was indicated by 6 patients remaining disease-free past one year. The median OS was 9 months.

A second receptor construct that is defined by the alteration in the single chain variable fragment (scFv) of CD19 (anti-CD19 scFv/4-1BB/CD3ζ) has shown similar results to the 19-28z CAR T cells in terms of overall CR. These cells, more simply referred to as CTL019, were infused into 16 children and 4 adults with relapsed/refractory ALL; a CR following therapy was achieved in 14 patients. Of these 20 patients, there was no response of the disease to treatment in 3 patients and disease response to therapy for an additional 3 patients was still under evaluation. A follow-up study of 25 children and 5 adults showed a morphologic CR of 90% (27 out of 30) of patients within a month of treatment and an OS of 78% (95% CI, 65%–95%) and EFS of 78% (95% CI, 51%–88%) at 6 months. There were 19 patients in sustained remission, of which 15 received no further therapy.

Another novel monoclonal antibody currently under clinical investigation is inotuzumab ozogamicin (InO). InO is an anti-CD22 antibody-drug conjugate that has shown high CR rates (57%) in a phase II study in patients with relapsed/refractory ALL (n = 49). An ongoing phase III study to evaluate the efficacy and safety of InO compared to SOC consisting of intensive chemotherapy has demonstrated higher CR/CRi (InO, 80.7% vs. SOC, 33.3%; P < .0001), higher duration of remission (InO, 4.6 months vs. SOC, 3.1 months; P = .0169), and higher MRD-negative rates (InO, 78.4% vs. SOC, 28.1%; P < .0001). Similar to previous studies, InO had a higher rate of liver toxicities (InO, 9% vs. SOC, 3%) and veno-occlusive liver disease (InO, 15 patients vs. SOC, 1 patient). Although study data are promising, InO is currently investigational and is not FDA-approved for any indication.

Based on findings from evidence-based review of the published literature, the American Society for Blood and Marrow Transplantation guidelines recommend HCT over chemotherapy alone for adult patients with ALL experiencing a second CR. Several studies have shown that for AYA patients in second CR, allogeneic HCT may improve outcomes, particularly for patients who have early bone marrow relapse or have other high-risk factors, such as T-cell ALL. In a retrospective analysis of children and adolescents (age 1–18 years) with pre-B-cell ALL experiencing a second CR after bone marrow relapse, outcomes were compared between patients who underwent allogeneic HCT (n = 186) and those who received chemotherapy regimens in the POG trials.
The study showed that among patients with early bone marrow relapse (<36 months from time of diagnosis), TBI-containing allogeneic HCT was associated with significantly lower risks of a second relapse (relative risk, 0.49; 95% CI, 0.33–0.71; \( P < .001 \)) or overall mortality (relative risk, 0.58; 95% CI, 0.41–0.83; \( P = .003 \)) compared with chemotherapy regimens. This advantage with TBI-containing allogeneic HCT was not observed among the subgroup with a late first relapse (≥36 months), and no advantages were seen with the use of non–TBI-containing HCT regimens regardless of the timing of first relapse.\(^{266}\) Thus, among patients with pre-B-cell ALL in second CR after early bone marrow relapse, TBI-containing allogeneic HCT may improve outcomes compared with chemotherapy alone; however, for patients with late bone marrow relapse, HCT may offer no advantage over chemotherapy regimens.

An earlier BFM study (BFM-87) evaluated long-term outcomes with intensive chemotherapy or HCT (for poor prognosis disease) in patients with ALL relapsing after frontline treatment (n = 207; aged up to 18 years).\(^{232}\) In this study, patients with poor prognosis included those with early bone marrow relapse (defined as relapse occurring during therapy or up to 6 months after completion of frontline treatment) or T-cell ALL. The 15-year EFS and OS rates for the entire patient cohort were 30% and 37%, respectively.\(^{232}\) The 10-year EFS rate was significantly higher among the patients who received allogeneic HCT after second CR (n = 27) compared with those who received chemotherapy/radiotherapy only (n = 145; 59% vs. 30%; \( P = .026 \)). All recipients of allogeneic HCT received TBI as part of the conditioning regimen. Based on multivariate regression analysis, timing and site of relapse (with early relapse and isolated bone marrow relapse associated with poor outcomes), T-cell lineage disease, and HCT were significant independent predictors of EFS outcomes.\(^{232}\) The more recent BFM study (BFM-90) in patients with ALL relapsing after frontline therapy (n = 525; age 1–18 years) further confirmed the benefits of allogeneic HCT in second CR.\(^{233}\) In this study, the timing of first relapse was defined as very early (within 18 months from initial diagnosis), early (>18 months from initial diagnosis and <6 months after completion of frontline therapy), and late (>6 months after completion of frontline treatment). The overall 10-year EFS and OS rates were 30% and 36%, respectively.\(^{233}\) Among the patients with high-risk disease (ie, presence of early isolated bone marrow relapse, early combined bone marrow and extramedullary relapse, very early bone marrow relapse, or T-ALL regardless of relapse timing), patients who received chemoradiotherapy alone had a significantly shorter 10-year EFS (n = 76; 20%) than those who received HCT (n = 84; 33%; \( P < .005 \)) or the subgroup of patients who received HLA-compatible allogeneic HCT (n = 53; 40%; \( P < .001 \)). This EFS benefit with HCT (or with allogeneic HCT) was not observed among the subgroup of patients with intermediate-risk disease (ie, late bone marrow relapse or isolated extramedullary relapse regardless of relapse timing). The preferred conditioning regimen for HCT in this study included TBI.\(^{233}\)

Seemingly contradictory data reported in the COG study CCG-1952 showed that prognosis after early bone marrow relapse in patients with standard-risk ALL (aged 1 to <10 years and WBC count <50 × 10\(^9\)/L) remained poor with no apparent advantage of HCT, regardless of timing (eg, early or late) of bone marrow relapse.\(^{234}\) No significant differences were observed in the EFS or OS rates between treatment with HCT (n = 77) or chemotherapy (n = 81). The 2-year estimated EFS rates with HCT and chemotherapy were 49.5% and 49%, respectively (\( P = .39 \)). Moreover, no significant differences in EFS rates were observed in the subgroup of patients with early or late bone marrow relapses.\(^{234}\) However, data were not available on the conditioning regimen used for HCT in this study for comparison with other trials.
A recent meta-analysis of 13 studies (n = 2962 patients) with Ph-negative ALL compared standard postremission therapy to determine if there is an advantage in survival among allogeneic HCT, autologous HCT, or chemotherapy. In this analysis, patients younger than 35 years of age had a significant survival advantage when receiving a matched sibling donor compared to autologous HCT (OR, 0.79; 95% CI, 0.70–0.90; P = .0003). This advantage was not maintained in patients who were 35 years of age or older (OR, 1.01; 95% CI, 0.85–1.19; P = .9), a difference attributed to a higher absolute risk of nonrelapse mortality for older patients. There was a trend towards an inferior survival in patients receiving autologous HCT compared to chemotherapy (OR, 1.18; 95% CI, 0.99–1.41; P = .06), though statistical significance was not reached. Similarly, a meta-analysis including 14 trials found that the 5-year leukemia-free survival was higher following allogeneic transplantation (45%; 95% CI, 38%–51%) compared to autologous transplant or chemotherapy (30%; 95% CI, 23%–37%).

NCCN Recommendations for Ph-Negative ALL

AYA Patients (Aged 15–39 Years) with Ph-Negative ALL

The panel recommends that AYA patients with Ph-negative ALL (regardless of risk group) be treated in a clinical trial, where possible. In the absence of an appropriate clinical trial, the recommended induction therapy should comprise multiagent chemotherapy regimens based on pediatric-inspired protocols, such as the CCG-1961, PETHEMA ALL-96, GRAALL-2003, COG AALL-0434 (for T-cell ALL) regimens, DFCI-00-01, CCG-1882, or the ongoing CALGB 10403 protocol. Treatment regimens should include adequate CNS prophylaxis for all patients. It is also important to adhere to the treatment regimens for a given protocol in its entirety. Testing for TPMT gene polymorphism should be considered for patients receiving 6-MP as part of maintenance therapy, especially in those who experience severe bone marrow toxicities.

For patients experiencing a CR following initial induction therapy, monitoring for MRD should be initiated (see NCCN Recommendations for MRD Assessment). In these patients, continuation of the multiagent chemotherapy protocol for consolidation and maintenance would be appropriate (particularly for patients with MRD-negative remission after induction). If a matched donor is available, consolidation with allogeneic HCT may also be considered, particularly for patients with residual disease as assessed with MRD assays, or for those with high-risk cytogenetic features (ie, hypodiploidy, complex karyotype, MLL rearrangements). The benefit of allogeneic HCT in the setting of MRD-positive remission is currently unclear. For AYA patients experiencing less than a CR after initial induction therapy (ie, presence of primary refractory disease), the treatment approach would be similar to that for patients with relapsed/refractory ALL.

For patients with relapsed/refractory disease after an initial CR, the approach to second-line treatment may depend on the duration of the initial response. For late relapses (ie, relapse occurring ≥36 months from initial diagnosis), re-treatment with the same induction regimen may be a reasonable option. Participation in a clinical trial is preferred, where possible. In the absence of an appropriate trial, the patient may be considered for second-line therapy with induction regimens not previously used, subsequent chemotherapy (with regimens containing clofarabine, nelarabine [for T-cell ALL], VSLI, cytarabine, or alkylating agents), or allogeneic HCT if a donor is available. For patients with Ph-negative precursor B-cell ALL, blinatumomab should be considered.

Adult Patients (Aged ≥40 Years) with Ph-Negative ALL

For adult patients with Ph-negative ALL, the panel also recommends treatment in a clinical trial, where possible. In the absence of an appropriate clinical trial, the recommended treatment approach would initially depend on the patient’s age and/or presence of comorbid...
conditions. Treatment regimens should include adequate CNS prophylaxis for all patients, and a given treatment protocol should be followed in its entirety, from induction therapy to consolidation/delayed intensification to maintenance therapy. Again, testing for TPMT gene polymorphism should be considered for patients receiving 6-MP as part of maintenance therapy, especially in those who develop severe bone marrow toxicities.

Although the age cutoff indicated in the guidelines has been set at 65 years, it should be noted that chronologic age alone is not a sufficient surrogate for defining fitness; patients should be evaluated on an individual basis to determine fitness for therapy based on factors such as performance status, end-organ function, and end-organ reserve.

For relatively fit patients (aged <65 years or patients with no substantial comorbidities), the recommended treatment approach is similar to that for AYA patients. Induction therapy should comprise multiagent chemotherapy such as those based on protocols from the CALGB 8811 study (Larson regimen), the Linker regimen, hyper-CVAD (with or without rituximab), or the MRC UKALL XII/E COG E2993 study. For patients experiencing a CR after initial induction therapy, monitoring for MRD should be initiated (see NCCN Recommendations for MRD Assessment). In these patients, continuation of the multiagent chemotherapy protocol for consolidation and maintenance would be appropriate (particularly for patients with MRD-negative remission after induction). If a matched donor is available, consolidation with allogeneic HCT may be considered for patients with residual disease as measured by MRD assays, although the benefit of allogeneic HCT in this setting is currently unclear. In addition, allogeneic HCT may also be considered for relatively fit adult patients with high-risk cytogenetic features (ie, hypodiploidy, complex karyotype, MLL rearrangements).

The effect of WBC counts on prognosis in adult patients with ALL is less firmly established than in pediatric populations. For adult patients experiencing less than a CR after initial induction therapy, the treatment approach would be similar to that for patients with relapsed/refractory ALL (as discussed below).

For patients who are less fit (aged ≥65 years or patients with substantial comorbidities), the recommended induction therapy includes multiagent chemotherapy regimens or corticosteroids. Dose modifications may be required for chemotherapy agents, as needed. Patients with a CR to induction should continue consolidation with chemotherapy regimens; maintenance therapy (typically weekly methotrexate, daily 6-MP, and monthly pulses of vincristine/prednisone for 2–3 years) is recommended. For patients with less than a CR to induction, the treatment option would be similar to that for patients with relapsed/refractory ALL.

For patients with relapsed/refractory disease after an initial CR, participation in a clinical trial is preferred, when possible. In the absence of an appropriate trial, patients may be considered for second-line therapy with induction regimens not previously used, subsequent chemotherapy (with regimens containing clofarabine, nelarabine [for T-cell ALL], VSLI, cytarabine, or alkylating agents), or allogeneic HCT (if a donor is available) in those physically fit enough to undergo transplantation. For patients with Ph-negative precursor B-cell ALL, blinatumomab may be considered.

For recommendations on the treatment of adult patients with mature B-cell ALL, refer to the NCCN Guidelines for NHL: Burkitt Lymphoma (to view the most recent version of these guidelines, visit NCCN.org).
Evaluation and Treatment of Extramedullary Disease

CNS Involvement in ALL

Although the presence of CNS involvement at diagnosis is uncommon (approximately 3%–7% of cases), a substantial proportion of patients (>50%) will eventually develop CNS leukemia in the absence of CNS-directed therapy.\(^1\)\(^,\)\(^4\)\(^0\) CNS leukemia is defined by a WBC count of 5 leukocytes/mcL or greater in the CSF with the presence of lymphoblasts.\(^1\)\(^,\)\(^4\)\(^0\) In children with ALL, CNS leukemia at diagnosis was associated with significantly decreased EFS rates.\(^8\)\(^9\),\(^2\)\(^1\)\(^0\),\(^2\)\(^6\)\(^9\) Factors associated with increased risks for CNS leukemia in children include T-cell immunophenotype, high WBC counts at presentation, Ph-positive disease, t(4;11) translocation, and presence of leukemic cells in the CSF.\(^9\)\(^5\) In adults with ALL, CNS leukemia at diagnosis has been associated with a significantly higher risk for CNS relapse in large trials, although no differences were observed in 5-year EFS or DFS rates compared with subgroups without CNS leukemia at presentation.\(^2\)\(^7\)\(^0\),\(^2\)\(^7\)\(^1\) CNS leukemia at diagnosis was associated with a significantly decreased 5-year OS rate in one trial (29% vs. 38%; \(P = .03\))\(^2\)\(^7\)\(^0\) but not in another trial (35% vs. 31%).\(^2\)\(^7\)\(^1\) Factors associated with increased risks for CNS leukemia in adults include mature B-cell immunophenotype, T-cell immunophenotype, high WBC counts at presentation, and elevated serum LDH levels.\(^3\)\(^3\),\(^2\)\(^7\)\(^0\) CNS-directed therapy may include cranial irradiation, intrathecal chemotherapy (eg, methotrexate, cytarabine, corticosteroids), and/or high-dose systemic chemotherapy (eg, methotrexate, cytarabine, 6-MP, L-asparaginase).\(^1\)\(^,\)\(^4\)\(^0\),\(^9\)\(^5\)

Although cranial irradiation is an effective treatment modality for CNS leukemia, it can be associated with serious adverse events, such as neurocognitive dysfunctions, secondary malignancies, and other long-term complications.\(^1\)\(^,\)\(^9\)\(^5\) With the increasing use of effective intrathecal chemotherapy and high-dose systemic chemotherapy regimens, studies have examined the feasibility of eliminating cranial irradiation as part of CNS prophylaxis. In studies of children with ALL who only received intrathecal and/or intensive systemic chemotherapy for CNS prophylaxis, the 5-year cumulative incidence of isolated CNS relapse or any CNS relapse was 3% to 4% and 4% to 5%, respectively.\(^8\)\(^7\),\(^2\)\(^1\)\(^0\) In adult patients with ALL who only received intrathecal chemotherapy and intensive systemic chemotherapy for CNS prophylaxis, the overall CNS relapse rate was 2% to 6%.\(^9\)\(^7\),\(^9\)\(^8\),\(^2\)\(^7\)\(^2\),\(^2\)\(^7\)\(^3\) Therefore, with the incorporation of adequate systemic chemotherapy (eg, high-dose methotrexate and cytarabine) and intrathecal chemotherapy regimens (eg, methotrexate alone or with cytarabine and corticosteroid, which constitutes the triple intrathecal regimen), the use of upfront cranial irradiation can be avoided except in cases of overt CNS leukemia at presentation, and the use of irradiation can be reserved for advanced disease. CNS prophylaxis is typically given throughout the course of ALL therapy starting from induction, to consolidation, to the maintenance phases of treatment.

**NCCN Recommendations for Evaluation and Treatment of Extramedullary Involvement**

Given the risks of neurologic adverse events associated with CNS-directed therapy, comprehensive neuropsychologic testing may be useful at baseline and during posttreatment follow-up. CNS involvement should be evaluated with lumbar puncture at timing in accordance to the specific treatment protocol used for each patient. Pediatric-inspired treatment regimens typically include lumbar puncture at diagnostic workup. The panel recommends that lumbar puncture, if performed, be conducted concomitantly with initial intrathecal therapy. All patients being treated for ALL should receive adequate CNS prophylaxis with...
intrathecal therapy and/or systemic therapy that incorporates methotrexate.

The classification of CNS status includes the following: CNS-1 refers to no lymphoblasts in the CSF regardless of WBC count; CNS-2 is defined as a WBC count less than 5 leukocytes/mcL in the CSF with the presence of blasts; and CNS-3 is defined as a WBC count of 5 leukocytes/mcL or greater with the presence of blasts. If the patient has leukemic cells in the peripheral blood and the lumbar puncture is traumatic (containing ≥5 WBC/mcL in CSF with blasts), then the Steinherz-Bleyer algorithm can be used to determine the CNS classification (if the WBC/RBC ratio in the CSF is at least 2-fold greater than the WBC/RBC ratio in the blood, then the classification would be CNS-3; if not, the classification would be CNS-2).

In general, patients with CNS involvement at diagnosis (ie, CNS-3 and/or cranial nerve involvement) should receive 18 Gy of cranial irradiation. The entire brain and posterior half of the globe should be included. The inferior border should be below C2. In younger AYA patients with high-risk ALL [ie, evidence of t(9;22) or BCR-ABL; t(4;11) or MLL-AF4] or T-cell ALL, use of prophylactic cranial irradiation may be an option. Notably, areas of the brain targeted by the radiation field in the management of patients with ALL are different from those targeted for brain metastases of solid tumors. In addition, patients with CNS leukemia at diagnosis should receive adequate systemic therapy and intrathecal therapy containing methotrexate throughout the treatment course. Adequate systemic therapy should also be given in the management of patients with isolated CNS or testicular relapse.

A testicular examination should be performed for all male patients at diagnostic workup; testicular involvement is especially common among patients with T-cell ALL. Patients with clinical evidence of testicular disease at diagnosis that is not fully resolved by the end of induction therapy should be considered for radiation to the testes in the scrotal sac. Radiation therapy is typically performed concurrently with the first cycle of maintenance chemotherapy. Testicular total dose should be 24 Gy.

**Response Assessment and Surveillance**

**Response Criteria**

**Response in Bone Marrow and Peripheral Blood**

A CR requires the absence of circulating blasts and absence of extramedullary disease (ie, no lymphadenopathy, splenomegaly, skin/gum infiltration, testicular mass, or CNS involvement). A bone marrow assessment should show trilineage hematopoiesis and fewer than 5% blasts. For a CR, absolute neutrophil counts (ANCs) should be greater than \(1.0 \times 10^9/L\) and platelet counts should be greater than \(100 \times 10^9/L\). In addition, no recurrence should be observed for at least 4 weeks. A patient is considered to have a CR with incomplete recovery of counts (CRi) if criteria for CR are met except the ANC remains less than \(1.0 \times 10^9/L\) or the platelet count remains less than \(100 \times 10^9/L\).

**Refractory disease** is defined as failure to achieve a CR at the end of induction therapy. **Progressive disease** is defined as an increase in the absolute number of circulating blasts (in peripheral blood) or bone marrow blasts by at least 25%, or the development of extramedullary disease. **Relapsed disease** is defined as the reappearance of blasts in the blood or bone marrow (>5%) or in any extramedullary site after achievement of a CR.

**Response in CNS Disease**

Remission of CNS disease is defined as achievement of CNS-1 status (no lymphoblasts in CSF regardless of WBC count) in a patient with CNS-2 or CNS-3 at diagnosis. CNS relapse is defined as development...
of CNS-3 status or development of clinical signs of CNS leukemia (eg, facial nerve palsy, brain/eye involvement, hypothalamic syndrome).

Response in Mediastinal Disease
A CR of mediastinal disease is defined as complete resolution of mediastinal enlargement by CT scan. An unconfirmed CR (CRu) is defined as residual mediastinal enlargement that has regressed by more than 75% in the sum of the products of the greatest perpendicular diameters (SPD). A partial response (PR) is defined as a greater than 50% decrease in the SPD of mediastinal enlargement. Progressive disease is defined as a greater than 25% increase in the SPD. No response indicates failure to meet the criteria for a PR and absence of progressive disease (as defined earlier). Relapsed mediastinal disease is defined as recurrence of mediastinal enlargement after achievement of a CR or CRu.

Mediastinal disease is currently detected by CT scan. Although FDG-PET may also be used to detect mediastinal disease, the possibility of misinterpreting the data currently limits its use. The intense FDG uptake due to rebound hyperplasia can be misdiagnosed as lymphoma. Until more studies are done to evaluate the use of FDG-PET in patients with ALL, it is not a recommended technique.

Surveillance
After completion of the ALL treatment regimen (including maintenance therapy), the panel recommends surveillance at regular intervals to assess disease status. During the first year after completion of therapy, patients should undergo a complete physical examination and blood tests (CBC with differential) on a monthly basis. Liver function tests should be performed every 2 months until normal values are achieved. Assessment of bone marrow aspirate, CSF, and an echocardiogram should be performed as clinically indicated. If a bone marrow aspirate is performed, comprehensive cytogenetics (including FISH), flow cytometry, and molecular tests should be considered. During the second year after completion of therapy, a physical examination (including a testicular examination for all male patients) and blood tests (CBC with differential) should be performed every 3 months. During the third year (and beyond) after completion of therapy, physical examination (including a testicular examination for all male patients) and blood tests (CBC with differential) can be performed every 6 months or as clinically indicated.

The COG has published guidelines on long-term survivorship issues for survivors of childhood cancers. These guidelines serve as a resource for clinicians and family members/caretakers, and have the goal of providing screening and management recommendations for late effects (those that may impact growth, cognitive function, emotional concerns, reproductive health, risks for secondary malignancies, and other important health issues) that may arise during the lifetime of an AYA cancer survivor as a result of the therapeutic agents used during the course of antitumor treatment.

Role of MRD Evaluation
MRD in ALL refers to the presence of leukemic cells below the threshold of detection using conventional morphologic methods. Patients who experienced a CR according to morphologic assessment alone can potentially harbor a large number of leukemic cells in the bone marrow: up to $10^{10}$ malignant cells.

The most frequently used methods for MRD assessment include multicolor flow cytometry to detect abnormal immunophenotypes and PCR assays to detect clonal rearrangements in immunoglobulin heavy chain genes and/or T-cell receptor genes. Current flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of...
fewer than $1 \times 10^{-4}$ (<0.01%) bone marrow mononuclear cells (MNCs). The concordance rate for detecting MRD between these methods is high. In a study that analyzed MRD using both flow cytometry and PCR techniques in 1375 samples from 227 patients with ALL, the concordance rate for MRD assessment (based on a detection threshold of $<1 \times 10^{-4}$ for both methods) was 97%. In a study that analyzed MRD using both flow cytometry and PCR techniques in 1375 samples from 227 patients with ALL, the concordance rate for MRD assessment (based on a detection threshold of $<1 \times 10^{-4}$ for both methods) was 97%.

The combined or tandem use of both methods would allow for MRD monitoring in all patients, thereby avoiding potential false-negative results. Numerous studies in both childhood and adult ALL have shown the prognostic importance of postinduction (and/or post-consolidation) MRD measurements in predicting the likelihood of disease relapse. New multiplexed PCR and next-generation sequencing for MRD are emerging methodologies. Currently these techniques may be labor- and resource-intensive for routine application in the clinical practice setting.

**MRD Assessment in Childhood ALL**

Among children with ALL who achieve a CR according to morphologic evaluation after induction therapy, approximately 25% to 50% may still have detectable MRD based on sensitive assays (in which the threshold of MRD negativity is $<1 \times 10^{-4}$ bone marrow MNCs). An early study in children with ALL ($n = 178$) showed that patients with detectable MRD after initial induction therapy (42% of patients) had significantly shorter time to relapse than patients with MRD-negative status ($P < .001$), defined by a PCR sensitivity level of less than $1.5 \times 10^{-4}$. Patients with MRD after induction had a 10-fold increase in risk of death compared with those without detectable MRD. Moreover, the level of detectable MRD was found to correlate with relapse: patients with MRD of $1 \times 10^{-2}$ or greater had a 16-fold higher risk of relapse compared with those who had MRD levels less than $1 \times 10^{-3}$. In another study in children with ALL ($n = 158$), patients with detectable MRD (flow cytometry sensitivity level $<1 \times 10^{-4}$) at the end of induction therapy had a significantly higher 3-year cumulative incidence of relapse than those who were MRD negative (33% vs. 7.5%; $P < .001$). Subsequent studies have confirmed these findings. In a study of 165 patients, the 5-year relapse rate was significantly higher among patients with MRD (flow cytometry sensitivity $<1 \times 10^{-4}$) versus those without detectable disease (43% vs. 10%; $P < .001$). In addition, the persistence of MRD during the course of therapy was associated with risk of relapse; the cumulative rate of relapse was significantly higher among patients with MRD persisting through week 14 of continued treatment compared with patients who became MRD-negative by 14 weeks (68% vs. 7%; $P = .035$). MRD evaluation was shown to be a significant independent predictor of outcome.

MRD assessments at an earlier time point in the course of treatment (eg, during induction therapy) have been shown to be highly predictive of outcomes in children with ALL. In one study, nearly 50% of patients had MRD clearance (MRD $<1 \times 10^{-4}$ by flow cytometry) before day 19 of induction therapy (about 2–3 weeks from initiation of induction); the 5-year cumulative incidence of relapse was significantly higher among patients with MRD at day 19 of treatment than those without detectable MRD (33% vs. 6%; $P < .001$). More recently, the prognostic significance of MRD detection at lower levels (sensitivity threshold, $\leq 1 \times 10^{-5}$, or $\leq 0.001\%$, according to PCR measurements) was evaluated in children with B-cell lineage ALL treated with contemporary regimens. At the end of induction therapy, 58% of patients had undetectable disease based on PCR values. Among the remaining patients with detectable MRD, 17% had MRD of 0.01% or greater, 14% had less than 0.01% (but $\geq 0.001\%$), and 11% had less than 0.001%. The 5-year cumulative incidence of relapse was significantly higher among patients with MRD of 0.01% or greater versus patients with less than 0.01% or undetectable disease (23% vs. 6%; $P < .001$). Furthermore, the 5-
year cumulative incidence of relapse was significantly higher among the subgroup of patients with MRD less than 0.01% (but ≥0.001%) versus those with MRD less than 0.001% or undetectable disease (13% vs. 5%; \( P < .05 \)). MRD status at the end of induction therapy strongly correlated with MRD levels (flow cytometry sensitivity level <0.01%) at day 19 during induction; all patients who had MRD of 0.01% or greater at the end of induction had MRD of 0.01% or greater at day 19. Although this study showed that a higher risk of relapse was seen among patients with MRD below the generally accepted threshold level (<0.01% but ≥0.001%) compared with those with very low MRD (<0.001%) or no detectable disease, further studies are warranted to determine whether this threshold should be used to risk stratify patients or guide decisions surrounding treatment intensification.\(^{283}\)

In one of the largest collaborative studies conducted in Europe (the AIEOP-BFM ALL 2000 study), children with Ph-negative B-cell lineage ALL \((n = 3184\) evaluable) were risk stratified according to MRD status (PCR sensitivity level ≤0.01%) at 2 time points (days 33 and 78), which were used to guide postinduction treatment.\(^{284}\) Patients were considered standard risk if MRD negativity (≤0.01%) was achieved at both days 33 and 78, intermediate risk if MRD was greater than 0.01% (but <0.1%) on either day 33 or 78 (the other time point being MRD-negative) or on both days 33 and 78, and high risk if MRD was 0.1% or greater on day 78. Nearly all patients with favorable cytogenetic/molecular markers such as the \(ETV6-RUNX1\) subtype or hyperdiploidy were either standard risk or intermediate risk based on MRD evaluation.\(^{284}\) The 5-year EFS rate was 92% for patients categorized as standard risk \((n = 1348)\), 78% for intermediate risk \((n = 1647)\), and 50% for high risk \((n = 189)\) \((P < .001)\); the 5-year OS rates were 98%, 93%, and 60%, respectively. MRD-based risk stratification significantly differentiated risks for relapse (between standard- and intermediate-risk subgroups) even among patient populations with \(ETV6-RUNX1\) or hyperdiploidy. Importantly, in this large-scale study, MRD remained a significant and powerful independent prognostic factor for relapse in the overall population.\(^{284}\)

A randomized controlled trial in children and young adults with low-risk ALL according to MRD compared treatment reduction to standard induction \((n = 521)\).\(^{285}\) Patients were randomized to receive either one or two delayed intensification courses consisting of pegaspargase on day 4; vincristine, dexamethasone (alternate weeks), and doxorubicin for 3 weeks; and cyclophosphamide and cytarabine for 4 weeks. The 5-year EFS between the two cohorts was not statistically significant (94.4% vs. 95.5%; OR, 1; 95% CI, 0.43–2.31; two-sided \( P = .99 \)). No statistical difference was seen regarding relapse or serious adverse events; however, there was a singular treatment-related death in the second delayed intensification cohort and 74 episodes of grade 3 or 4 toxic events. The results suggest that treatment reduction is reasonable for children and young adults with ALL who have a low risk of relapse based on MRD at the end of induction.

A recent randomized study investigated whether improved outcome could be seen with augmented post-remission therapy for children and young adults stratified by MRD.\(^{286}\) In this trial, 533 patients with a high risk of MRD (defined as clinical standard-risk and intermediate-risk patients with MRD of 0.01% or higher at day 29 of induction) were randomized to receive standard therapy or augmented post-remission therapy. The augmented treatment regimen included eight doses of pegaspargase, 18 doses of vincristine, and escalated-dosing of intravenous methotrexate without folinic acid rescue during the interim maintenance courses. The 5-year EFS was higher in patients receiving the augmented regimen versus the standard treatment group (89.6% vs. 82.8%; OR, 0.61; 95% CI, 0.39–0.98; \( P = .04 \)). However, it should...
be noted that more adverse events were seen with the augmented regimen and no statistically significant benefit was seen in OS at 5 years (92.9% vs. 88.9%; OR, 0.67; 95% CI, 0.38–1.17; \( P = .16 \)).

Stratification based on MRD may also indicate which patients should undergo allogeneic HCT versus continued chemotherapy. Children with an intermediate-risk of relapse based on MRD were stratified based on a cutoff MRD level of \( 10^{-3} \). Patients with greater than or equal to MRD of \( 10^{-3} \) were allocated to receive HCT (\( n = 99 \)). In this group, 83% had donors and underwent HCT versus 17% who had no suitable donor and therefore continued chemotherapy. The EFS was higher for patients receiving HCT (64% ± 5%) versus patients remaining on chemotherapy (24% ± 10%). Patients who had a low level of MRD (less than \( 10^{-3} \)) were directed to receive continued chemotherapy (\( n = 109 \)). Within this cohort, 83 patients received either chemotherapy or radiotherapy alone and 22 patients received an allogenic HCT. There was no significant difference in EFS between these two groups (66% ± 6% vs. 80% ± 9%; \( P = .45 \)). Results indicate that MRD can be useful to further risk stratify patients with intermediate risk of relapse to the appropriate treatment regimen. However, the study acknowledges that cutoff values for MRD are regimen dependent as indicated by the divergence from the earlier ALL R3 trial. While the earlier trial also advocated the use of MRD to stratify patients for HCT, a higher threshold for MRD level was used (\( 10^{-4} \)), a difference that may reflect the more intensive induction regimen. Therefore MRD levels may influence treatment decisions, but the application of this prognostic factor must be carefully evaluated on a regimen-by-regimen basis.

Approximately 20% of children treated with intensive therapies for ALL will ultimately experience disease relapse. MRD assessment may also play a prognostic role in the management of patients in the relapsed setting. In patients (\( n = 35 \)) who experienced a second remission (morphologic CR) after reinduction treatment, MRD (measured by flow cytometry with sensitivity level <0.01%) after reinduction (day 36) was significantly associated with risks for relapse; the 2-year cumulative incidence of relapse was 70% among patients with MRD of 0.01% or greater versus 28% among those with MRD less than 0.01% (\( P = .008 \)). In addition, among the subgroup of patients who experienced first relapse after cessation of treatment, the 2-year cumulative incidence of second relapse was 49% among those with MRD of 0.01% or greater versus 0% for those with MRD less than 0.01% (\( P = .014 \)). Both the presence of MRD at day 36 of reinduction therapy and at first relapse occurring during therapy, were significant independent predictors of second relapse based on multivariate analysis. In another study, MRD (PCR sensitivity level <0.01%) was evaluated in high-risk children with ALL (\( n = 60 \)) who experienced first relapse within 30 months from the time of diagnosis. Categories based on MRD evaluation after the first chemotherapy cycle (3–5 weeks after initiation of reinduction treatment) included MRD negativity (undetectable MRD), MRD positive but unquantifiable (levels <0.01%), and MRD of 0.01% or greater. The 3-year EFS rate based on these MRD categories was 73%, 45%, and 19%, respectively (\( P < .05 \)). Thus, MRD assessment can identify patients with a high probability of second relapse, which may offer an opportunity for risk-adapted second-line treatment strategies in these patients.

Several studies suggest early assessment of MRD during induction treatment (eg, day 15 from initiation of treatment) may be highly predictive of subsequent relapse in children with ALL. This raises the possibility of identifying patients with high-risk disease who may potentially benefit from earlier intensification or tailoring of treatment regimens, or for potentially allowing less-intensive treatments to be administered in patients at low risk for relapse based on early MRD
measurements. Large trials are warranted to address these possibilities, although serial MRD measurements may likely be needed to monitor leukemic cell kinetics during the long course of treatment.

**MRD Assessment in Adult ALL**

Studies in adults with ALL have shown the strong correlation between MRD and risk for relapse, and the prognostic significance of MRD measurements during and after initial induction therapy. In an analysis of postinduction MRD (flow cytometry sensitivity level <0.05%) in adult patients with ALL (n = 87), median RFS was significantly longer among patients with MRD less than 0.05% at day 35 compared with those with MRD of 0.05% or greater (42 vs. 16 months; P = .001). A similar pattern emerged when only the subgroup of patients with morphologic CR at day 35 was included in the MRD evaluation. Although patient numbers were limited, 90% of patients with MRD less than 0.03% at an earlier time point (day 14 during induction therapy) remained relapse-free at 5 years. MRD after induction therapy was a significant predictor of relapse in a subgroup analysis from the MRC UKALL/ECOG study of patients with Ph-negative B-cell lineage ALL (n = 161). The 5-year RFS rate was significantly higher in patients with MRD negativity versus those with MRD of 0.01% or greater (71% vs. 15%; P = .0002).

Postinduction MRD can serve as an independent predictor of relapse even among adult patients considered to be standard risk based on traditional prognostic factors. In a study of adult patients with Ph-negative ALL (n = 116), MRD status after induction therapy (flow cytometry sensitivity level <0.1%) was significantly predictive of relapse regardless of whether the patient was standard risk or high risk at initial evaluation. Among patients who were initially classified as standard risk, those with MRD of less than 0.1% after induction had a significantly lower risk of relapse at 3 years compared with patients who had higher levels of MRD (9% vs. 71%; P = .001). Interestingly, MRD measured during the post-consolidation time point was not significantly predictive of outcomes. In the German Multicenter ALL (GMALL) 06/99 study, patients with standard-risk disease (n = 148 evaluable) were monitored for MRD (PCR sensitivity level <0.01%) at various time points during the first year of treatment. Only patients with ALL who met all of the following criteria for standard risk were enrolled in this study: absence of t(4;11) MLL translocation or t(9;22) BCR-ABL translocation; WBC count less than 30 × 10⁹/L for B-cell lineage ALL or less than 100 × 10⁹/L for T-ALL; aged 15 to 65 years; and achievement of morphologic CR after phase I of induction treatment. At the end of initial induction therapy (day 24), patients with MRD of 0.01% or greater had a 2.4-fold higher risk (95% CI, 1.3–4.2) of relapse than those with MRD of less than 0.01%. Moreover, this study identified distinct risk groups according to MRD status at various time points. Patients categorized as low risk (10% of study patients) had MRD of less than 0.01% at both days 11 and 24 (during and after initial induction), and had 3-year DFS and OS rates of 100% (for both endpoints). Patients in the high-risk group (23%) had MRD of 0.01% or greater persisting through week 16, and 3-year DFS and OS rates of 6% and 45%, respectively. All other patients (67%) categorized as intermediate risk had 3-year DFS and OS rates of 53% and 70%, respectively. Importantly, a multivariate Cox regression analysis that included gender, age, WBC count, B- or T-cell lineage, and MRD in the model showed that MRD was the only independently significant predictor of outcome in this patient population.

A recent prospective study (Japan ALL MRD2002) evaluated outcomes by MRD status in adult patients with Ph-negative ALL. Among the patients who achieved a CR after induction/consolidation (n = 39), those who were MRD negative (<0.1%) after induction had a significantly
higher 3-year DFS (69% vs. 31%; \(P = .004\)) compared with patients who were MRD positive; 3-year OS was higher among patients with MRD-negative status after induction, although the difference was not statistically significant (85% vs. 59%). Based on multivariate Cox regression analysis, older age (>35 years) and MRD positivity after induction were significant independent factors predictive of decreased DFS. WBC counts and MRD status after consolidation were not significant predictors of DFS outcomes. Thus, MRD evaluation postinduction may provide additional risk stratification criteria among patients who would otherwise be considered standard risk according to traditional evaluation of prognostic factors.

MRD assessment after consolidation therapy has been shown to have prognostic significance, offering the possibility to adjust post-consolidation treatment approaches. In a study that evaluated MRD (PCR sensitivity level <0.01%) after consolidation therapy (weeks 16–22 from initiation of induction) in adult patients with ALL (n = 142), patients with MRD of less than 0.01% (n = 58) were primarily allotted to receive maintenance chemotherapy for 2 years, whereas those with MRD of 0.01% or greater (n = 54) were eligible to undergo allogeneic HCT after high-dose therapy. The 5-year DFS rate was significantly higher among patients with MRD negativity versus those with MRD of 0.01% or greater (72% vs. 14%; \(P = .001\)); similarly, the 5-year OS rate was significantly higher for patients with MRD-negative status post-consolidation (75% vs. 33%; \(P = .001\)). In a follow-up to the GMALL 06/99 study mentioned earlier, patients with standard-risk ALL (as defined by Bruggemann et al\(^{294}\)) who experienced MRD negativity (PCR sensitivity <0.01% leukemic cells) during the first year of treatment underwent sequential MRD monitoring during maintenance therapy and follow-up. Among the patients included in this analysis (n = 105), 28 (27%) became MRD-positive after the first year of therapy; MRD was detected before hematologic relapse in 17 of these patients.\(^{300}\) The median RFS was 18 months (calculated from the end of initial treatment) among the subgroup that became MRD-positive, whereas the median RFS has not yet been reached among patients who remained MRD-negative. The median time from MRD positivity (at any level, including non-quantifiable cases) to clinical relapse was 9.5 months; the median time from quantitative MRD detection to clinical relapse was only 4 months.\(^{300}\) Detection of post-consolidation MRD was highly predictive of subsequent hematologic relapse and introduced the concept of molecular relapse in ALL.

A subsequent analysis by GMALL investigators evaluated the potential advantage of intensifying or modifying treatment regimens (eg, incorporation of allogeneic HCT) based on post-consolidation MRD status. In one of the largest studies to assess the prognostic impact of MRD on treatment outcomes in adult patients with Ph-negative ALL (n = 580 with CR and evaluable MRD results; patients from GMALL 06/99 and 07/03 studies; aged 15–55 years), molecular CR (defined as MRD <0.01%) after consolidation was associated with significantly higher probabilities of 5-year continuous CR (74% vs. 35%; \(P < .0001\)) and OS (80% vs. 42%; \(P = .0001\)) compared with molecular failure (MRD ≥0.01%).\(^{301}\) Based on multivariate analysis, molecular response status was a significant independent predictor of both 5-year continuous CR and OS outcomes. Among the patients with disease that did not result in a molecular CR, the subgroup who underwent allogeneic HCT in clinical CR (n = 57) showed a significantly higher 5-year continuous CR (66% vs. 12%; \(P < .0001\)) and a trend for higher OS (54% vs. 33%; \(P = .06\)) compared with the subgroup without HCT (n = 63).\(^{301}\) In this latter subgroup of patients with disease that did not result in a molecular CR and who did not undergo HCT, the median time from MRD detection to clinical relapse was approximately 8 months.\(^{301}\) This analysis showed...
that MRD status following consolidation was an independent risk factor for poorer outcomes in adults with ALL, and may identify high-risk patients who could potentially benefit from allogeneic HCT.

Studies in children and adult patients with ALL suggest that differences may exist in the kinetics of leukemic cell eradication between these patient populations. Among children treated on contemporary regimens, 60% to 75% experienced clearance of MRD at the end of induction therapy (typically 5–6 weeks after initiation of induction). In one study, nearly 50% of children had MRD clearance (<0.01% by flow cytometry) at day 19 of induction therapy. Adult patients seem to have a slower rate of leukemic cell clearance compared with children, with 30% to 50% of adult patients having MRD negativity after initial induction. Approximately 50% of cases remained MRD positive at 2 months after initiation of induction, with further reductions in the proportion of MRD-positive cases occurring beyond 3 to 5 months. Possible determinants for differences in the kinetics of leukemic cell reduction in the bone marrow may be attributed to the therapeutic regimens, variations in the distribution of immunophenotypic or cytogenetic/molecular features, and other host factors.

NCCN Recommendations for MRD Assessment

Collectively, studies show the high prognostic value of MRD in assessing risk for relapse in patients with ALL, and the role of MRD monitoring in identifying subgroups of patients who may benefit from further intensified therapies or alternative treatment strategies. Flow cytometry or PCR methods can detect leukemic cells at a sensitivity threshold of fewer than $1 \times 10^{-4}$ (<0.01%) bone marrow MNCs. The concordance rate for detecting MRD between these methods is high. However, high-sensitivity PCR assays (for analysis of immunoglobulin or T-cell receptor gene rearrangements) require the identification of patient-specific markers that involve direct sequencing, and may therefore be labor- and resource-intensive for routine application in the clinical practice setting. Recommendations for the minimal technical requirements for MRD assessment (both for PCR and flow cytometry methods) and definitions for response based on MRD results (eg, MRD negativity, non-quantifiable MRD positivity, quantifiable MRD positivity) were published as a result of a consensus meeting held by ALL study groups across Europe. The recommendations were made in an effort to standardize MRD measurements and reporting of data within the context of clinical trials. The panel strongly recommends that MRD assessments be performed at specialized treatment centers with access to Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories that have expertise in MRD assays.

The timing of MRD assessment varies depending on the ALL treatment protocol used, and may occur during or after completion of initial induction therapy. Therefore, it is recommended that the initial measurement be performed on completion of induction therapy; additional time points for MRD evaluation may be useful depending on the treatment protocol or regimen used. For MRD evaluation by multicolor flow cytometry, sampling of bone marrow MNCs is preferred over peripheral blood samples. At least $1 \times 10^6$ MNCs are required for analysis (approximately 2 mL of bone marrow or 5–10 mL of peripheral blood provide a sufficient number of cells for multiple analysis). For MRD evaluation with the real-time quantitative PCR (RQ-PCR) assay, sampling of bone marrow MNC is preferred. At least $1 \times 10^7$ MNCs are required for initial marker characterization and generation of individual dilution series; $1 \times 10^6$ MNCs are sufficient for follow-up analysis. The minimal limit of assay sensitivity (to declare MRD negativity) should be less than $1 \times 10^{-4}$ (<0.01%).
Supportive Care for Patients with ALL

Given the highly complex and intensive treatment protocols used in the management of ALL, supportive care issues are important considerations to ensure that patients derive the most benefit from ALL therapy. Although differences may exist between institutional standards and practices, supportive care measures for patients with ALL generally include the use of antiemetics for prevention of nausea and vomiting, blood product transfusions or cytokine support for severe cytopenias, nutritional support for prevention of weight loss, gastroenterology support, pain management, prevention and management of infectious complications, and prophylaxis for TLS. In addition, both short- and long-term consequences of potential toxicities associated with specific agents used in ALL regimens should be considered, such as with steroids (eg, risks for hyperglycemia or peptic ulcerations in the acute setting; risks for osteonecrosis or avascular necrosis with long-term use) and asparaginase (risks for hypersensitivity reactions, hyperglycemia, coagulopathy, hepatotoxicity, and/or pancreatitis).

Supportive care measures should be tailored to meet the individual needs of each patient based on factors such as age, performance status, extent of cytopenias before and during therapy, risks for infectious complications, disease status, and the specific agents used in the ALL treatment regimen.

NCCN Recommendations for Supportive Care

Most chemotherapy regimens used in ALL contain agents that are at least moderately emetogenic, which may necessitate antiemetic support before initiating emetogenic chemotherapy. Antiemesis prophylaxis may include the use of agents such as serotonin receptor antagonists, corticosteroids, and/or neurokinin-1–receptor antagonists. Recommendations for antiemetic support for patients receiving chemotherapy are available in the NCCN Guidelines for Antiemesis. For patients with ALL, the routine use of corticosteroids as part of antiemetic therapy should be avoided given that steroids constitute a major component of ALL regimens. For patients experiencing greater than 10% weight loss, enteral or parenteral nutritional support should be considered. Regimens to maintain bowel movement and prevent the occurrence of constipation may need to be considered for some patients. Daily doses of docusate sodium may be useful, and laxatives should be administered promptly when symptoms arise.

For patients requiring transfusion support for severe or prolonged cytopenias, only irradiated blood products should be used. Growth factor support is recommended during blocks of myelosuppressive therapy or as directed by the treatment protocol being followed for individual patients (see NCCN Guidelines for Myeloid Growth Factors).

Patients with ALL undergoing intensive chemotherapy or allogeneic HCT are highly susceptible to infections. Immunosuppression caused by the underlying disease and therapeutic regimens can predispose patients to common bacterial and viral infections, and to various opportunistic infections (eg, candidiasis, invasive mold infections, Pneumocystis jirovecii, cytomegalovirus [CMV] reactivation and infection), particularly during periods of prolonged neutropenia. Patients with ALL should be closely monitored for any signs or symptoms of infections. Cases of febrile neutropenia should be managed promptly with empiric anti-infectives and inpatient admission. For recommendations for the prevention and management of infections in patients with cancer, see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections. For patients with ALL, antibacterial prophylaxis should be considered in those with expected duration of neutropenia (ANC <1000/mcL) of more than 7 days. Antiviral prophylaxis is recommended in herpes simplex virus (HSV)–seropositive patients receiving induction/consolidation chemotherapy,
during neutropenia, and at least 30 days after allogeneic HCT. A longer period of prophylaxis may need to be considered in allogeneic HCT recipients with GVHD or with frequent HSV reactivations before transplantation. In addition, varicella zoster virus (VZV) prophylaxis during the 12-month period after allogeneic HCT may be recommended in patients who are VZV-seropositive pretransplant; agents used for HSV prophylaxis are generally also active against VZV. For allogeneic HCT candidates who are seropositive for hepatitis B virus (HBV; hepatitis B surface antigen positive and/or hepatitis B core antibody positive), HBV prophylaxis should be considered until at least 6 to 12 months after HCT and during periods of GVHD (see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections). Antifungal prophylaxis should be considered for all patients with ALL treated with chemotherapy. If an amphotericin B product is used for antifungal prophylaxis, a lipid formulation is generally preferred because of less infusional and renal toxicity compared with conventional amphotericin B. Antifungal prophylaxis with posaconazole, itraconazole, and voriconazole should be avoided in patients receiving vinca alkaloids (eg, vincristine, which is included as a component of nearly all treatment regimens for ALL) because of the potential of these azoles to inhibit the cytochrome P450 3A4 isoenzyme, potentially reducing clearance of vinca alkaloids. Trimethoprim/sulfamethoxazole (TMP-SMX) for P. jirovecii prophylaxis is effective in preventing Pneumocystis pneumonia in patients with acute leukemias, and should be considered for all patients receiving chemotherapy for ALL. Clinicians should be aware of potential drug interactions when using TMP-SMX, as this agent can increase systemic exposure to methotrexate (due to decrease in renal clearance), thereby increasing the risks for myelotoxicity with methotrexate. High doses of methotrexate can result in toxic plasma methotrexate concentrations (>10 microM/L beyond 42–48 hours) in patients with delayed methotrexate clearance. While this is more commonly seen in osteosarcoma and soft tissue tumors due to the higher dose of methotrexate in treatment, the FDA has approved the use of glucarpidase as a rescue product in patients with ALL. Leucovorin should also be given as part of the treatment of methotrexate toxicity (see Supportive Care in the algorithm). CMV monitoring and preemptive anti-CMV therapy should be considered for all patients. In particular, routine CMV monitoring and preemptive therapy is strongly recommended for patients undergoing allogeneic HCT until at least 6 months after transplantation. Additional CMV surveillance should be strongly considered during chronic GVHD requiring immunosuppressive therapy and until the CD4-positive count is 100/mcL or greater (see the NCCN Guidelines for the Prevention and Treatment of Cancer-Related Infections; available at NCCN.org). It is important to note that the local susceptibility and resistance patterns of pathogens must be considered in the choice of antifungal agents used for the prevention or treatment of infections.

Patients with ALL may be at high risk for developing acute TLS, particularly those with highly elevated WBC counts before induction chemotherapy. TLS is characterized by metabolic abnormalities stemming from the sudden release of intracellular contents into the peripheral blood because of cellular disintegration induced by chemotherapy. If left untreated, TLS can result in profound metabolic changes leading to cardiac arrhythmias, seizures, loss of muscle control, acute renal failure, and even death. Recommendations for the management of TLS are available in the Tumor Lysis Syndrome section of the NCCN Guidelines for NHL (available at NCCN.org). Standard prophylaxis for TLS includes hydration with diuresis, alkalinization of the urine, and treatment with allopurinol or rasburicase. Rasburicase should be considered as initial treatment in patients with rapidly increasing blast counts, high uric acid, or evidence of impaired renal function.
Although relatively uncommon in patients with ALL, symptomatic hyperleukocytosis (leukostasis) constitutes a medical emergency and requires immediate treatment, as recommended in the NCCN Guidelines for Acute Myeloid Leukemia (available at NCCN.org). Leukostasis is characterized by highly elevated WBC count (usually >100 × 10^9/L) and symptoms of decreased tissue perfusion that often affect respiratory and CNS function. Although leukapheresis is not typically recommended in the routine management of patients with high WBC counts, it can be considered with caution in cases of leukostasis that is unresponsive to other interventions.

Key components of the ALL treatment regimen, such as corticosteroids and asparaginase, are associated with unique toxicities that require close monitoring and management. Corticosteroids, such as prednisone and dexamethasone, constitute a core component of nearly every ALL induction regimen, and are frequently incorporated into consolidation and/or maintenance regimens. Acute side effects of steroids may include hyperglycemia and steroid-induced diabetes mellitus. Patients should be monitored for glucose control using the Insulin Sliding Scale (ISS) to minimize the risks of developing infectious complications.

Another acute side effect of steroid therapy includes peptic ulceration and dyspeptic symptoms; the use of histamine-2 receptor antagonists or proton pump inhibitors is recommended during steroid therapy to reduce these risks. Although uncommon, the use of high-dose corticosteroids can be associated with mood alterations, psychosis, and other neuropsychiatric complications in patients with malignancies; dose reductions may be required in these situations. A potential long-term side effect associated with steroid therapy includes osteonecrosis/avascular necrosis. Osteonecrosis most often affects weight-bearing joints, such as the hip and/or knee, and seems to have a higher incidence among adolescents (presumably because of the period of skeletal growth) than younger children or adults. In children and adolescents (aged 1–21 years) with ALL evaluated in large studies of the CCG, the cumulative incidence of symptomatic osteonecrosis increased with age, from approximately 1% in patients younger than 10 years, to 10% to 13.5% in patients between the ages of 10 and 15 years, to 18% to 20% in patients aged 16 years and older. In the Total XV study in children with ALL, symptomatic osteonecrosis occurred in 18% of patients, with most cases occurring within 1 year of treatment initiation. Older children (aged >10 years) had a significantly higher cumulative incidence of osteonecrosis (45% vs. 10%; P < .001) compared with younger children (aged ≤10 years). In this study, factors such as older age, lower serum albumin levels, higher serum lipid levels, and higher exposure to dexamethasone were associated with risks for osteonecrosis. Moreover, higher plasma exposure to dexamethasone (as measured by area under the concentration curve at Week 8 of therapy) and lower serum albumin were significant factors associated with the development of severe (grade 3 or 4) osteonecrosis, even after adjusting for age and treatment arm.

In a recent DFCI ALL Consortium study in children and adolescents that included randomization to postinduction therapy with dexamethasone versus prednisone, dexamethasone was associated with a significantly increased 5-year EFS but, in older children, the increased cumulative incidence of osteonecrosis was comparable with prednisone. An earlier CCG study (CCG-1882) had reported a higher incidence of symptomatic osteonecrosis among children randomized to receive an augmented ALL regimen with 2 courses of dexamethasone compared with those who received 1 course (23% vs. 16%; P = not significant). These studies appeared to suggest that dexamethasone, particularly in higher doses, may be associated with increased risks for osteonecrosis.
in older children and adolescents. To further investigate these findings, the CCG-1961 trial randomized patients (n = 2056; aged 1–21 years) to postinduction intensification treatment with intermittent dose scheduling of dexamethasone (10 mg/m² daily on days 0–6 and days 14–20) versus continuous doses of dexamethasone (10 mg/m² daily on days 0–20). Among older children and adolescents (aged ≥10 years) who had rapid response to induction, use of intermittent dexamethasone during intensification phase was associated with significantly decreased incidence of osteonecrosis compared with the standard continuous dose of dexamethasone (9% vs. 17%; P = .0005). The difference was particularly pronounced among adolescent patients 16 years and older (11% vs. 37.5%, respectively; P = .0003). This randomized trial suggested that the use of intermittent (alternative week) dexamethasone during intensification phases may reduce the risks of osteonecrosis in adolescents. To monitor patients for risks of developing symptomatic osteonecrosis, routine measurements for vitamin D and calcium levels should be obtained, and periodic radiographic evaluation (using plain films or MRI) should be considered.

Asparaginase is also a core component of ALL regimens, most often given during induction and consolidation for Ph-negative disease. Three different formulations of the enzyme have been approved by the FDA: native Escherichia coli (E coli)-derived asparaginase (E coli asparaginase); asparaginase derived from E coli that has been modified with a covalent linkage to PEG (pegaspargase); and asparaginase derived from a different Gram-negative bacteria Erwinia chrysanthemi (Erwinia asparaginase). These formulations differ in their pharmacologic properties, and may also differ in terms of immunogenicity. Regardless of the formulation, asparaginase can be associated with potentially severe hypersensitivity reactions (including anaphylaxis) arising from the production of anti-asparaginase antibodies. Pegasparase seems to be associated with a lower incidence of neutralizing antibodies compared with native asparaginase. However, cross-reactivity between neutralizing antibodies against native E coli asparaginase and pegasparase has been reported. Moreover, a high anti-asparaginase antibody level after initial therapy with native E coli asparaginase was associated with decreased asparaginase activity during subsequent therapy with pegasparase. A study from the DFCI ALL Consortium showed the feasibility and activity of using Erwinia asparaginase in pediatric and adolescent patients who developed hypersensitivity reactions to E coli asparaginase during frontline therapy. Importantly, treatment with Erwinia asparaginase did not negatively impact EFS outcomes in these patients. Native E coli asparaginase is no longer available; therefore, the NCCN panel recommends the use of pegasparase in the treatment of patients with ALL. For patients who develop severe hypersensitivity reactions during treatment with pegasparase, Erwinia asparaginase should be substituted (see Supportive Care: Asparaginase Toxicity Management in the algorithm). Erwinia asparaginase is currently approved by the FDA for patients with ALL who have developed hypersensitivity to E coli–derived asparaginase. Asparaginase can be associated with various toxicities, including pancreatitis (ranging from asymptomatic cases with amylase or lipase elevation to symptomatic cases with vomiting or severe abdominal pain), hepatotoxicity (eg, increase in alanine or glutamine aminotransferase), and coagulopathy (eg, thrombosis, hemorrhage). Detailed recommendations for the management of asparaginase toxicity in AYA and adult patients were
published and have been incorporated into the NCCN Guidelines for ALL (see Supportive Care: Asparaginase Toxicity Management in the algorithm).
References


115. Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and


177. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in


203. Tachibana T, Numata A, Tanaka M, et al. Successful treatment with dasatinib and allogeneic peripheral blood stem cell transplant for imatinib-resistant Philadelphia chromosome-positive acute lymphoblastic leukemia relapsing after bone marrow transplant and


216. Stock W, Luger SM, Advani AS, et al. Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403


268. Messori A, Fadda V, Maratea D, Trippoli S. Acute lymphoblastic leukemia in first complete remission: temporal trend of outcomes in studies comparing allogeneic transplant with autologous transplant or...
Acute Lymphoblastic Leukemia


295. Holowiecki J, Krawczyk-Kulis M, Giebel S, et al. Status of minimal residual disease after induction predicts outcome in both standard and...


